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Abstract 
Blastocystis is an important parasite that infects humans and a wide range of 
animals like rats, birds, reptiles, etc. infecting a sum of 60% of world population. 
It belongs to the Stramenopiles, a Heterologous group that includes for example 
the Phythophthora infestans the responsible for the Irish potato famine. Previous 
work had reported the presence of an unusual fusion protein that is composed of 
two of the main glycolytic enzymes; Triosephosphate isomerase-glyceraldehyde-
3-phosphate dehydrogenase (TPI-GAPDH). Little is known about this protein. 
Blastocystis TPI-GAPDH and Blastocystis enolase were both characterized 
biochemically and biophysically in this project. The phylogenetic relationships of 
those two proteins among other members of either Stramenopiles, or other 
members of the kingdom of life were examined and found to be grouping within 
the chromalveolates. Our studies revealed that those two proteins, Blastocystis 
enolase and Blastocystis TPI-GAPDH, had a peptide signal targeting them to the 
mitochondria. This was an unusual finding knowing that text books always 
referred to the glycolytic pathway as a canonical cytoplasmic pathway. Structural 
studies had also been conducted to unravel the unknown structure of the fusion 
protein Blastocystis TPI-GAPDH. X-ray crystallography had been conducted to 
solve the protein structure and the protein was found to be a tetrameric protein 
composed of a central tetrameric GAPDH protein flanked with two dimmers of 
TPI protein. Solving its structure would be the starting point towards reviling the 
role that TPI-GAPDH might play in Blastocystis and other organisms that it was 
found in as well. Although a fusion protein, the individual components of the 
fusion were found to contain all features deemed essential for function for TPI 
and GAPDH and contain all expected protein motifs for these enzymes.  
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Chapter 1.  Introduction  
1.1. Blastocystis  
1.1.1. History and background 
More than hundred years ago Blastocystis had been described in the literature, 
and drawings of it were published together with other parasites examined in a 
stool sample. It was first described in 1849 by London and Swayne who called it 
cholera bodies, and annular cells respectively, in almost every insect, bird, reptile 
and mammal studied. They first considered it as the pathogen responsible for 
cholera disease which was a serious health concern at the time, knowing that the 
first pandimic started in the 1817 and moved to hit Europe in 1826-1837. It later 
transpired that their work actually related to Ascaris lumbiocides ova, the giant 
roundworm. It is therefore more likely that Blastocystis was actually discovered 
in 1899, as it appeared in a written description by Perroncito, unfortunately, this 
paper did not include any drawings. This work was followed by a description of 
the same organism by Perroncito’s assistant in 1901(Zierdt 1991). In 1911, the 
first description including an appropriate nomenclature was introduced by Alexieff 
who called it Blastocystis enterocola. He however classified it as yeast but 
perhaps some shared morphological features led to this erroneous classification. 
In light microscopy, and similar to yeast, Blastocystis has a glistening 
appearance, due to its central vacuole, but lacks pseudopodia and is immotile 
(Zierdt 1991). Blastocystis has several morphological forms which has hampered 
the proper classification of this organism. It has moved repeatedly across the 
eukaryotic tree of life due to various different classifications. For a long time, it 
had been classified as a cyst of a yeast but it has also been considered as fungus, 
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a flagellate and a plant (Zierdt 1991). Finally it was classified by Zierdt as a protist 
in 1967. This classification was due to several features such as the presence of 
one or more nuclei, Golgi bodies, mitochondria-like organelles, and its failure to 
grow on fungal media and resistance to anti-fungal drugs. Moreover, it was found 
to be sensitive to anti-protozoal drugs such as metronidazole (Flagyl) and 
emetine (Zierdt 1988, Zierdt, Donnolley et al. 1988, Zierdt 1991). Blastocystis has 
finally found its home in the stramenopiles in 1996 by the work of Silberman and 
colleagues after electron microscopic studies failed to place Blastocystis in any 
particular group. Silberman et al sequenced the small sub-unit of the ribosomal 
RNA genes of two Blastocystis subtypes and a thorough phylogenetic analysis 
clearly placed Blastocystis in the Stramenopiles (Silberman, Sogin et al. 1996). 
Stramenopila are a large grouping of a seemingly heterogeneous assemblage of 
organisms that includes unicellular as well as cellular organisms. It contains 
heterotrophic and photosynthetic organisms. Examples include many algae 
(including the giant kelp), water moulds and diatoms. One of the best known 
members of the Stramenopiles is Phytophthora infestans which was the 
causative agent of the infamous Irish Potato Famine (also called the Great 
Hunger) which led to the death of 30% of the population and displacement and 
emigration of about 2,400,000 from their houses (1849-1854) in the middle of the 
19th Century. Blastocystis is thought to cause blastocystosis, a disease 
manifested by abdominal and gastrointestinal symptoms. Although there are 
several pathogens in the stramenopiles,  Blastocystis is generally considered the 
only human pathogen of this whole group (Silberman, Sogin et al. 1996).  
Because it is often found in human stool samples, it was called Blastocystis 
hominis, because of this; additional Blastocystis isolates were named after their 
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host. For example, a Blastocystis isolated from rat became Blastocystis rattis. 
This ‘explosion’ of Blastocystis species, based on host, lacked any founding in 
evolutionary relationships and once molecular markers were used to unravel the 
relationships between all these isolates, it soon became clear the system was 
completely flawed. This led to an international effort to rectify the Blastocystis 
taxonomy and this system will from now on be used in this thesis (Clark, 
Stensvold et al. 2007).   
Blastocystis is an obligatory anaerobic protist (Zierdt 1991) which inhabits the 
human intestines. In addition to humans, Blastocystis can be found in a range of 
different hosts such as pig, rat, and birds (Zierdt 1991). Blastocystis has a large 
geographic spread. The prevalence of this parasite varies from 5-10% in 
developed countries to up to 60% in developing countries. Higher prevalence is 
linked to animal handling or living in close proximity to animals such as at farms.  
There is also a reported  increase in incidence in immuno-compromised patients 
(Tan 2008).  
In addition to the long controversy regarding its classification, the role of 
Blastocystis in disease is still being debated. For over three quarters of a century 
it was believed that Blastocystis was a harmless commensal yeast which was 
confused with Entamoeba histolytica, the causative agent of amoebiasis (Zierdt 
1983). This is mainly due to the fact that Blastocystis is found in both symptomatic 
as well as in asymptomatic cases. In addition, when present in symptomatic 
cases, Blastocystis is always accompanied by other organisms that might also 
be blamed for causing the symptoms. It was always considered as a gut 
commensal parasite, but it has been proven this parasite to be a true pathogen 
(Hussein, Hussein et al. 2008, Tan 2008). 
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1.1.2. Nomenclature  
As mentioned above, Blastocystis has gone through various different 
classifications. The additional naming of isolates based on the host species gave 
the impression of a tight host specificity (Stenzel and Boreham 1996). The 
description of different morphological phenotypes further contributed to the 
confusion and these phenotypes were thought to be related to the different hosts 
the organism was found in. Developments in sequencing techniques indicated 
that Blastocystis does not show any host specificity. In addition, many 
discrepancies were noticed in the literature regarding Blastocystis and some of 
these seem attributable to different protocols or equipment used to identify 
species types and variations (Carbajal, DelCastillo et al. 1997). There was an 
obvious need for standardization of Blastocystis research to avoid a continued 
confusion in the literature and an associated inability to assign hosts and or even 
the label ‘pathogen’ to this organism. Based on small subunit ribosomal RNA 
gene analyses of as many isolates as possible, a nomenclature for Blastocystis 
was proposed. A total of 17 genetically different Blastocystis subtypes were 
identified (Clark, Stensvold et al. 2007). 
Nine of these subtypes were found to be associated with humans and might 
therefore potentially be real human pathogens (Clark, van der Giezen et al. 2013). 
No relationship was found between subtypes and host specificity  (Stensvold 
2013). Furthermore, it seems that Blastocystis subtypes can be transmitted 
between humans, between animals and also between animals and humans. So, 
after over a century of confusion, a consensus nomenclature was established for 
Blastocystis. It was decided to collapse the expanded naming for the various 
supposedly host-specific names and to call all isolates Blastocystis sp. together 
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with its subtype number which currently ranges from 1-17 (Clark, Stensvold et al. 
2007). 
1.1.3. Structure of morphological forms and proposed functions 
Although Blastocystis sp. belongs to the stramenopiles, which is a large and 
heterogeneous group, it is nonetheless considered as an atypical member of this 
group. Despite the heterogeneous nature of the stramenopiles overall, there are 
common features that the members of this group share. For example, tripartite 
tubular hairs on the cell surface is considered a standard stramenopile feature. A 
long interior flagellum is also considered standard. However, Blastocystis sp. 
contains neither. They do however contain mitochondria with tubular cristae. 
Blastocystis generally has a spherical cell shape, though irregular shapes are 
reported as well. It can have a large central vacuole which leaves a very thin layer 
of cytoplasm squeezed near the outside of the cell. Blastocystis cell has a 
carbohydrate surface coat with a variety of carbohydrates (Tan 2008) and is 
covered by a bacterial layer in most of reported cases (Dunn, Boreham et al. 
1989, Lanuza, Carbajal et al. 1996). The presence of this layer of bacteria has 
been suggested to provide a nutritional role or to be important for survival (Tan 
2008). As Tan study pointed out to the fact that Blastocystis surface coat thins 
out during laboratory cultivation, while it is at its thickest once freshly isolated 
from faeces. This was thought to be due to the coat role of capturing bacteria for 
nutritional purposes, which is not necessary during laboratory cultivation with 
nutritious media provided. Several nuclei have been reported (up to four), and 
those were always localized at one end of the cell along with other organelles 
(Dunn, Boreham et al. 1989). As mentioned, Blastocystis has several 
morphological forms which confused proper taxonomic classification but also 
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diagnosis in a clinical setting and often it has been misdiagnosed with other 
organisms such as Entamoeba histolytica. This might possibly explain the very 
high reported prevalence of Blastocystis (Zierdt 1983). Blastocystis diagnosis is 
traditionally based on direct examination using the light microscope of wet mount 
faeces culture and in vitro cultivation. More recently, polymerase chain reaction 
(PCR) is being used. Studies using scanning and transmission electron 
microscopy helped revealing the several forms of Blastocystis. The main four 
forms reported are the vacuolar, granular, amoeboid and cyst form (Zierdt 1991, 
Stenzel and Boreham 1996), (see Figure 1.1.) No specific role has been assigned 
for each form, but several studies proposed a reproductive (Zierdt 1988, Dunn, 
Boreham et al. 1989, Zierdt 1991) and metabolic (Dunn, Boreham et al. 1989, 
Stenzel and Boreham 1996) role of the vacuole in the vacuolar and the granular 
form. In the Dunn et al. study about ultrastructural variation in Blastocystis cell 
types, they showed the presence of cytoplasmic budding towards the central 
vacuole, and also showed budding from the vacuole towards the cytoplasm. They 
hypothesized that this might reflect a system of nutrient transport and expelling 
waste products or a means of storing. All of these would indicate a metabolic role 
of the vacuole but none have been proven yet. The same study also posited that 
the vacuole might also play a reproductive role similar to the schizogony 
proposed by (Zierdt 1991). However, only binary fission seen in electron and light 
microscopy was put forward as supporting this notion (Dunn, Boreham et al. 
1989). 
The central body, previously called the vacuole, occupies a large fraction of the 
whole cell volume, ranging from 50-90% of the total cell. As mentioned earlier, in 
the most extreme cases, this leaves a thin rim of cytoplasm and a large central 
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vacuole (Dunn, Boreham et al. 1989). Another form is the granular form which 
gets its granulated appearance due to the high concentration of mitochondria in 
the cytoplasm. In a study that tried to identify a possible link between the 
vacuolated and the granular form, it was found that the central vacuole arises 
from the coalescing of small granules which, over time, form the large central 
vacuole. This suggests that perhaps those morphological forms are sequential 
stages of cell degeneration where the central body presents the degenerative 
form of the parasite (Vdovenko 2000).  The cystic form is another morphology 
that can be observed for Blastocystis., Zierdt considered that there was no cyst 
form for Blastocystis (Zierdt 1991), However, Blastocystis does have a form that 
is resistant to the environment. This is considered the infectious form that is 
transmitted through the faecal–oral route and causing infection (Mehlhorn 1988). 
Subsequent ultrastructural studies showed both a thick and thin cyst wall (Dunn, 
Boreham et al. 1989) and a large glycogen content which is assumed to play a 
role in energy storage during the encystations stage (Zaman, Howe et al. 1995). 
There are also multi–vacuolar and amoebic forms of Blastocystis which are 
proposed to develop from the vacuolar form through extrusion of the outer 
membrane (Zierdt, Donnolley et al. 1988, Clark, van der Giezen et al. 2013). It 
was originally presumed that these different shapes were artefacts due to several 
environmental factors or due to crowding of cells in the culture (Dunn, Boreham 
et al. 1989, Tan, Howe et al. 2001). However, the amoeboid form is also reported 
in symptomatic cases in diarrheal fluid. It is less often, or not at all, seen in in vitro 
cultures where it is thought to revert to the vacuolar form. The amoeboid form is 
often mistaken for leukocytes. However, a way to distinguish between leukocytes 
and Blastocystis is to use the Gram stain as the former will stain but the latter will 
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lyse (Zierdt 1991). A study by Dunn et al investigating the ultrastructural variation 
between Blastocystis stages reported that the amoeboid and vacuolar forms are 
phagocytic. They also showed that amoeboid buds contain lysosomes, lipid 
droplets and degraded bacteria. This might suggest that Blastocystis pseudopods 
have a role in bacterial phagocytosis  (Dunn, Boreham et al. 1989). A recent 
microscopic study studied living Blastocystis in their natural microbial 
environment (Nagel, Gray et al. 2015).  
 
 
Figure 1.1 Morphological forms of Blastocystis sp. subtype 4 by phase-contrast microscopy. 
Vacuolar (V), multi-vacuolaar (MV), granular (G) form with distinct granular inclusions within the 
central vacuole, Amoeboid forms occasionally seen in culture showing pseudo-pod-like cytoplasmic 
extensions, and Cyst form. Bar, 10 m.  Credits to (Tan 2008) in this figure. 
 
All previously discussed microscopic observations were based on dead/fixed 
cells However, no differences were found between the forms apart from the 
observation that binary fission occurs in both vacuolar and granular forms (Nagel, 
Gray et al. 2015). The role of the granules in the granular and vacuolar form was 
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investigated and it was proposed to have metabolic or reproductive function 
(Zierdt 1991). The fluorescent DNA-specific dye (DAPI)  only gave a strong signal 
for the nucleus and less so for the mitochondria but no staining was found in the 
granules or the vacuole, negating the proposed reproductive roles of the vacuole 
or the granules within it (Stenzel and Boreham 1996). The vacuolar form is most 
common in both culture and stool, while the granular form can only be seen in 
culture when the serum concentration is high. It is rarely seen in stool samples 
(Dunn, Boreham et al. 1989). The amoeboid form is most often found in faeces 
and in symptomatic patients with diarrhoea (Stenzel and Boreham 1996, Tan and 
Suresh 2006, Casero, Mongi et al. 2015). Few studies have suggested that the 
amoeboid form could be a result of microbial imbalance in the gut and actually 
not as a cause of it. Katsarou et al suggested that Blastocystis upsets gut 
homeostatis in their case study of a Caucasian male who reported with acute 
urticaria. The amoeboid form made 7% only of Blastocystis cells reported 
(Katsarou-Katsari, Vassalos et al. 2008). While in Tan et al a percentage of 2% 
amoeboid form of Blastocystis ST2 and ST4 to 13.7% of ST1 Blastocystis in the 
amoeboid form was noticed.  A peak of 28% was seen in day 3-6 of cultivation of 
ST1, declining after that (Tan and Suresh 2006). On the other hand, those 
amoeboid forms were found in ST3 of symptomatic patients, or asymptomatic 
who developed symptoms later (Vassalos, Spanakos et al. 2010). The correlation 
between the presence of the amoeboid forms and symptomatic patients was 
negated by Souppart et al, who reported asymptomatic cases with amoeboid 
forms Souppart, Sanciu et al. (2009). It has also been suggested that the central 
vacuole might play a role as a reservoir of cysteine proteases in Blastocystis 
(Puthia, Lu et al. 2008). 
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Several others less common morphological forms have also been reported which 
adds to the difficulties in diagnosis solely based on basic light microscopic 
methods. Some of these less common forms were multi–vacuolar, rod shaped, 
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1.1.4. Epidemiology and prevalence  
Due to its high prevalence Blastocystis has been considered by the World Health 
Organization (WHO) as one of the main causes for diarrhoea in both developed 
and developing countries. The highest prevalence was reported in developing 
countries due to poor hygienic conditions and the fact that it is a water-borne 
disease. In the developing countries the prevalence of Blastocystis was reported 
to fall between 0.4 -18% compared to Dientamoeba fragilis which was 0.4-6.3% 
(Fletcher, Stark et al. 2012). This clearly shows the high impact this parasite 
exerts on public health systems. We should also not forget the effects on 
domestic animals as well. Anecdotal evidence suggests that everyone has 
Blastocystis in their gut (Zierdt 1983). However, this is likely an exaggeration, yet 
it does reflect the very high occurrences of this parasite which was reported many 
decades ago. Casero et al study including 270 patients showed that 24% of them 
were Blastocystis positive. The population was picked from Cordoba city in 
Argentina, and the study revealed the high percentage of this parasite in adults 
in comparison to the number in children. Urticaria was more prevalent in 
symptomatic adults (56%) compared with to asymptomatic children (33%). 
Gastrointestinal symptoms tended to be higher in children (67%) than in adults 
(Casero, Mongi et al. 2015). Another study was carried out on Philippino children 
in a group of residential, street community where a poor sanitation and water 
quality was reported. In this study a significant number of children were positive 
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for Blastocystis reaching up to 40% of the study group (Baldo, Belizario et al. 
2004) . 
1.1.5. Genetic diversity and specific correlation with the host  
There has been a surprising amount of confusion and uncertainly linked to 
Blastocystis. There have been issues regarding its classification, its 
pathogenicity, and its morphology. As mentioned earlier, several studies have 
reported the diverse cell-types of Blastocystis. The literature until the late 1990s 
assumed these differences were due to adaptation to the metabolic status of the 
host cell. This morphological adaptability was apparently such, that the parasite 
was able to display these even in in vitro culture (Dunn, Boreham et al. 1989). 
Several studies using different Blastocystis stocks have found morphological 
differences between these cultures. Surprisingly, this variation was maintained 
even after laboratory culture. This would indicate that differences in metabolic 
status of the host cannot be the sole reason that explains the morphological 
flexibility. As discussed earlier, another source of confusion was the supposed 
host specificity of Blastocystis. This problem was clearly resolved with the 
development of sequencing approaches to distinguish between isolates. This 
also made the huge genetic diversity within Blastocystis apparent. A still 
outstanding question is whether Blastocystis is a primary pathogen and whether 
this ability is strain specific. A study which included only one patient reported a 
case of mixed inter and intra infection of Blastocystis STs in the same individual. 
They identified ST3, ST4 and ST2 respectively, and in each identified subtype 
several clones were also reported by PCR using STs specific primers. The mainly 
identified subtype was ST3 making 76% of the three subtypes found (Meloni, 
Poirier et al. 2012). This study showed that ST3 clones exhibited a large intra ST 
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variation due to (89-100%) variation in the identity of ST3, while ST4 on the other 
hand showed a higher degree of homogeneity (Meloni, Poirier et al. 2012). Due 
to the limited scope of this study (only based on one patient), these results can 
hardly be called conclusive and much larger cohort studies are required to shed 
light on the pathogenicity of Blastocystis.  
A study by Yoshikawa et al performed on patients of a major hospital in north 
eastern Thailand, showed that the most prevalent form is ST3 followed by ST1 
then ST6 and ST7 were less available and considered minor in this group of 
search, knowing that they are considered more avian subtype (Jantermtor, 
Pinlaor et al. 2013). Several studies have been done and most consider subtype 
3 as the type most often associated with humans. For example, the Casero et al 
study on the population of Cordoba in Argentina found a prevalence of 71.6% for 
ST3, followed by 14.9% for ST1, 7.5% for ST6  and 5.9% for ST2 (Casero, Mongi 
et al. 2015).  
 
 
1.1.6. Mode of transmission, people with high risk and clinical symptoms 
As with many other parasitic infections, more incidents with Blastocystis are 
recorded within the vulnerable population, including immune-compromised 
patients, patients with cancer and children. There is an increased risk of being 
infected in low hygiene situations, when lacking hygienic habits and for people in 
contact with animals such as on farms (Wawrzyniak, Poirier et al. 2013).  
For decades it has been reported that Blastocystis is clinically associated with 
symptoms related to the gastro-intestinal tract. Nausea, vomiting, abdominal 
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pain, constipation, diarrhoea, urticaria, flatulence and irritable bowel syndrome 
(IBS) have been linked to Blastocystis (Kaya, Cetin et al. 2007, Casero, Mongi et 
al. 2015) . Although another case-controlled study performed in Denmark on an 
adult population from internet-based research institute, have ruled out the role of 
the suspect (Blastocystis and Dientamoeba fragilis) in IBS. This study has found 
that a greater proportion of control than patients carried the parasites 
(Krogsgaard, Engsbro et al. 2015). There have also been reports that Blastocystis 
is related with cases of acute and chronic gastroenteritis (Kaya, Cetin et al. 2007). 
Most importantly, Blastocystis has often been considered as an important 
candidate as a causative agent for irritable bowel syndrome (IBS). IBS is a 
functional gastrointestinal disorder with changes in bowel habits, and abdominal 
pain. Several studies on IBS have reported infection with Blastocystis ST2. 
However, Blastocystis is not the only organism that has been put forward as 
possible causative agent for IBS (Krogsgaard, Engsbro et al. 2015). In order to 
be able to prove a role for Blastocystis in IBS, studies have to link the concomitant 
eradication of the parasite with the relief of IBS symptoms. 
In addition to gastrointestinal symptoms, Blastocystis has also been linked to 
cutaneous symptoms (Wawrzyniak, Poirier et al. 2013, Casero, Mongi et al. 
2015). Urticaria has been reported in a case of Caucasian male reported with 
itchy wheals over his body and extremities. After the failure of the treatment with 
antihistamines, and having normal blood tests, the stool was examined and he 
was diagnosed with Blastocystis ST3 and specifically the amoeboid form was 
found in 7% of the total Blastocystis morphological manifestations (Katsarou-
Katsari, Vassalos et al. 2008). The urticaria was limited after treating the patient 
with metronidazole for 10 days and discontinuing the antihistamines. It was 
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suggested that the amoeboid form adheres to the intestinal epithelia and causes 
an inflammatory response in the host which results in the urticaria (Valsecchi, 
Leghissa et al. 2004). 
1.1.7. Insight into Blastocystis pathogenesis  
Clinical studies have correlated Blastocystis with intestinal inflammation and with 
modulating the immune response. Blastocystis has also been considered as an 
opportunistic parasite as it was reported in AIDS cases, cancer and 
immunocompromised patients, where those patients were diagnosed with 
Blastocystis associated diarrhoea (Tan, Ong et al. 2009). However, the molecular 
mechanisms by which this parasite is supposed to cause inflammation are not 
clear and there is no clarity about possible virulence factors expressed of this 
organism. Although pathogenicity is not yet well elucidated in Blastocystis, 
several studies have reported a correlation between certain subtypes and 
symptoms, mainly Blastocystis ST3 and ST4 in Europe (Clark, van der Giezen et 
al. 2013), and ST1 in Asia and the Middle East. Hussein et al studied the effect 
of Egyptian Blastocystis isolates and their effect on rats where they observed a 
role in pathogenesis for subtype 1, while they did not find relation between 
symptoms and infection with ST2. Subtype 3 and 4 both manifested in 
symptomatic and asymptomatic cases in this study (Hussein, Hussein et al. 
2008). It is therefore more likely that variations in clinical manifestation are  due 
to genetic diversity and geographic distribution (Clark, van der Giezen et al. 
2013).  
Several studies have been conducted to investigate the pathology of this parasite. 
Most commonly studied were cysteine proteases which play various roles in cells, 
ranging from cell size regulation to pathogenicity. Other studies have shown that 
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proteases play important roles in protozoan virulence with a clear difference 
between pathogenic and non-pathogenic infection in, for example, Entamoeba 
histolytica. Here, it was found that some of the serine proteases that are linked 
with pathogenicity are more abundant in pathogenic strains than in the non-
pathogenic Rahman strain of E. histolytica (Davis, Schulze et al. 2007). These 
proteases also played a role in inducing the pro-inflammatory cytokines of the 
host cells.  Blastocystis cysteine protease have been found to cause degradation 
of human secretory Ig A (Puthia, Vaithilingam et al. 2005) and an ability of 
inducing the interleukin IL-8 response in colonic epithelial cells (Puthia, Lu et al. 
2008). It was found that there is a correlation between cell size, generation time 
and cysteine protease levels in Blastocystis (Mirza and Tan 2009). In this study 
they compared Blastocystis in avian (subtype 7) and rodent (subtype 4) strains in 
terms of cell size, generation times and cysteine protease levels. An increased 
level of cysteine protease activity was associated with increased cell size (Mirza 
and Tan 2009). However, clinical observations indicated that the rodent 
Blastocystis strain was symptomatic while the avian strains were asymptomatic. 
It was suggested that this might be due to intra-variations between similar 
subtypes isolated, they suggested that more work would be required to 
investigate a possible qualitative difference between cysteine protease activity 
(Mirza and Tan 2009). Blastocystis infections have been linked with certain 
vulnerable groups. In one study, it was reported in cancer patients that 7.7% of 
the sample group (24 patients) were infected with Blastocystis. However, a total 
of 49 (19.8%) of HIV/AIDS patients were co-infected with Blastocystis. In this 
study, subtype 3 was the most prevalent subtype followed by subtype 4 and 1. 
None of the subtypes 5-7 were found (Tan, Ong et al. 2009). Nonetheless, a 
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conclusion regarding Blastocystis pathogenicity is still inconclusive and 
controversial. To clearly demonstrate that this is linked to certain subtypes is 
dependent on more diagnosis which should be based on both clear clinical 
diagnosis linked to molecular sub–typing (Tan, Singh et al. 2002, Clark, van der 
Giezen et al. 2013) 
1.1.8. Linkage with irritable bowel syndrome (IBS) 
In recent years, epidemiological studies have highlighted a high prevalence of 
Blastocystis cases in patients with IBS compared to healthy individuals or patients 
with gastrointestinal disorders. IBS is a functional gastrointestinal disorder with 
symptoms showing as abdominal pain and changes in bowel habits (constipation, 
diarrhoea or both). The prevalence of this disease (IBS) is 5 to 24% in industrial 
countries (Poirier, Wawrzyniak et al. 2012). Diagnosis of IBS is performed based 
on clinical criteria (symptom-based diagnosis) based on what is called the Rome 
III criteria; the recurrence of abdominal symptoms for at least three days per 
month for the last three months associated with at least two of the following: 
improvement with defecation, commencement associated with change of 
frequency of defecation, and commencement related with change of stool 
appearance (Bellini, Gambaccini et al. 2015). Several factors have been 
investigated in an attempt to understand the disease pathology. A bacterial 
imbalance was reported and thought to play a role in this disease due to the 
change of gas and metabolite production such as short chain fatty acids. These 
fatty acids play a role in gas production and the increase of this production might 
be the cause of bloating; the most predominant symptom of IBS Intestinal 
pathogens such as Giardia intestinalis and Entamoeba histolytica were found to 
disrupt the intestinal mucosal integrity by using proteinases which were found to 
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induce the immune response in host cells (Buret 2007). Such proteases were 
also used as an explanation of Blastocystis pathogenicity in several studies as 
previously discussed in 1.1.7 paragraph of insights into Blastocystis 
pathogenesis.  
 Studies regarding potential causative mechanisms were focusing on 
modifications in the microbiota environment, postulating that the gastrointestinal 
movement and dysbiosis of the gastrointestinal microbiota might be the causative 
factor. Recently, it was noted that there is a co-occurrence of IBS cases with 
Blastocystis in faecal samples. This might suggest a role of the parasite in the 
pathophysiology of IBS. However, presence of these parasites will manifest in 
symptoms close to IBS symptoms and this might mislead an IBS diagnosis with 
a parasitic infection. Other studies had indeed disproved this role. A retrospective 
study on IBS patients in Denmark (Where the IBS prevalence is 16% compared 
to 11% globally) has revealed that more cases of infection with Blastocystis and 
Dientamoeba fragilis were reported in control cases of symptomatic patients 
compared to IBS patients (identified with Rome III criteria), negating the proposed 
role of parasites in causing the disease (Krogsgaard, Engsbro et al. 2015). 
However, this study has several limitations. Firstly, a lack of clinical evaluation, 
and thus possibility of miss-diagnosis. Secondly, only men and people of old age 
provided stool samples resulting in a possible gender or age bias. Finally, 
information whether patients were on metronidazole and/or antibiotic treatment 
was lacking. Usage of these medications would reduce chances of observing 
possibly causative microbes. Another study has found linkage between IBS 
symptoms and Blastocystis incidence to be significant in men only, with a 
prevalence of Blastocystis in IBS patients of 36.8% of the study population 
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(Nourrisson, Scanzi et al. 2014). The same study also observed that Blastocystis 
affects the natural intestinal bacteria community. They found a significant 
decrease in Bifidobacterium sp. in patients infected with Blastocystis. 
However, considering the wide range of genetic subtypes that Blastocystis has, 
in addition to its wide geographical distribution, it will be hard to blame 
Blastocystis for being the causing agent of IBS. As Clark et al concluded in their 
recent review about the developments in Blastocystis research (Clark, van der 
Giezen et al. 2013), more studies need to be performed that include molecular 
sub-typing of IBS samples in addition to the clinical diagnosis. These studies will 
have to be performed in different parts of the world as well in order to be able to 
rule out or condemn certain Blastocystis subtypes of being pathogens or not 
(Poirier, Wawrzyniak et al. 2012). 
 
1.1.9. Treatment  
Zierdt had reported the use of metronidazole in Blastocystosis infections and 
suggested that treatment failure was caused by the inadequacy of the dose used 
in these cases. He has also examined other drugs in terms of their efficacy and 
discussed the benefits of using the following in terms of importance from higher 
to less effective: emitine, metronidazole, furazolidone, trimethoprime-
sulfamethoxazole (Zierdt 1983). Metronidazole is found to induce programmed 
cell death, while keeping the plasma membrane integrity. This will in turn keep 
the parasite’s internal proteases in the cell and not released to the host. (Puthia, 
Lu et al. 2008).  
    
 
39 
 
In addition to its efficacy, metronidazole is the drug of choice due to its low cost 
and general availability. Yet, despite its efficacy, metronidazole also showed 
cases of resistance or failure of treatment. This might be due to several factors. 
One of the main factors that might play a role in drug resistance is the fact of the 
known high genetic diversity within Blastocystis sub types. Even within the same 
subtype genetic diversity can vary to up to 5% in most of the cases (Clark, van 
der Giezen et al. 2013). 
Antimicrobial eradication has also showed to be effective as well in Blastocystis 
eradication. This might be due to the fact that the microbial flora is essential for 
Blastocystis survival. Others suggest that the responsiveness or the clearance of 
symptoms after treatment with either metronidazole of cotrimoxazole 
(trimethoprim-sulfamethoxazole) could be due to the clearance of other co-
infectors rather than Blastocystis (Coyle, Varughese et al. 2012). In another case, 
paromomicine was successfully used for 10 days in urticaria case for a patient 
who proved positive for Blastocystis. Pruritis decreased a week after end of 
paromomicine therapy, two months later stool samples were negative of 
Blastocystis. Allergy or other causes were ruled out by blood tests (Valsecchi, 
Leghissa et al. 2004). It is obvious that more studies have to be performed to 
better understand the role of these drugs and to find a specific cure for 
blastocystosis. 
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1.1.10. Mitochondrial derived organelles 
1.1.10.1. Blastocystis mitochondrial organelle (MLO)  
To add to the paradox and enigma surrounding Blastocystis, this parasite is a 
strict anaerobic organism. However, it does contain several mitochondria in its 
cytoplasm, it is the predominant organelle compared to other organelles in this 
parasite (Zierdt 1991). Blastocystis has mitochondria with cristae and the 
organelles looks similar to those in closely related organisms. However, these 
mitochondria have lost many of their classical features: Blastocystis has no 
cytochromes (Zierdt 1986), it lost the activities of typical mitochondrial enzymes 
such as the pyruvate dehydrogenase complex, the ketoglutarate dehydrogenase 
complex, isocitrate dehydrogenase, glutamate dehydrogenase, and cytochromes 
c oxidase (Zierdt 1991). According to Zierdt, it is unlikely that these ‘crippled’ 
mitochondria are non-functional organelles. In his 1991 paper he presumed that 
a non–functional organelle would not be maintained by an organism. In addition, 
they stain brightly with active dyes that indicate the presence of a physiologically 
active organelle. They take the typical rosette shape. Their numbers also seem 
to be regulated as there is a  varied number of mitochondria present in the 
different cell forms, ranging from 2-4 in the vacuolated form and increasing in 
numbers in the rapidly growing forms during log growth phase, while they might 
reach hundreds in the granular form (Zierdt 1991).    
The Blastocystis mitochondrial genome is highly reduced compared to other 
members of stramenopiles. This might be due to the transfer of mitochondrial 
genome to the nucleus preceded by a loss of the loss of unnecessary genes in 
the mitochondria (Clark, Perez-Brocal et al. 2010). It is clear that Blastocystis has 
an uncommon mitochondrial like organelle (MLO) that sits somewhere in 
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between classic mitochondria and hydrogenosomes. This MLO contains a 
classical a hydrogenosomal enzyme (hydrogenase), yet it is not demonstrated 
that it actually does produce molecular hydrogen (Stechmann, Hamblin et al. 
2008). 
1.2. Glycolysis 
The central carbon metabolism contains glycolytic and pentose phosphate 
pathways. Glycolysis is the most common and conservative pathway in 
eukaryotes, widely conserved in prokaryotes as well. Glycolysis is the 
biochemical pathway by which glucose is converted to pyruvate with the 
generation of 2 mole of ATP/ mole of glucose, providing part of the energy utilized 
by most cells (Stryer 1995). 
Glycolysis is a defined sequence of ten enzyme-catalysed reactions. The 
intermediates of these reactions are considered as entry points to glycolysis, and 
hence many mono-saccharides such as fructose can be converted to one of 
those intermediates.  
Glycolysis is oxygen independent process, though the molecular oxygen might 
be used to dispose some intermediates, such as NADH, pyruvate and H+ forming 
what is called aerobic glycolysis, while otherwise called anaerobic glycolysis. This 
process is widely abundant in both eukaryotes and prokaryotes, indicating how 
ancient it is. Usually this process takes place in the cytosol. The most common 
type is Embden-Myerehof-Parnas. This pathway is divided into two steps; the 
preparatory phase where energy is consumed, and hence called the investments 
phase, and the payoff phase where energy is produced. 
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The preparatory phase starts by the conversion of glucose into glucose-6-
phosphate (G6P) by the help of hexokinase enzyme and the consumption of one 
ATP molecule. G6P will be rearranged into fructose-6-phosphate (F6P) by 
phosphohexose isomerase. This in turn will be phosphorylated by 
phosphofructokinase 1 (F1,6BP) into fructose 1,6 bisphosphate (F1,6BP) with the 
consumption of another energy molecule ATP.  And the last step in the 
preparatory phase involves the breakdown of the (F1,6BP), a six carbon 
molecule, into two 3-carbon units i.e. glyceraldehydes-3-phosphate (GAP), and 
dihydroxyacetone phosphate (DHAP), which both can interconvert to each other 
by the help of triosephosphate isomerase (TPI). This step is the fourth step in 
glycolysis and last step in the preparatory phase which ended by consuming two 
ATP molecules in total. 
The second half of glycolysis is composed of six steps. It starts by the 
dehydrogenation of GADP into 1,3 bisphosphoglycerate (1,3 BPG), using two 
inorganic phosphate molecules and producing two molecules of NADH and H+,  
performed by the enzyme glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH). 
1,3BPG is then dephosphrelated by phosphoglycerate kinase into 3-
phosphoglycerate (3PG) and producing two molecules of ATP. 3PG is then 
isomerized into 2-phosphoglycerate (2PG) by phosphoglycerate mutase in a 
reversible reaction. 2PG is enolized by enolase enzyme into 
phosphoenolpyruvate (PEP), losing two molecules of water. And finally PEP is 
dephosphorelated by pyruvate kinase producing two molecules of ATP, a 
diagram representing the whole glycolytic process is shown in Figure 1.2. 
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I have sought in this project to study part of the glycolysis enzymes, namely the 
ones in the payoff phase i.e. enolase, GAPDH and TPI, for complying with the 
project objectives of unravelling unusual features in some of the glycolytic 
enzymes, especially in the payoff phase.   
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Figure 1. 2 Simple representation of the Embden-Mayerhof-Parasan, the complete glycolytic 
pathway. Credits of this picture go to http://biologyguide.net  
 
1.2.1. Enolase (Phosphopyruvate hydratase) 
Enolase (EC number 4.2.1.11), also called phosphopyruvate hydratase, is a 
glycolytic enzyme that participates in the step before the last in glycolysis. It is a 
member of the big enolase family, which consists of two main domains, enolase 
N (which is the N – terminal domain) and enolase C (which is the C terminal 
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domain). It is a metalloenzyme, that catalysis the conversion of 2-
phosphoglycerate (2PG) to phosphoenolpyruvate (PEP). It has also been 
involved in other roles rather than glycolysis only, making it a very good example 
of what is known as a moonlighting protein. Enolase has traditionally been 
considered as an enzyme with no regulatory properties. However, it has been 
suggested in some cases that enolase expression varies according to the cell 
metabolic or developmental conditions. 
1.2.1.1. Enolase structure 
Enolase is a highly conserved protein, for this it is considered as a molecular 
marker as it highly conserved at the sequence level. It is found in eukaryotes and 
prokaryotes. In mammals, enolase has three subunits, i.e. α, β and γ, each 
encoded by a distinct gene, and each has specific localization in the body cells 
(Joseph, Cruz-Sanchez et al. 1996). Enolase is usually active as a dimeric 
protein. And those subunits in mammals, are found to form both homodimers as 
well as heterodimers formed of those three subunits as seen in the mouse 
muscle-specific β-enolase (Merkulova, Lucas et al. 1997). Those are tissue 
specific. In other organisms, enolase is usually found as a dimer (Huther, Psarros 
et al. 1990), except in some bacterial cases reported to be found as an octamer 
protein which was reported in hyper thermophilic bacterium Thermotoga maritime 
(Schurig, Rutkat et al. 1995).  
Enolase is a metalloprotein, that it needs a metal molecule for its activity, (i.e. 
Mg2+ Zn2+ and Mn2+). Those divalent metal ions can on the other hand have 
inhibitory effect if used over certain concentration (Schreier and Hocker 2010). 
Enolase activity requires two Mg2+ in general. The first divalent metal ion is 
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required for the correct conformation of the active site, while the other one will 
interact directly with the substrate PGA.  
Enolase is a very highly conserved protein, and shares a large identity between 
species in general. The most conserved regions are the ones involved in metal 
binding, substrate binding, and catalysis activation sites. 
The most important residues for enolase activity in general are His 172, Glu 224, 
Lys 358, His 386, Arg 387, Ser 388 (in our study) which are the essential five 
active sites catalytic residues. 
Being a member of the enolase family, it shares enolase family motif. The enolase 
family motif takes the following sequence (SHRSGETED) usually located at the 
C-terminal of the protein sequence. It also posses another conserved region 
called enolase signature which shares the following sequence 
(LLLKVNQIGSVTES).  
Other conserved regions, but not found in all organisms, is the plasminogen 
binding site, which follows the (TYDENKKQY) sequence. It was found that some 
enolases has the property of plasminogen binding which helps as a virulence 
factor in some organisms as seen in Clonorchis sinensis enolase (Wang, Chen 
et al. 2011).  This plasminogen binding capacity was found to be correlated to 
fibrinolytic activity which helps in host-tissue invasion (Sun 2006). 
1.2.1.2. Enolase function and moon lighting  
Enolase is a glycolytic protein that plays an important role in the payoff phase of 
glycolysis. It catalysis the conversion of 2-phosphoglycerat into 
phosphoenolpyruvate. In addition to its role in energy conversion and glucose 
metabolism, enolase was found to play several other roles, changing the 
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traditional assumption about enolase being a house keeping enzyme, it is now a 
widely known multifunctional enzyme, making a very good example of a 
phenomenon called protein moonlighting. Those proteins were found to possess 
non-enzymatic activity in both prokaryotes and eukaryotes, an example of those 
proteins is aldolase which was found to have actin-binding ability, this in turn 
plays a role facilitating the parasite to glide across surfaces, and penetrate the 
host tissues by forming a kind of a bridge between certain protein and the 
skeleton, enabling the parasite for its gliding across the membrane (Collingridge, 
Brown et al. 2010). Enolase was found to be a very good example of a multi-
functional protein. It plays a role as a plasminogen binding property as reported 
in mouse muscle-enolase and Schistosoma japonicum enolase (Merkulova, 
Lucas et al. 1997, Yang, Qiu et al. 2010). In human brain enolase was found to 
play a role in tumour cell’s growth. Being over-expressed in many tumour cells, 
suggests that this might enhance aerobic glycolysis of cancer cells, and thus 
enhancing the disease malignancy (Liu 2007).  
Other un-defined and possible functions that enolase might do was suggested by 
(Takishita, Patron et al. 2005). They referred to the event of enolase forming a 
fusion protein with GAPDH. This was suggested to play a role different from 
glycolysis-gluconeogenesis, basically because another version of those proteins 
(enolase and GAPDH) was localized to the cytosol as a standalone version. 
1.2.2. Glyceraldehyde-3-phosphatedehydrogenase (GAPDH) 
The glycolytic protein glyceraldehyde-3-phosphate dehydrogenase (EC 
1.2.1.12.) (GAPDH) is an enzyme in the glycolytic pathway that catalyses the 
oxidative phosphorylation of glyceraldehyde-3-phosphate (G3P) to form 1,3-
bisphosphoglycerate. This reaction happens in two steps; the first one we find 
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that the active site cysteine residue attaches to G3P forming thiohemiacetal 
intermediate, which transfers a hydrid ion to NAD forming thioacyl enzyme. The 
second step includes the phosphorylation of the resulting thioester and forming 
the end product. This happens via a nucleophilic attack of an inorganic phosphate 
ion on the carbonyl atom of the thiacyl group, leading to the formation of 1,3 –
bisphosphoglycerate. 
 
1.2.2.1. GAPDH structure 
GAPDH protein in general contains 340 amino acids in its polypeptide chain. It is 
usually found as homo tetramer, composed of four identical subunits, to form the 
active protein. It makes about 150 kDa, with each subunit making almost 37 kDa. 
The active protein has four active sites, binding four NAD+ in each active site of 
the four subunits (Sirover 1999). A common feature between GAPDHs structures 
is that it has two main regions; NAD+ binding domain and the catalytic domain. 
The catalytic domain binds the substrate glycerol-3-phosphate and is usually 
found at the N-terminal region of the protein. While the NAD+ binding domain 
(also contains Rossmann fold) is located at the C-terminal region. There are two 
critical residues in GAPDH structure for its glycolytic function; cysteine and 
histidine which are usually found at 149, and 176 respectively, in addition to its 
tetrameric structure (Sirover 1999, Colell A 2009). 
The NAD+ binding domain consists of beta sheets connected by alpha helices. 
This region, NAD+ binding region, (contains Rossmann fold, also called βαβ fold) 
is not only important for its role in GAPDH activity, it also important for other 
dehydrogenases activity. Rossmann fold is probably playing an important role in 
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other functions of GAPDHs than the glycolytic role such as its RNA and 
glutathione binding ability which was located within the N-terminal region of 
GAPDHs (Sirover 1999).  
The catalytic region is composed of antiparallel beta sheets and parallel helices. 
GAPDH active site has a conserved cysteine residue corresponding to Cys139 
in Sulfolobus solfataricus (Isupov, Fleming et al. 1999), Cys141 in Thermococcus 
kodakarensis (Jia, Linh le et al. 2011), and Cys152 in humans has a conserved 
His179 residue and a conserved hydrogen bond with Cys 149 
GAPDH is a very abundant protein in the cell making about 10-20% of the total 
cell content and a highly conserved protein in the tree of life (Sirover 1999). This 
protein occurs universally through Bacteria, Eukaryotes, and Archaea domains 
of life. And although it is highly conserved protein, the archaeal one shares less 
identity with the other life domains, 16-20%, and shows dual cofactor specificity 
for both NAD+ and NADP+ (Littlechild and Isupov 2001), while others have only 
NAD as a cofactor (Isupov, Fleming et al. 1999). A special sequence signature 
was found to predict the binding ability of GAPDH either to NAD+ or NADP+, which 
is the presence of the GXGXXG, replacing glycine by alanine would make the 
protein (GAPDH) bind NADP+ instead of NAD+ (Hanukoglu 2015).  
 
1.2.2.2. Functional diversity of GAPDH 
GAPDH has always been considered as a housekeeping gene used as internal 
marker in when doing DNA, RNA or protein work (Zhang, Zhang et al. 2015). In 
addition to GAPDH role in glycolysis pathway, several studies have proposed 
other function that GAPDH might play than being a solely glycolytic enzyme. It 
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was demonstrated that GAPDH is functioning in diverse other functions as 
transcription, nuclear tRNA export, neuronal apoptosis, DNA replication and 
repair, endocytosis and exocytosis (Sirover 2005, Guo, Liu et al. 2013). 
More evidence now has been found to support the role of glycolytic pathway in 
carcinogenic events, and one of its important components was GAPDH. GAPDH 
was found to be up-regulated in cancer cases as in lung, colorectal and renal 
cancer, which made it a potential marker for cancer progression and invasiveness 
(Guo, Liu et al. 2013). This could be explained by the need of energy supply by 
the cancerous cells which use glucose as their source of survival. So GAPDH 
role in cancer could either be explained by its role in glycolysis or by its role in 
cell cycle events (Guo, Liu et al. 2013). It was found that GAPDH is up-regulated 
in hypoxia, a condition of low oxygen levels, encountered by cancer cells. This 
up-regulation of GAPDH would offer an increase in the aerobic glycolysis, the 
main source of energy for cancerous cells, and hence providing a way for the 
tumour to proliferate (Zhang, Zhang et al. 2015). GAPDH is regulated by several 
cancer related factor such as insulin, nitric oxide (NO), hypoxia and p53, which 
why it is used as a tumour prognosis or progression marker (Zhang, Zhang et al. 
2015). Other studies has proposed that GAPDH is a pro-apoptotic agent, other 
said it is down regulated in cancer helping in controlling the cell death, all of which 
makes the role of GAPDH in tumour cell fate still inconsistent  issue (Colell A 
2009).  
Several theories have been put forward explaining GAPDH protein multi-
functionality. One hypothesized that the protein multi-functionality is attributed to 
different localization in the cell (Sirover 1999). Other related its multi-functionality 
to the post-translational modifications this protein undergoes. Like in the case of 
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being phosphorylated by hypoxia in cancer, making it up-regulated in the cancer 
cases. 
GAPDH was also found to play several other physiological roles in the cells from 
apoptosis to other roles in neurological disease as in cases like huntingtin disease 
(HD) or Alzheimer’s disease, where they found that the protein’s activity is 
reduced in those diseases. In HD the protein is found to be of higher molecular 
weight that is supposed to be due to interactions between GAPDH and huntingtin 
protein (Mazzola and Sirover 2002).  
A study made by Kolln et al showed the decreased activity of this enzyme in the 
cerebrospinal fluid (CSF) where anti GAPDH IgGs were found in high 
concentration in the intrathecal of multiple sclerosis (MS) patients compared to 
other neurological diseases (OND) (Kolln, Zhang et al. 2010).  
1.2.3. Trioephosphate isomerase (TPI) 
Triosephosphate isomerase (EC 5.3.1.1), (TPI), also called D-glyceraldehyde-3- 
phosphate ketol-isomerase, catalyses the fifth reaction of the glycolytic pathway. 
It is an essential enzyme in the energy production of many pathogens. TPI 
catalysis the isomerisation between glycelaldehyde-3-phosphate (G3P) and 
dihydroxyacetone phosphate (DHAP). It is a ubiquitous enzyme, reported in 
eukaryotes, prokaryotes, and seen basically as a homodimer, although cases of 
tetramer were reported in Arachaeal Methanothermus fervidus and Pyrococcus 
woesei TPI where it is suggested that this tetrameric structure is a nature’s 
strategy to stabilize the native protein in extreme temperatures (Kohlhoff, Dahm 
et al. 1996).  
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1.2.3.1. Triosephosphate isoerase structure 
TPI is usually a homodimer protein of two subunits, 27 kDa each subunit, and 
248 amino acids each, TPI spatial structure belongs to the TIM barrel enzyme 
family. This TIM barrel fold is composed of eight β sheets alternate in sequence 
with eight α helices, taking the following pattern (βα)8 (Orosz, Olah et al. 2009). 
Those will form a parallel β sheets closed in a cylindrical topology, Figure 1.3, 
leaving a pocket where the ligand is located in the active form of the enzyme. 
This TIM-barrel is found in several other enzymes with different functions like 
enolase and other enzymes from functionally distinct protein families (Tiwari and 
Reuter 2016). The active site is almost always located at the carboxyl end of the 
barrel (Tiwari and Reuter 2016).   
The active site loop in TPI, loop 6, is essential for the protein activity. This loop 
takes one of two conformations; either open loop when the protein is in 
unliganded (apo enzyme), and closed conformation when the protein is bound to 
its ligand (holo enzyme), see Figure 1.4. The change in conformational position 
of this loop gave it other names such as: the lid loop where it rests on border 
residues that function as hinges. catalytic residues , and also called the flexible 
loop, as it is taking a swung out conformation between the open and closed in 
about 8Å with a concomitant shift of the main catalytic residue by 2Å (Pareek, 
Samanta et al. 2016). Loop 6 is composed of a conserved amino acid sequence 
AYEPVWAIGTGKTA which contains the catalytic base E167 (Jimenez, Vibanco-
Perez et al. 2000). Other active site residues are N10, K12, H94 and E97 are also 
highly conserved (Pareek, Samanta et al. 2016).  And finally the highly conserved 
hexapeptide helical segment GHSERR, which contains a highly conserved serine 
residue.  
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Figure 1. 3 Schematic representation of triosephosphate isomerasse structure, showing the alpha 
helices and beta sheets taking the TIM barrel fold (βα)8. β sheets are referred to as βx, and α helices 
are referred to as Hx, where x is number (1-8). Loops are also referred to in number between1-8. A 
pocket formed in the middle of TIM barrel can also be seen in the representation. The 32 black dots 
indicate the location of the interface residues with the other TPI subunit, credits to (Wierenga, Noble 
et al. 1991).  
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Figure 1. 4 Cartoon representation of the conformational changes of loop 6 in triosephosphate 
isomerase protein when changing between holo and apo enzyme of the protein (close and open 
conformation respectively). Adapted from (Wierenga, Noble et al. 1991). 
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1.2.3.2. Triosephoashate isomerase physiological roles  
In addition to its role in glycolytic pathway, TPI was found to play several 
physiological roles in pathogens. Its main role as a glycolytic pathway, and the 
fact that several pathogens rely on glycolysis as their only source of energy, made 
TPI a highly targeted protein for drug delivery. Several vaccination trials have 
been conducted targeting TPI  and  other  glycolytic enzymes of parasites causing 
tropical disease, such as Trypanosome brucei (Coley, Dodson et al. 2011), the 
causative agent of sleeping sickness, others were to find a vaccine against 
schistosomiasis (Wright, Davern et al. 1991), knowing that glycolysis is their main 
source of energy. 
In addition to finding cure of disease, TPI  deficiency in humans was found to 
cause genetic disease of autosomal recessive disorder developmental 
retardation and manifested by neuromuscular dysfunction, cardiomyopathy and 
haemolytic anaemia, symptoms usually fatal (Orosz, Olah et al. 2006, Orosz, 
Olah et al. 2009). 
Recent studies have found that TPI can play other roles than glycolysis. Recent 
study has demonstrated that surface-exposed TPI of Staphylococcus aureus (for 
example) binds plasminogen and to a less but not negligible degree with 
fibronectin. This was suggested to play a role in host-pathogen interaction, as 
such protein can play a role in adherence and invasiveness (Furuya and Ikeda 
2011). Both TPI and GAPDH were reported in Lactobacillus plantarum to be 
functioning as adhesion, and thus playing an important role in colonization 
(Ramiah, van Reenen et al. 2008). 
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A study performed by Bao, Chen et al has also shown a possible role for TPI in 
cyto-adherence of Mycoplasma gallisepticum to the host cell, where antibodies 
raised against this protein in glass inhibited the cell adherence. This adds to its 
possible role in host-pathogen interaction (Bao, Chen et al. 2015).  
 
1.2.4. Moonlighting proteins pros and cons  
Moonlighting proteins are those protein found to perform two or more function, 
operated by the same poly peptide chain. Gene products that perform more than 
one function could also be referred to as gene sharing, multitasking proteins, or 
moon-lightening. It is a reasonably newly characterised phenomenon, only 
discovered in the late 1980s, when lens crystallins were found to be the same as 
metabolic enzyme (Wistow and Piatigorsky 1987). Several factors can imply an 
enzyme to be multifunctional of not; cell type, cell compartment, ligand 
concentration or protein localization in the cell. More than 280 proteins have now 
been assigned to be moonlighting, and the number is increasing, but it is only 
dependant on total serendipity. It was first noticed that those multitasking proteins 
belong or have tendency to belong to the Intrinsically Disordered Proteins (IDP) 
class but this was negated afterwards as seen that there is no such tendency 
(Hernández 2012).  
Several explanation were attempted to explain this phenomenon in the cells. One 
of which is that it is a way of economizing in the cell, as by this way the cell can 
perform so many functions in a small number of genes (Hernandez, Ferragut et 
al. 2014). That was found in proteins that perform several functions in addition to 
their traditional function as seen in previously mentioned cases of enolase, 
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GAPDH and TPI. Hernandez has also suggested that this phenomenon has kind 
of evolved through evolution where unused spaces became more used offering 
new binding sites. Moonlighting proteins seem to offer new way of virulence, by 
facilitating interaction with the host as reported in Candida albicans. GAPDH was 
found to be benefiting from the fact that it is in the host cytosol which helped in 
severity of invasion (Karkowska-Kuleta and Kozik 2014). In Trichomonas 
vaginalis infection, GAPDH was highly expressed after exposing to iron and is 
up-regulated during growth and multiplication, and it was also found on the 
surface of trichomonads. It is speculated that GAPDH plays a role in the virulence 
of trichomonas, though this work had shown that there might be other surface 
binding proteins that are to be found which  help in the virulence as well  (Lama, 
Kucknoor et al. 2009, Karkowska-Kuleta and Kozik 2014). TPI was also found to 
play a role in pathogenesis of Schistosoma mansoni as it was located on the 
surface membrane of the pathogen larva making it as a target of vaccine 
development.  
Moonlighting phenomenon is relatively new and might be exploited for developing 
drug targets as those proteins new roles might play a role in virulence, hence 
drugs and vaccines might be developed against the pathogen. On the negative 
side, moonlighting phenomenon, has shed doubts on phenotypes predicted for 
gene expressing those proteins. So moonlighting proteins which has been 
considered for long time as housekeeping gene should now be taken with 
scepticism. 
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1.2.5. Aim of the project  
Blastocystis is a wide spread parasite in both developed and developing 
countries. Understanding this parasite would have an economic impact globally 
by minimizing number of cases seeking medical help, as will help developing 
drugs against this parasite. Little is known about this parasite’s metabolism and 
bioinformatic analysis had shown special features in Blastocystis glycolysis 
pathway. Therefore, this thesis aims to understand the metabolic glycolysis 
pathway, and specifically three of its enzymes, i.e. enolase, triosephosphate 
isomerase and glycerldehyde 3-phosphate dehydrogenase. Enolase was chosen 
as a model for the project since it is widely studied protein, while the fusion was 
chosen due to its specificity and the fact that it wasn’t approached in details in 
literature before. 
Specific thesis objectives include:  
1) Biochemically characterize enolase, and the fusion protein TPI-GAPDH.  
2) In silico analyses of those enzymes seeking any subtle differences from the 
host’s version of those enzymes, which might help developing drug target. 
3) Solve the structure of the fusion protein TPI-GAPDH, which will be the first 
report to interpret this structure after being mentioned before in work of other 
Stramenopils. 
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Chapter 2.  Materials and methods 
2.1. Materials  
2.1.1. Microbiological work 
2.1.1.1. Bacterial and Protist strains  
Various bacterial and protist species and strains have been used in this study. 
Table 2.1 lists all strains used and made during this study. 
Table 2. 1 List of bacterial and protist strains used in this study. 
Name of Strain Source Experiment 
Escherichia coli strains 
α-select silver efficiency Bioline  All cloning experiments 
BL21 pLysY Bioline Enolase, TPI-GAPDH, PGK, TPI, and GAPDH, 
recombinant gene expression 
Rosetta 2 (DE3) pLysS 
  
Novagen Enolase, TPI-GAPDH, recombinant gene 
expression 
Arctic express Agilent Technologies Enolase, TPI-GAPDH, recombinant gene 
expression 
XL10-goldSuper competent cell Agilent Mutant TPI-GAPDH recombinant gene 
expression   
Blastocystis ST. strains 
ST4, ST8 
 
Dr. Graham Clark, London 
School of Hygiene and 
Tropical Medicine, UK 
All experiments 
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2.1.1.2. Bacterial and protist media and solutions 
Media and solutions used in this study for growth of bacteria and protists and 
chemicals utilized in all experiments are all listed in the following sections.  
Luria-Bertani (LB) broth, 1,000 ml 
o 10 g Bacto-tryptone 
o 5 g Yeast extract 
o 10 g NaCl 
Adjust to 1 L final volume using dH2O and sterilize by autoclaving for 20 minutes 
at 120°C. 
LB agar, 1000 ml  
As for LB broth with addition of 10 g agar. 
SOC medium a super optimal broth (SOB) supplied with added glucose/sucrose 
for catabolite repression, or what is known as the glucose effect) 
o 20 g Tryptone (Melford Ltd) 
o 5 g Yeast extract 
o 0.5 g NaCl 
o 0.186 g KCl 
o 3.6 g Glucose 
o 0.95 g MgCl2 
Adjust to 1L final volume using dH2O and sterilize by autoclaving for 20 minutes 
at 120°C. 
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ZYM-5052, To make 400 ml, add the following: 
o 1% N-Z-amine (tryptone or other casein digest) 
o 0.5%  yeast extract 
Add demineralised water to 380 ml and autoclave. To the autoclaved mixture the 
following sterile stocks are added: 
o 8 ml 50 X M solution 
o 8 ml 50 X 5052 solution 
o 800 µl 1 M MgSO4 (400 µl 2M MgSO4) 
o 80 µl 1000 X metals   
Antibiotics added according to the cells and plasmids used. 
50 X M Solution 
o 25 mM Na2HPO4 
o 25 mM KH2PO4 
o 50 mM NH4Cl   
o 5 mM Na2SO 
50 X 5052 Solution    
0.5% glycerol = 54 mM 
0.05% glucose = 2.8 mM 
0.2% α-lactose = 5.6 mM 
 
1000 X metals, in 100 ml 
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o 36 ml sterile H2O 
o 50 ml  0.1  M FeCl2 in ˷ 0.12 M HCl 
o 2 ml   1 M CaCl2  
o 1 ml   1 M MnCl2-4H2O 
o 1 ml   1 M ZnSO4-7H2O 
o 1 ml   0.2 M CoCl2-6H2O 
o 2 ml   0.1 M CuCl2-2H2O 
o 1 ml   0.2 M NiCl2-6H2O 
o 2 ml   0.1 M Na2MoO4-2H2O 
o 2 ml   0.1 M Na2SeO3-5H2O 
o 2 ml   0.1 M H3BO3 
o 1 ml   0.2 M CoCl2-6H2O 
o 2 ml   0.1 M CuCl2-2H2O 
 
 
NZY + Broth (per Litre) 
o 10 g of NZ amine (casein hydrolysate) 
o 5 g of yeast extract 
o 5 g of NaCl  
Add deionised water to a final volume of 1 litre, adjust to pH 7.5 using NaOH, 
Autoclave. Before use, add the following filter sterilised supplements: 
12.5 ml of 1 M MgCl2  
12.5 ml of 1 M MgSO4  
20 ml of 20% (w/v) glucose (or 10 ml of 2 M glucose) 
12.5 ml of 1 M MgCl2  
Ampicillin (100 mg/ml) 
Ampicillin powder (Sigma-Aldrich) was dissolved in deionised water, filter 
sterilised through a 0.2 µm filter, and stored at - 20°C. The final working 
concentration is 100 µg/ml. 
 
 
Tetracycline hydrochloride (5 mg/ml)  
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Tetracycline hydrochloride salt was dissolved in ethanol and used in a final 
working concentration of 50 µg/ml. 
X-Gal (20 mg/ml) 
X-Gal was dissolved in dimethylformamide and used at a final concentration of 
80 μg/ml and stored at - 20°C. 
Isopropyl-beta-D-thioglactopyranoside (IPTG), 1 M stock solution 
IPTG was dissolved in deionised water, filter sterilised through a 0.2 µm filter and 
stored at - 20°C. 
 
2.1.1.3. Protist media and solutions 
Blastocystis was the only protist used in this project, and this parasite could be 
grown xenically and axenically. Most often Blastocystis was grown xenically in 
LYSGM (Clark and Diamond 2002). Several attempts to grow Blastocystis 
axenically were also performed by several labs and here in this project using 
several different media (Tan, Singh et al. 1996, Tan, Singh et al. 1996). The 
media used to grow Blastocystis are listed below. 
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Xenic culture media 
LYSGM Base  
1.4 g dibasic potassium phosphate (19.7 mM) 
0.2 g monobasic potassium phosphate (3.3 mM)   
3.75 g NaCl (128.3 mM)     
0.25 g liver extract    
1.25 g yeast extract      
Water up to 475 ml  
Divide media into 95 ml aliquots and add 0.1 g gastric mucin per 100 ml bottle. 
Autoclave at 121°C for 15 min. Add heat inactivated adult bovine serum before 
use in a final concentration 5%. 
Axenic culture solution and media 
Iscove's Modified Dulbecco's Media IMDM 
This media was used for axenic cultivation trials of Blastocystis and purchased 
ready made from PAA (GE Healthcare). IMDM consists of several metals, trace 
metals and trace elements supplemented with 10 % heat inactivated horse 
serum. For a detailed description of the IMDM media composition please refer to 
Appendix 1.  
 
Diphasic  media Axenic cultivation method was first described by Zierdt and 
Williams (Zierdt and Williams 1974). In 2002 Clark and Diamond reviewed the 
modified method developed by Lanuza et al. (Lanuza, Carbajal et al. 1997) (Clark 
and Diamond 2002). 
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Liquid phase 
o 5 g glucose 
o 16 g sodium chloride 
o 0.4 g calcium chloride 
o 0.4 g potassium chloride 
o 0.02 g magnesium chloride 
o 4 g sodium phosphate dibasic 
o 0.8 g sodium bicarbonate 
o 0.6 g potassium phosphate monobasic 
The liquid phase ingredients were mixed and dissolved in a litre of distilled water. 
A. Solid phase 
o 12.5 ml Luck’s solution  
o 45 ml whole egg  
The solid phase components were mixed and homogenized in a blender, filtered 
through gauze into a flask and put under vacuum to remove bubbles. The mixture 
is subsequently dispensed in 5 ml portions each in culture glass tubes. This was 
autoclaved for 10 min at 100°C with a slant position. The mixture is then cooled 
down and overlaid with the liquid phase, and autoclaved at 121°C for 15 min. 
After autoclaving, caps were tightened and the slant tubes were refrigerated up 
to 6 months. 
Adult bovine serum 
Purchased from PAA, and heat in activated at 55°C for 30 minutes. 
Horse-serum heat inactivated 
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Purchased from PAA. 
Soft agar plates, consists of a mixture of IMDM, horse serum (HS), and Bacto™ 
agar in the following proportions: 
o 2 X  IMDM filtered and supplemented with 10% HS 
o 0.72% Bacto™  agar dissolved in distilled water and autoclaved at 121°C  
for 15 min 
Mix equal volume of both components and pour in sterile Petri dishes.  
Soft agar plates with sodium thioglycollate 
o 2 X IMDM filtered and supplemented with 10% HS. 
o 0.05% sodium thioglycollate  
o 0.72% Bacto™ agar 
Dissolve the suspension of Bacto™ agar and thioglycollate in distilled water then 
autoclave at 121°C for 15 min.  Mix equal volumes of the suspension and 2 X 
IMDM in a Petri dish. 
Solid agar plates 
o 2 X  IMDM filtered and supplemented with 10 % HS 
o 2% Bacto™ agar  ( autoclave at 121°C for 15 minutes) 
Plates were made by mixing equal volumes of molten (40°C) 2% Bacto™ agar 
and 2 X IMDM-HS (warmed at 40°C). Leave the plates to solidify at room 
temperature, pre-reduce in an anaerobic jar for 24 hours before use.   
10 X ampicillin /streptomycin for axenization experiment 
40 mg/ml streptomycin     -      10 mg/ml ampicillin 
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2.1.2. Molecular biology 
2.1.2.1. Primers list   
Many primers were used in this study to amplify the genes of interest. Some 
primers were designed to amplify genes from genomic DNA or cDNA and several 
new sets of primers containing restriction sites were designed to incorporate the 
gene of interest into an expression vector, mainly pET-14b in this study. Other 
primers were designed to introduce point mutations in genes, using the 
QuickChange Lightning Site directed mutagenesis kit (Agilent Technologies). 
Sequencing primers were designed for the purpose of checking that mutations 
were introduced at the correct site.  The table below lists all the primers used in 
this project and the restriction sites are highlighted in italics. See Table 2.2  
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Table 2. 2 Primers used in this study. Restriction sites are italicized when applicable.  
Primer Sets Sequence 5' - 3' Amplification product 
Whole gene amplification primers 
BhEno F 
BhEno R 
ATGCTTTCTCGTCTTTCTAC 
TTAACAACGATCCGGAGTAC Enolase 
Recombinant gene expression primers 
BhEno pET F 
BhEno pET R 
AGAAGACATATGGCCTCTACGATTACTG
CCGTTAAC 
TCTTCTGGATCCTTAACAACGATCCGGA
GTACG 
Enolase with NdeI, BamHI 
restriction sites 
TPI-GAPDH pET F 
 
TPI-GAPDH pET R 
AGAAGACATATGTTCGTCGGTGGCAATT
GGAAGTGCAA 
TCTTCTGGATCCTTAAGAGCGATCCACC
TTCGCCA 
TPI-GAPDH with NdeI restriction 
site  
TPI-GAPDH with BamHI 
restriction site 
Sequencing primers 
FTPGA1401 
FTPGA901 
RTPGA400  
 
CTACAACATCATCCCGTCCTCCA 
TTCATCACGCCCGACTACAT 
TCAGACCGTTCTTCTGAGCGTAAG 
Reading along the whole mutant 
constructs to check that no 
unwanted mutations have been 
introduced.  
TPI-GAPDHmut 
check F 
TPI/GAPDHmut 
check R 
GACCCGAAGAAGATCCAGTG 
 
GGACGGGATGATGTTGTAGC 
 
Internal primers used to check 
that the mutation was inserted 
and the rest of the gene is still 
correct.  
Mutation insertion primers 
RMM073 
RMM074 
GTCGAACGCGTCCGCCACGACGAACTG 
CAGTTCGTCGTGGCGGACGCGTTCGAC 
 Mutant TPI-GAPDH in GAPDH 
C416A 5' and 3' 
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2.1.2.2 Plasmids list  
Constructs made in this project were produced in several vectors divided between 
expression and cloning vectors. For general cloning purposes pGEM-T-Easy 
(Promega) was used. Some trials were also performed using pJET 1.2 
(Fermentas), but work has not been continued with this vector because of the 
satisfactory results achieved with pGEM-T-Easy. For gene expression purposes 
pET-14b was the vectors used throughout the study. Table 2.3 lists the plasmids 
used, the constructs, their sizes and the suppliers of these plasmids. 
Table 2. 3 Plasmids used in this study. 
Plasmid Information Size 
(kb) 
Source 
pJET 1.2 Blunt end cloning vector 2.97 Fermentas 
pGEM®-T_Easy T overhangs for easy cloning of PCR products 3.015  Promega 
pET-14b  
 
Expression vector adds His-tag to N or C-
terminus of protein to be expressed. 
4.7 Novagen  
 
Eno/pGEM®-T_Easy BhEno PCR product cloned into pGEM®-T 
Easy. 
4.365 Made in this study 
Eno/pET-14b BhEno PCR product cloned into pET-14b 6.05 Made in this study 
TPI-GAPDH/pJET1.2 TPI-GAPDH PCR product cloned into pJET 1.2 4.78 Made in this study 
TPI-GAPDH/pET-14b TPI-GAPDH  PCR product cloned into pET-14b 6.5 Made in this study 
mTPI-GAPDH/pET-
14b 
Mutant TPI-GAPDH PCR product cloned into 
pET-14b 
6.5 Made in this study 
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2.1.2.3. Molecular biology Solutions 
2.1.2.3.1. DNA work solutions 
50 X Tris-acetic acid-EDTA (TAE) electrophoresis buffer, 1000 ml 
o 18.6 g Ethylenedccciaminetetraacetic acid (disodium salt) (EDTA) 
o 57.1 ml of glacial acetic acid 
o 242 g Tris-base 
Dissolve in distilled water to a final volume of 1,000 ml (pH 8.0) 
DNA isolation solutions 
CTAB lysis buffer, 100 ml 
o 3.72 g EDTA 
o 0.25 g SDS 
Instructions as above, pH to 8.0  
 
10% CTAB in 0.7 M NaCl, 100 ml 
10 g CTAB 
Up to 100 ml with 0.7 M NaCl 
 
Proteinase K, 2 mg/ml 
Dissolve Proteinase K powder in distilled water then filter sterilise through a 2 µm 
filter. The final concentration used is 0.1 mg/ml. 
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DNA marker 
Bioline Hyperladder I was used unless otherwise stated (see Fig 2.1) 
 
 
 
Figure 2. 1 Bioline Hyperladder I DNA marker. The left lane of the above image shows DNA bands 
stained with ethidium bromide. The intensity of the bands corresponds to the amount of DNA as 
indicated by the fluorescence, corresponding to 5 µl overall load. Sizes are indicated in bp and 
corresponding amounts of DNA as ng/band. Image was taken from the Bioline website.  
2.1.2.3.2. Protein work solutions  
2.1.2.3.2.1. Sodium dodecyl sulphate (SDS) gel and solutions 
SDS gels used in this project were 12 and 15% gels. 15% SDS gels were used 
for PGK, TPI and GAPDH protein experiments, while 12% gels were used for 
recombinant Blastocystis enolase, Blastocystis TPI-GAPDH and Blastocystis 
mTPI-GAPDH recombinant proteins experiments. Table 2.4 details the 
composition of the gels. 
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Table 2. 4 Composition of SDS polyacrylamide gels. 
 6% stacking gel 12% resolving gel 15% resolving gel 
H2O 8.7 ml 8.6 ml 7.1 ml 
40% acrylamide 2.25 ml 6 ml 7.5 ml 
1.5 M Tris-HCl, pH 8.8 - 5 ml 5 ml 
0.5 M Tris-HCl, pH 6.8 3.75 ml -  - 
10% SDS 150 µl 200 µl - 
10% APS 150 µl 200 µl 200 µl 
TEMED 15 µl 20 µl 20 µl 
 
SDS loading buffer, 100 ml 
o 2.42 g Tris base 
o 6.17 g DTT 
o 8 g SDS 
o 0.4 g Bromophenol blue 
o 40 ml Glycerol 
pH to 6.8, H2O up to 100 ml. 
SDS running buffer 
o 30.29 g Tris base 
o 150 g Glycine 
o 100 g SDS 
H2O up to 1000 ml 
 
Coomassie Blue stain 
o 0.025% Coomassie Brilliant Blue 
o 40% Methanol 
o 14% Acetic acid 
H2O up to 100 ml 
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Destaining solution I 
o 40% Methanol 
o 7% Acetic acid 
H2O up to 100 ml 
Destaining solution II 
o 5% Methanol 
o 7% Acetic acid 
H2O up to 100 ml 
Protein marker 
Fermentas Spectra Multicolor Broad Range Protein Ladder was used (See Fig. 
2.2). 
 
Figure 2. 2 Spectra Multicolor Broad Range Protein Ladder Fermentas. The sizes of the shown 
protein bands are given in kDa. Image was taken from the Fermentas website. 
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2.1.2.3.2.2. Native gel solutions 
Native gels were used to determine the native molecular weight of target proteins 
of this study and thereby estimate their oligomeric status. Table 2.5 details the 
composition of the native gels used in this study.  
Table 2. 5 Composition of native gels with different concentrations. 
 5% stacking gel 
(ml) 
10% resolving 
gel (ml) 
12% resolving 
gel (ml) 
15% 
resolving 
gel (ml) 
H2O 11.1  14.7 13.2 10.95 
40% acrylamide 1.875 7.5 9 11.25 
1.5 M Tris-HCl, 
pH 8.8 
- 7.5 7.5 7.5 
1 M Tris-HCl, pH 
6.8 
1.875 - - - 
10% APS 0.15 0.3 0.3 0.3 
TEMED 0.015 0.012 0.012 0.012 
 
Separating gel buffer 1.5 M Tris HCl, pH = 8.8. 
Stacking gel buffer 1 M Tris HCl, pH = 6.8  
Sample buffer (5x)  
o 15.5 ml of 1 M Tris-HCl pH  6.8  
o 1%  solution Bromophenol blue  2.5 ml 
o H2O 7.0 ml 
o Glycerol 25 ml 
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Electrophoresis buffer 
o 3.0 g Tris base 
o 14.4 g  Glycine 
Dissolve in water to a final volume of 1 litre (PH 8.3). 
In the case of blue native gels the solutions used are as follows:   
Cathode buffer   
o Bis-tris  15 mM 
o Tricine  50 mM 
o Commassie blue G250  0.02% 
Prepare 1 litre as a 10 x stock, adjust pH to 7.0 with HCl, and store at 4°C. Dilute 
before use with deionised water. 
Anode buffer 
o Bis-tris  50 mM 
Prepare 1 litre as a 10 x stock, adjust pH to 7.0 with HCl, and store at 4°C. Dilute 
before use with deionised water. 
Protein stain and de-stain solutions 
A standard Coomassie stain / de-stain was used to stain native gels. 
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2.1.2.3.2.3. Western blotting solutions 
Towbin transfer buffer, 1000 ml 
o 3.028 g Tris base 
o 15.14 g Glycine 
o 100 ml methanol 
Dissolve all components in H2O up to a final volume of 1,000 ml. 
5 x TBST, 1000 ml 
o 12.112 g Tris base 
o 12.86 g NaCl 
o 50 ml Tween-20 
Dissolve all components in H2O up to a final volume of 1,000 ml, adjust pH to 7.6. 
1 x TBST + 5% milk, 500 ml 
o 100 ml 5 X TBST 
o 25 g fat-free dried milk powder 
Dissolve the components in H2O up to 500 ml final volume. 
Ponceau S, 100 ml 
o 1.5 g Ponceau S 
o 5 ml acetic acid 
Dissolve the components in H2O up to 100 ml final volume. 
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2.1.2.3.2.4. Colony hybridization solutions (colony blot) 
Solution  A  10% SDS 
Solution  B  0.5 N NaOH, 1.5 M NaCl 
Solution  C 0.5 M Tris-Cl, 1.5 M NaCl pH 7.4 
Solution  D 2 X SSC 
20 X SSC 173 g  NaCl  (3 M) 
88.2 g Sodium citrate (0.3 M) 
Adjust pH to 7 and the final volume to 1 L with distilled water, sterilise by 
autoclaving.  
2.1.2.3.2.5. Enzyme activity assay solutions  
2.1.2.3.2.5.1. Blastocystis enolase activity assay solution 
A. Triethanolamine buffer, TEA 
18.565 mg/ml Triethanolamine Hydrochloride in H2O, adjust to pH 7.4 with 1 M 
NaOH at 25°C 
B. 2-Phosphoglycerate solution (DPG) 
14.112 mg/ml D (+) 2-phosphoglyceric acid in water. 
C. ß-Nicotinamide adenine dinucleotide, reduced form solution (ß-NADH) 
4.9658 mg/ml ß-nicotinamide adenine dinucleotide dissolved in water, prepare 
fresh. 
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D- Magnesium sulphate with potassium chloride solution (MgSO4/KCl) 
300.92 mg/5 ml magnesium sulphate 
745.5 mg/5 ml potassium chloride 
Dissolved in water to a final volume of 5 ml.  
E- Adenosine 5'-diphosphate solute on (ADP) 
8.544 mg/ml adenosine 5'-diphosphate, sodium Salt, in water, prepare fresh. 
F- PK/LDH mixed enzymes 
o 900-1400 units/ml lactic dehydrogenase   
o 600-1000 units/ml pyruvate kinase    
G- Tris-HCl with bovine serum albumin (enzyme diluent) 
o 1.817 g/ml Trizma base 
o 0.020 mg/ml albumin, bovine 
Adjust to pH 7.4 at 25°C with 1 M HCl. 
H- Enolase enzyme solution 
Immediately before use, prepare a solution containing 0.25-0.5 unit/ml of enolase 
in cold Reagent G. 
2.1.2.3.2.6. Protein purification solutions 
Proteins studied in this project were purified throughout the work using different 
techniques. All purifications started by using nickel affinity columns for His-tagged 
proteins. For some proteins, ion exchange chromatography columns, which 
depend on the isoelectric point (PI) of the protein, were used (data not shown). A 
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size exclusion chromatography (SEC) column was used as a final step of protein 
purification. This technique depends basically on the size of the molecule and the 
molecular weight of the protein. The table below, Table 2.6 lists all the buffers 
used in the work.  
Table 2. 6 Buffers used in different protein purification steps. 
Buffer  Component 
SP XL buffer A 0.05 M HEPES, Na+ , pH 7.0–8.0 
SP XL buffer B 0.05 M HEPES, Na+  
1 M NaCl, pH 7.0–8.0 
Q FFbuffer A 0.1 M Tris-HCl,   pH 8.2 
Q FF  buffer B 0.1 M Tris-HCl 
1 M NaCl ,pH 8.2 
Nickel affinity chromatography 
(NAC) buffer A  
0.1 M Tris-HCl 
0.1 M NaCl 
cOmplete Protease Inhibitor Cocktail Tablets (Roche), pH 8.2 
Nickel affinity chromatography 
(NAC)  buffer B 
0.1 M Tris-Hcl 
0.1 M NaCl 
0.5 M Imidazole 
cOmplete Protease Inhibitor Cocktail Tablets (Roche), pH 8.2 
Gel filtration chromatography 
(GF) buffer  
0.02  M Tris-Hcl 
0.1 M NaCl     
0.2 5 mM EDTA, pH 8.2 
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Recharging Nickel beads solution:  
Stripping buffer          
100 mM EDTA                                        
Charging buffer       
o 100 mM NiCl2 
o 500 mM NaCl / 20 mM Tris, pH 8.0    
2.1.2.3.2.7. Crystallography work. 
After protein purification, and for the purpose of growing crystals, the protein is 
incubated in a multitude of conditions varying in buffer composition, pH, 
precipitant composition, salt concentration, and plate incubation temperature. We 
can screen hundreds of conditions for crystals formation using commercially 
available screens supplied by different companies. In this project we used several 
screen including PEG-ION and Index (Hampton Research Company), Emerald 
Wizard III+IV (Emerald), and PACT premier, JCSG, Morpheus (Molecular 
Dimensions).  
2.1.2.3.2.8. Differential scanning fluorimetry (DSF) buffers. 
A set of screening buffers were used in this experiment, with different pH degrees, 
and different salt concentration (Niesen, Berglund et al. 2007). Table 2.7 lists all 
buffers used during differential scanning fluorimetry.       
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Table 2. 7 Buffers used to study protein stability using Differential Scanning Fluorimetry (DSF). 
number  Buffer name Buffer 
abbreviation 
1 400 mM Sodium acetate-AcOH, pH 5, 600 mM NaCl AcOH 
2 400 mM Bicin, pH 8.3, 600 mM NaCl Bicin 
3 400 mM Bis-Tris-HCl, pH 6, 600mM NaCl Bis-tris 
4 400 mM MES-NaOH, pH 6, 600 mM NaCl MES 
5 400 mM Imidazole-HCl, pH 7, 600 mM NaCl Imi 
6 400 mM PIPES-NaOH, pH 7, 600 mM NaCl PIPS 
7 400mM MOPS-NaOH, pH7.2, 600 mM NaCl MOPS 
9 400 mM Tricine-NaOH, pH 8, 600 mM NaCl Tricine 
10 400 mM Tris-HCl, pH 8.1, 600 mM NaCl Tris-Hcl 
12 400 mM Glycine-NaOH, pH 9, 600 mM NaCl Gly 
14 400 mM CHES-NaOH, pH 9.5, 600 mM NaCl CHES 
15 400 mM Ethanolamine-HCl, pH 9.5, 600 mM NaCl Etha 
16 400 mM CAPS-NaOH, pH 10, 600 mM NaCl CAPS 
17 400 mM HEPES-NaOH, pH 7.5 HEPES 
18 400 mM HEPES-NaOH, pH 7.5, 200 mM NaCl HEPES1 
19 400 mM HEPES-NaOH, pH 7.5, 600 mM NaCl HEPES2 
21 400 mM HEPES-NaOH, pH 7.5, 2 M NaCl HEPES3 
22 400 mM HEPES-NaOH, pH 7.5, 600 mM NaCl, 20 % glycerol HEPES, gly1 
23 400 mM HEPES-NaOH, pH 7.5, 600 mM NaCl, 40 % glycerol HEPES, gly2 
24 400 mM HEPES-NaOH, pH 7.5, 2 M NaCl, 20 % glycerol HEPES, gly3 
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2.2 Methods 
2.2.1. Molecular biology methods 
2.2.1.1 DNA extraction  
DNA was extracted from Blastocystis ST4 and ST8 using the cetyl-trimethyl-
Ammonium Bromide (CTAB) method. The cells were harvested as described in 
2.2.2.4, and the pelleted cells were re-suspended in 250 µl CTAB lysis buffer and 
proteinase K (0.1 mg/ml). Suspended cells were incubated for 1 h at room 
temperature. After 1 hour incubation, NaCl was added to a final concentration of 
0.7 M followed by addition of 10% CTAB to 1%. The mixture was mixed well and 
incubated at 65°C for 15 min. 
Equal volume of chloroform: isoamyl alcohol (24:1) was mixed and centrifuged at 
14,000 X g for 10 min. The resulting phase was then extracted with equal volume 
of phenol: chloroform (1:1) and centrifuged as before, the supernatant was 
precipitated with 2.5 volumes ethanol, incubated for 10 min and centrifuged as 
before. The pellet was washed once in 70% ethanol and centrifuged for an 
additional 5 minutes at 14,000 X g. After removing the liquid, the pellet was left 
to air dry before being rehydrated in small amount of sterile water (50 µl H2O). 
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2.2.1.2. PCR reactions 
A Techne TC-312 PCR machine was used for all standard PCR reactions. All 
primers were ordered from Eurofins MWG Operon, and primers were re-
suspended in distilled water to a final concentration of 100 pmol/ µl and stored at 
-20°C. 
2.2.1.2.1. PCR cycling conditions 
PCR reactions were executed using two sets of polymerases in this study; in 
amplification reactions where high fidelity was not needed, GoTaq Green Master 
Mix was utilized, as in colony PCR experiments. While Pfu DNA polymerase was 
used when high accuracy was needed.  Pfu DNA polymerase was also used 
when the addition of adenine overhang was needed for TA cloning. In this 
instance, a mixture of two different polymerases was used: GoTaq polymerase 
(for A tailing) and Pfu Taq polymerase 5’-3’ (for proof-reading ability) (both 
Promega). Table 2.8 sets a comparison between the two reactions’ components. 
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   Table 2. 8  PCR cycling condition using PfuTaq DNA polymerase and Gotaq master mix. 
 
 
Table 2. 9 PCR cycling condition using PfuTaq DNA polymerase and Gotaq master mix. 
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2.2.1.2.2 Mutagenesis PCR conditions 
QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent technologies) was 
used for introducing mutations in a desired site. Manufacturer’s instructions were 
followed. The basic reaction uses the whole double stranded plasmid with the 
insert of interest, two sets of primers with the desired mutation and a derivative 
of the high fidelity DNA polymerase (PfuUltra high-fidelity (HF) DNA polymerase). 
Extension of the designed oligonucleotides resulted in the formation of the 
mutated plasmid. The resulted mutant plasmid was then treated with a newly 
optimized DpnI enzyme to remove template plasmid. 
The reaction composition was as follow: 
5 µl of 10 X reaction buffer 
1 µl DNA (up to 100 ng) 
1 µl PfuUltra high-fidelity (HF) DNA polymerase 
X µl (100 ng each primer for 1–3 primers; 50 ng each primer for 4–5 primers) 
The reaction mix was topped up with double distilled water to a final volume of 25 
µl. 
Details about the conditions used for setting the PCR reaction for mutagenesis 
reactions for site directed mutagenesis can be found in Table 2.10. 
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Table 2. 10 PCR cycling parameters using Quick change lightning Site-directed mutagenesis kit. 
Cycle step Number of cycles Temperature   Time  
PCR cycling condition  
Initial denaturation 1 95°C 2 minutes 
Denaturation 
Annealing  
Extension  
18 cycle 95°C 
60°C 
68°C 
20 sec 
10 sec 
30  sec/kb of plasmid 
length 
Final extension    1 68°C 5 minutes 
 
 
2.2.1.3. DNA electrophoresis 
Agarose gels were used to analyse DNA fragments and check for PCR products 
according to the DNA band sizes. Agarose gels were made in this project using 
1% agarose dissolved in TAE buffer by boiling. Ethidium bromide was used to 
visualize DNA bands as a nucleic acid stain with a concentration of 0.04 µl/ml of 
gel. DNA fragments were mixed with the 5 X running buffer, and loaded on the 
gel, with 5 µl of DNA HyperLadder™1 (Bioline) and electrophoreses at 100 Volts 
for different times according to the fragment being analysed, allowing the 
estimation of DNA bands of sizes ranging from 200 bp and 10 kb, (See Fig2.1.). 
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2.2.1.4. Isolation and purification of DNA fragments 
DNA fragments were excised from agarose gels and purified using The QIAquick 
Gel Extraction (Qiagen), following manufacturer’s instructions. Otherwise, a 
QIAquick PCR Purification (Qiagen) was used to clean PCR products when no 
other products are observed. All steps were performed at room temperature 
(R.T.). These two kits remove primers, primer dimers, dNTPs and restriction 
enzymes to aid downstream processes. 
2.2.1.5. Cloning of PCR products. 
2.2.1.5.1. Ligation into cloning vector. 
Primary PCR products were cloned in the pGEM®-T-Easy vector, which is a 
linear vector that contains thymidine tri-phosphate overhangs allowing the 
hybridization of the PCR product and the vector, see Fig2.3. Vector pJET1.2 was 
also used in this study. This vector has blunt ends allowing the cloning process 
without any further processing for PCR products apart from purification.  
 
Figure 2. 3The general cloning vector pGEM-T-Easy showing the multiple cloning site (MCS) that 
comes after the T7 promoter site, antibiotic resistance site, and the sequencing primers: T7, SP6, 
M13 forward and reverse. Figure drawn using SnapGene.  
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2.2.1.5.2. Transformation of competent cells with plasmid DNA 
The transformation procedure of any construct into E. coli competent cells was 
carried out by aliquoting 50 µl of the desired competent cells. Those cells were 
then kept on ice. 1-8 µl (1-50 ng of DNA) of the plasmid were added to the 
Eppendorf tube containing the competent cells, and mixed gently by flicking the 
tube. This mixture was placed on ice for 20 minutes, and then moved to a 
preheated water bath at 42°C for 45 seconds. After this step of heat-shock to the 
cells, the tube was re-placed on ice for another 2 minutes. A 1 ml of LB medium 
or SOC medium were added before incubating the mixture in a water bath at 37°C 
for 1 hour. Finally 100 µl and 50 µl of the mixture were plated on LB agar plates 
containing the required antibiotic, with IPTG, and XGAL for cells that needs blue-
white screening, and those plates were incubated at 37°C overnight. The 
transformation is then checked by colony PCR and/or digestion of the plasmid 
after plasmid isolation from the growing colonies. 
 
2.2.1.5.3. Plasmid DNA isolation 
10 ml overnight culture of the transformed cells was grown at 37°C incubator 
shaking at 220 rpm. 5 ml of this culture was used for plasmid extraction using a 
QIAprep Spin Miniprep Kit (Qiagen). The manufacturer’s instructions were 
followed, and the whole procedure was performed at RT. This procedure depends 
on alkaline lysis of the cells; the lysed cells were neutralized and centrifuged to 
remove proteins and cells debris. The final step includes loading the DNA on 
silica membrane to remove impurities and elution with elution buffer. DNA was 
stored until use at - 20°C. 
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2.2.1.5.4. Sanger sequencing 
To check that the plasmid construct has the desired insert, constructs were sent 
to Eurofins MWG for sequencing. Inserts in pET-14b vector were sequenced 
using T7 forward and reverse primers, while those ligated in pGEM-T-Easy were 
sequenced using M13 forward and reverse primers. Constructs in pJET1.2 used 
proprietary primers from Fermentas (see Table 2.1) 
Table 2. 11 Forward and reverse PCR primers used for Sanger sequencing of pGEM-T-Easy, pET-14b 
and pJET1.2 plasmids. 
Primer Sequence 
T7 Forward  5’-TAATACGACTCACTATAGGG-3’ 
T7 Reverse 5’-GCTAGTTATTGCTCAGCGG-3’ 
M13 Forward 5’-GTAAAACGACGGCCAGT-3’ 
M13 reverse 5’-AACAGCTATGACCATG -3’ 
pJET1.2for CGA CTC ACT ATA GGG AGA GCG GC  
pJET1.2rev AAG AAC ATC GAT TTT CCA TGG CAG 
 
2.2.1.5.5. Restriction enzyme digestion of DNA 
Fermentas Fast Digest Enzymes were used in this study. Fermentas’ protocol 
was followed. Table 2.12 shows the digestion reaction contents. After brief 
centrifugation of the digestion mix, it was placed on heat block for 10 minutes at 
37°C. 
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Table 2. 12 Fermentas Fast Digest reaction composition for both plasmid and PCR products. 
 Plasmid DNA PCR product 
Nuclease free water 15 µl 17 µl 
10xFastDigest Green Buffer 2 µl 2 µl 
DNA 1 µl 10 µl 
FastDigest Enzyme 1 µl 1 µl 
Total volume 20 µl 30 µl 
 
2.2.1.5.6. Cloning of DNA fragment into expression vector 
The expression vector used in this study was pET-14b (Novagen). Ligation of the 
PCR product into this vector necessitates digesting of both vector and insert using 
the same restriction enzymes. NdeI and BamHI restriction sites were added to 
the 5’ and 3’ ends of the genes in this study. The pET-14b vector has a poly-His 
tag that will flank the gene on the N-terminus region after being digested with 
BamHI and NdeI. The gene was inserted in the BamHI and NdeI position of the 
pET-14b plasmid in frame with the N-terminal His-tag. This tag helps in further 
purification steps of the protein. The digestion products were cleaned using a 
QIAquick Gel Extraction (Qiagen) or QIAquick PCR Purification (Qiagen). These 
products were subsequently ligated using a Takara Mighty DNA Ligation kit, using 
the 3:1 ratio of DNA:  plasmid, and incubated at 25°C for 30 minutes. The ligation 
mix was transformed to E. coli expression cells as described in section 2.2.1.5.2.  
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 Gene expression was driven by a T7 promoter and ampicillin resistance allowed 
for selection of positive clones, which was further confirmed by colony PCR, 
digestion and sequencing. 
 
Figure 2. 4The gene expression plasmid pET-14b featuring a backbone size of 4.6 kb, the multiple 
cloning sites with NdeI and BamHI restriction sites used in this study, antibiotic resistance site and 
the T7 forward sequencing primer. Figure drawn using SnapGene. 
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2.2.2. Microbiological methods 
2.2.2.1. Growth measurement 
Cell growth was measured by aliquoting 1 ml of growing cells in disposable plastic 
cuvettes, and the optical density was recorded at  595 nm using a WPA CO 8000 
Biowave Cell Density Meter. 
2.2.2.2. E. coli growth 
Starter cultures of 5-10 ml were grown overnight at 37°C from glycerol stocks, or 
preferably from single colonies on a previously streaked agar plate containing the 
appropriate antibiotic. This starter culture was then inoculated in 1 L LB medium 
to be induced later, or in ZYM medium for autoinduction experiments. 
2.2.2.3. Long-term storage of bacterial clones 
Cells were preserved by mixing equal volumes of the re-suspended cell pellet in 
fresh LB medium, with 50% cooled-autoclaved glycerol (glycerol in LB). This was 
vortexed to mix and snap frozen in liquid nitrogen and stored at -80 °C. 
Note: glycerol concentration varies from 15 - 25% for long term storage. 
2.2.2.4. Bacterial harvesting 
All bacterial cells were harvested by centrifugation at 4,700 X g for 30 minutes at 
4°C. 
2.2.2.5. Blastocystis purification and harvesting 
Cells were harvested at 800 X g for 5 minutes and re-suspended in 100 µl of 
LYSGM medium. To remove bacterial flora from xenic cultures, re-suspended 
cells were layered carefully on top of 10 ml Histopaque 1077 and centrifuged for 
further 30 minutes at 2,000 X g. A thin layer of Blastocystis cells is noticeable 1 
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cm from the top of the multiple-layers solution, this was pipetted out and 
centrifuged and washed with PBS (Parkar, Traub et al. 2007). This is either re-
inoculated in IMDM for axenization experiment (Ho, Singh et al. 1993) or in 
LYSGM for further xenic cultivation (Clark and Diamond 2002), or collected via 
centrifugation at 275 X g for cryopreservation. 
2.2.2.6. Long-term preservation of Blastocystis sp. strains 
Blastocystis cells were centrifuged at 275 X g for 5 minute and the supernatant 
was decanted. Two tubes were prepared as follows: five ml of the culturing 
medium (LYSGM) with five ml heat inactivated adult bovine serum in the first 
tube, then 5 ml of the first tube was transferred to the second tube with the 
addition of 750 µl of DMSO to reach a final concentration of 15% DMSO. 
The cells were re-suspended with two ml of tube one (having 50% serum and 
50% media). Then 500 µl of the cells suspension were transferred to each of the 
cryo-tubes. To this suspension 500 µl of tube two that contains 15% DMSO were 
added. This mixture was then left in 36°C incubator for about 15 minutes, allowing 
Blastocystis cells to absorb the DMSO. Then cells were rapid-cooled by 
transferring them into a pre-chilled isopropanol bath at -80°C for 48 hours 
(isopropanol bath should be pre-chilled at least 24 hours before use). 
After two days the cryo-tubes were moved to a liquid nitrogen container (Dewar). 
Cells should be stored for seven days before reviving cells for checking for 
viability.  
2.2.2.7. Recovering cryo-preserved Blastocystis cells 
Cryo-preserved cells were rapidly thawed in a water bath at 36° C, and left without 
agitating for 10-15 minutes. These cells were then transferred to tubes containing 
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10 ml of pre-warmed LYSGM and incubated in 36° C incubator. After incubating 
for 2-3 days and visual inspection, the medium was decanted and replaced with 
fresh medium. This was checked after a further 72 hours and sub-culturing 
continued as normal.  
2.2.2.8. Blastocystis ST cultivation method 
2.2.2.8.1. Xenic culturing method 
Blastocystis cells were grown xenically in LYSGM medium. The cells were 
cultured twice a week in borosilicate tubes containing pre-warmed 10 ml liquid 
medium supplemented with 5% heat inactivated adult bovine serum. The fresh 
media tubes were inoculated with 100 µl of 3-4 days old culture and kept vertically 
in 37°C incubator. The cells were sub-cultured every 3-4 days (twice a week).  
2.2.2.8.2. Axenization trials 
Several trials were performed for axenizing Blastocystis cells, using two-phase 
(egg slant medium using modified Luck’s solution) and single-phase medium 
IMDM.  
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2.2.3. Biochemistry methods 
2.2.3.1. Induction of gene expression 
10 ml overnight cultures were inoculated by a single colony from a particular 
strain at 37°C at 220 rpm for 12-16 hours. This overnight culture was inoculated 
in 1 L LB medium or ZYM for autoinduction experiments. 
To check for over-expression, cells were exposed to different conditions. Cells 
induced with IPTG were grown at different temperatures: 37°C, 28°C and 10°C 
and for different induction times from (2 hours to overnight). Several IPTG 
concentrations were used as well (1 µM-1 mM).  
An auto-induction method was also used for protein production purpose (Studier 
2005), these were grown at 20°C for 24 hours or 48 hours at 220 rpm. 
A sample of the over-expressed culture was taken, centrifuged to collect cells 
and analysed on SDS-PAGE. 
2.2.3.2. Cell lysis 
The induced cells were harvested by centrifugation at 6,000 X g for 30 min. The 
bacterial cell pellet was re-suspended using a suitable homogenisation buffer 
containing protease inhibitor (cOmplete Protease Inhibitor Cocktail Tablets 
(Roche) (1 tablet/50 ml buffer). Cell suspensions were lysed using the sonication 
method (sonoporation), to disrupt cell membrane and release cell content. The 
solution was sonicated using a Soniprep 150 Sonicator (Sanyo), at a frequency 
of 25 kHz and  60% amplitude on ice for a total of 5 pulses (cycle), with 15 
seconds on/25 seconds off cycles to prevent overheating and degradation of the 
enzymes or aggregation of the targeted protein. Lysed cells were centrifuged at 
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20,000 X g for 30 minutes (or until having a clear soluble fraction) to pellet cells 
debris and insoluble fractions. 
2.2.3.3. Protein purification 
All proteins studied were His-tagged, which enabled the use of the Immobilized 
Metal Affinity Chromatography (IMAC) technique. This was done manually or 
using the ÄKTA purifier (GE Healthcare). When required, protein was further 
purified by ion exchange (IEX) chromatography. Proteins were also purified using 
size exclusion chromatography columns (Gel Filtration, GF). Table2.7 
summarises all buffers used in this study for purifying proteins. Those buffers 
were vacuum filtered through 0.2 μm nylon membrane. The protein concentration 
was determined by measuring the absorbance at 280 nm using the ÄKTA column 
or by using a Bradford assay using bovine serum albumin (BSA) standard curve.   
2.2.3.3.1. Immobilized metal affinity chromatography (IMAC) 
The crude soluble fraction of the lysed cells was loaded on 1 ml nickel column 
(column loaded with X ml of metal chelating cellulose charged with Ni2+) using a 
“Super loop”.  A 1 ml nickel affinity column (HisTrap column/ GE Healthcare) was 
equilibrated with 5 column volume of nickel affinity column (NAC) buffer A, 
detailed in Table 2.6. Protein was loaded using the “super loop” (GE Health care) 
and the unbound protein was washed out using 5 X column volume of NAC buffer 
A. The desired protein was eluted using 5 column volume of NAC buffer B (Table 
2.6.) using a step gradient of buffer B up to 100% of this buffer. A further washing 
of the column was performed using 2 X column volume of buffer B. The fractions 
were collected in 1 ml fractions.  
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The fractions representing the desired protein were collected and concentrated 
using a 30 kDa cut-off membrane (Millipore, Amicon® Ultra-15 Centrifugal Filter 
Unit) at 4,000 X g, at 4°C until a final volume of 1 - 5 ml was collected to be used 
in further purification steps. 
2.2.3.3.2. Ion Exchange Chromatography (IEC) 
Protein purified using HisTrap columns was, for further purification, isolated using  
HiTrap Q Sepharose FF (Q FF) fast flow column for anion exchange or an SP XL 
column for cation exchange. The buffers used in this experiment are listed in 
Table 2.6.  Protein was loaded on the Q FF column on ÄKTA using “Super loop”. 
This column was equilibrated using 5 X column volume. Unbound protein was 
washed off with 3 column volumes of Q FF buffer A, while the target protein was 
eluted with 5 column volumes of Q FF buffer B. The fractions were 1 ml unless 
otherwise stated. The eluted protein was checked on SDS gel, and the fractions 
corresponding to the target protein were pooled and concentrated to 1-5 ml final 
volume using a 30 kDa cut-off membrane filters (Millipore, Amicon® Ultra-15 
Centrifugal Filter Unit) at 400 X g at 4°C. This fraction was used for the gel 
filtration (GF) purification step afterwards.  
 
2.2.3.3.3. Gel Filtration chromatography (GF column) 
The final protein purification step was through gel filtration. A Superdex 200 
HiLoad 16/60 (GE Healthcare) (or 75 for analytical column used for molecular 
weight and oligomeric status determination) gel filtration column was first 
equilibrated with the chosen elution buffer mentioned in Table 2.6. The 
equilibration step was performed using one column volume at a flow rate of 1 
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ml/min. The sample was loaded by injection into loops of different size depending 
on the pooled concentrated protein. The protein was eluted with 1 column volume 
of GF buffer, with elution fractions of 1 ml unless otherwise stated. The protein 
concentration was measured at 280 nm, and analyzed using SDS-PAGE. 
Fractions corresponding to the target protein were pooled and concentrated for 
further experiments.  
The Superdex 200 (or 75) gel filtration column was calibrated with the protein 
standards mentioned in Table 2.13 in materials and methods, in triplicates.  
Those protein were analysed on the column equilibrated using the same buffer 
as used in protein elution. The void volume was determined by measuring the 
elution volume of the protein standard dextran (2,000 kDa). The calibration curve 
obtained from plotting log MW against Kav was used to estimate the molecular 
weight of the native protein. Void volume value for GF column Superdex 200 was 
38.89 ml.  
Where Kav is calculated using the following equation:  
      Kav =  
 
For details of the calibration curve refer to Appendix 2.  
 
 
 
Ve- Vo 
Vt- Vo 
Equation 2.1 
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2.2.3.4. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Proteins were analysed by SDS PAGE gels, a method based on Laemmli (1970), 
for separating proteins according to their molecular weight. Gels were prepared 
in concentrations depending on the size of protein studied, where large proteins 
were analysed with 12% SDS PAGE separating gels, and smaller size protein 
were analysed using 15% SDS PAGE separating gels. Stacking gel 
concentration was always 6%. The protein molecular weight was usually 
determined visually by Fermentas Spectra Multicolor Broad Range Protein 
Ladder molecular weight marker (Fig 2.2). See Table 2.5 for detailed composition 
of different gel concentrations. The gel was exposed to an electric current of 25 
mA per gel, using a Bio-Rad mini-protean-Tetra cell (Bio-Rad Laboratories Ltd). 
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2.2.3.5. Native gel 
Native gel electrophoresis was used to determine the oligomeric status of 
proteins. These gels are prepared in non-denaturing buffers, which maintain the 
protein in its secondary structure, and therefore proteins separate according to 
their charge-to-mass ratio. The protein usually has an acidic or slightly basic 
charge, and by applying a current, the protein migrates to the negative charge. In 
this technique the gel filtrated protein sample is incubated with sample buffer for 
15 minutes on ice. After loading the protein sample and the markers (20 µl each), 
and in the case of blue native gel, overlay the sample well and each well with a 
sample cathode buffer. The inner chamber is filled with cold cathode buffer, and 
the outer chamber is filled with cold anode buffer.  The gel is then run by applying 
a constant current of 10 - 20 mA for about 3 hours (100 V), or at 150 V for 1 hour 
or until the dye reaches the running front of the gel (in the case of blue native 
gel), the work is all performed at 4°C (Wittig, Braun et al. 2006, Fiala, Schamel et 
al. 2011). For more details about the expanded composition of the native gels 
see Table 2.6. The markers used in this method were a native protein marker 
(Sigma-Aldrisch). See Table 2.13 for marker composition. 
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Table 2. 13 Proteins used as native molecular weight marker. 
 
Another marker was used in this study, NativeMark™ Unstained Protein 
Standard (LifeTechnologies), see Fig. 2.5.     
 
 
 
 
 
 
 
 
             
Protein Marker Concentration mg/ml Molecular weight kDa 
Carbonic anhydrase  3 30 
Albumin  10 66.5 
Alcohol dehydrogenase 5 150 
Β amylase 4 200 
Apoferritin 10 440 
Thyroglobuline  8 660 
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Figure 2. 5. Unstained native protein standard NativeMark™ for native gel from Life Technologies.  
Protein marker is shown under different running conditions. The table shows the proteins 
representing each band with their corresponding molecular weight. 
 
2.2.3.6. Second dimension SDS-PAGE 
To check for the identity of native proteins obtained in native gel electrophoresis, 
the whole lane that contains the protein of interest was excised, placed in 2 X 
SDS sample buffer, left shaking for about 10 minutes at room temperature and 
boiled for 20 seconds in the microwave. The band was then incubated in the hot 
SDS sample buffer for another 15 minutes before being analysed on standard 
SDS gel. The excised band was loaded by inserting the excised lane in a pre-
prepared SDS gel containing only one large well, overlaid with SDS sample buffer  
and subsequently electrophoresed as normal (Fiala, Schamel et al. 2011). This 
will enable the determination of the molecular weight of the proteins of interest.  
2.2.3.7. Western blotting 
After SDS gel electrophoresis, the gel was disassembled and proteins transferred 
to nitrocellulose membrane via Western blotting set from Bio-Rad and using Mini 
Trans-Blot® Cell. The gel, membrane, and blotting papers were equilibrated in 
Towbin buffer by gently rocking at room temperature for 10 minutes prior to 
Protein Band kDa 
IgM Hexamer 1,236 
IgM Pentamer 1,048 
Apoferritin band 1 720 
Apoferritin band 2 480 
Β-phycoerythrin 242 
Lactate Dehydrogenase 146 
Bovine Serum Albumin 66 
Soybean Trypsin Inhibitor 20 
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transfer. The transfer cassette used was assembled as follows, placing the white 
side of the cassette at the bottom submerged in the transfer buffer (facing the 
positive electrode):  
Sponge 
Blotting paper (thick) 
Nitrocellulose membrane 
SDS PAGE gel 
Blotting paper (thick) 
Sponge 
This sandwich of layers was put on top of each other and a test tube was gently 
rolled over the assembly to remove any air bubbles, which might affect the 
transfer. The cassette was closed with the black side which will face the negative 
electrode later. The transfer chamber was covered with Towbin buffer to the top 
and protein transfer was performed for 1 hour and 15 minutes, at 400 mA, with 
the whole transfer unit was kept in ice to protect the protein against denaturation 
during transfer. 
The quality of transfer was checked by briefly staining the nitrocellulose 
membrane with Ponceau S for several minutes. Unbound dye was removed by 
washing in water leaving the transferred protein visible as red stained bands.  
2.2.3.8. Colony hybridization (colony blot) 
Colony blot was used to identify clones that expressed the gene of interest and 
to have an estimation of the variation in expression levels between colonies. This 
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was performed after transformation, which enables identifying clones to be 
selected for subsequent expression experiments. To start a replicate plate of the 
transformation plate was grown up overnight at 37°C. The replicate was removed 
out of the incubator to let the condensation dry off for about 10 minutes. A dry 
nitrocellulose membrane was placed on top of the colonies (by holding it with 
forceps and place it gently starting from the middle of the plate to the edges to 
minimize air between the membrane and the cells). On this membrane three 
points were pierced on the edges of this filter through the agar using a needle, 
which help in the alignment of plate and membrane after the detection step. The 
membrane was then peeled off the membrane in one movement and placed on 
another AMP-LB-Agar plate containing 250 µM IPTG to induce gene expression 
in the cells. The attachment was made so that the first contact point between the 
membrane and the plate in the middle, and lower from that point to the sides. The 
plate was incubated for about 4 hours at 37°C, while the master plate was 
incubated at 30°C incubator to allow the master colonies grow again. Four plates 
were hence prepared for next steps. Each Petri dish contained Whatman paper 
soaked in each of the solutions mentioned in 2.1.2.3.2.4 successively, and 
marked as A, B, C, and D corresponding to the solution they contain. Excess of 
those solutions were discarded leaving them moist but not wet. The nitrocellulose 
membrane was incubated for a further 10 minutes in solution A, five minutes in 
solution B, five minutes in solution C twice, and finally 15 minutes in solution D, 
as follows: 
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The membrane was subsequently developed in the same way as explained in the 
Western blotting protocol (2.2.3.7).  
It is advised to have the following plates as controls with the main experiment:  
* A plate of empty host bacteria without the expression plasmid.  
* A plate with host cells with the empty expression vector. 
 
1.2.3.9. Blastocystis enolase assay  
The reaction was measured in 4 ml quartz-cuvettes over a period of 5 minutes. 
The first minute was used to allow for NADH auto-degradation, until absorbance 
was stabilised. At which point the protein was added to initiate the reaction.   
The final assay mixture contained the following: 81 mM triethanolamine, 1.9 mM 
2-phosphoglycerate, 0.12 mM ß-nicotinamide adenine dinucleotide reduced 
form, 25 mM magnesium sulphate, 100 mM potassium chloride, 1.3 mM 
adenosine 5'-diphosphate, 7 units pyruvate kinase, 10 units L-lactic 
dehydrogenase and 0.025-0.05 unit Enolase.  Where one enzyme unit is defined 
as the amount that will convert 1 µmole of the substrate (2- phosphoglycerate) to 
Solutions in order Incubation time 
Solution A 10 minutes 
Solution B 5 minutes 
Solution C 5 minutes, two times  
Solution D 15 minutes 
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phosphoenolpyruvate per minute at pH 7.4 at 25°C, see Equation 2.2 below for 
calculations. 
 
 
Where:  
 3= volume (in millilitres) of assay 
df= dilution factor  
6.22= millimolar extinction coefficient of β-NADH at 340 nm 
0.1= volume (in millilitre) of enzyme used 
 
For the determination of kinetic parameters (Michaelis-Menten, Km and Vmax), 0.5 
unit of the recombinant Blastocystis enolase in GF buffer was used with substrate 
concentrations ranging from 0.025-10 mg/ ml. The Michaelis-Menten Equation 
2.3 was followed. 
 
                                 V0 = Vmax * [S] / Km + [S] 
Where V0 is the initial velocity of the enzyme, while Vmax is the maximal velocity. 
S is the substrate (2-phosphoglycerate) concentration used in the assay and Km 
Equation 2.3 
 
Equation 2.2 
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is Michaelis-Menten constant representing the substrate concentration at which 
the reaction velocity is half the maximal velocity. SigmaPlot version 7 was used 
to calculate the Km and Vmax. 
1.2.3.10. Biochemical and biophysical characterisation of the 
proteins 
All activity assays and standard curves were performed using biological and 
technical triplicates 
2.2.3.10.1. BSA Standard curve 
A serial dilution of Bovine Serum Albumin (BSA) was made in concentration 
range from 0.25-2 mg/ml. The concentration was measured by mixing 20 µl of 
BSA of the serial dilutions with 980 µl Bradford reagent after being brought to 
room temperature and measuring the colour intensity using a spectrophotometer 
at 590 nm. A standard curve was produced and used for the measurement of the 
concentration of other unknown proteins studied in this project. 
2.2.3.10.2. Dynamic Light scattering, DLS 
Light passing through biological solutions will be scattered by the molecules it 
encounters through its path. In static light scattering, we analyse the intensity of 
the light, while in dynamic light scattering we measure the light’s fluctuation which 
is due to the Brownian motion of the particles. Dynamic light scattering measures 
the diameter of a particle that moves the same way as the studied protein.  In this 
method there is no need to know the concentration of the molecules, it only needs 
enough light to be scattered.  Light scattering measures the diffusion of the 
molecule in the solution and the statistics of the scattered signal is analysed in 
relation with a correlator and inverted to size distribution measurements 
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(Nobbmann, Connah et al. 2007). This method is a good non-invasive method, 
that requires small amounts of the protein, and able to detect a trace amount of 
aggregation in the sample. 
The protein sample was centrifuged for 20 min at 16,000 X g at 4°C. 18 µl of the 
purified centrifuged protein was injected in a special, cleaned, quartz cuvette. 
Several measurements (10 measurements in this case), with 10 acquisitions 
each measurement  and 20 seconds each acquisition time were recorded at 25°C 
using DynamPro Titan (Wyatt Technology Corporation). Data was analysed using 
the DYNAMICS programme (protein solution, USA). 
2.2.3.10.3. Differential Scanning Fluorimetry, DSF 
Aggregation might be a critical bottleneck towards drug development and protein 
production experiments. Many factors which were found experimentally and via 
observations, play an important role in protein stability, mainly the composition of 
the solution in which the protein is purified or crystallized in. Thermal shift assay 
is one of the valuable methods used to estimate the stability of the protein in 
different conditions in addition to the ability of having an insight into the protein-
ligand interactions (Senisterra, Chau et al. 2012)   
DFS was developed by Johnson and Johnson to overcome the problems met 
when developing new drugs faced through aggregation problems encountered 
when using different ligands, buffers or substrates. In this experiment the protein 
is mixed with a dye (SYPRO Orange in this case) that fluoresces once the protein 
is unfolded or aggregated. This extrinsic fluorescence signal is measured in terms 
of increments by 1°C/min, when a rise of temperature is introduced to the mix 
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between 25 - 95°C. The signal produced by this procedure is amplified by the 
machine and the plate fluorescence is captured using a CCD camera. 
The raw data is fitted according to standard equations to measure fluorescence 
intensity vs. temperature. Any changes in the composition of the protein solution 
would have a direct effect on the melting temperature of the protein, and hence 
affecting its stability (Mezzasalma, Kranz et al. 2007). A schematic representation 
of the thermal shift status that a protein undergoes is depicted in Figure 2.6. 
 
Figure 2. 6 Schematic diagram representing the theory of thermal shift assay. A: the shift in 
absorption is noticeable after exposure to high temperature. B: the mechanism by which SYPRO 
Orange get quenched by the protein after being heat- denatured (from Johnson & Johnson 
Pharmaceutical Research & Development).  
To estimate the thermodynamic stability of the protein, there is a need of 
estimating the equilibration between folded and unfolded protein (Niesen, 
Berglund et al. 2007) whether this denaturing is induced by a denaturant or by 
heat. 
Several dyes have previously been used in this context. Of which SYPRO Orange 
(excitation at 465 nm and emission at 610 nm) was proven to have several 
A 
B 
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beneficial characteristics: bright fluorescence, chemical stability, high 
fluorescence quantum yield and spectral properties suitable for RT-PCR 
instruments (Shi, Semple et al. 2013). The main benefit of using SYPRO Orange 
is its high signal to noise ratio (Senisterra and Finerty 2009). SYPRO Orange 
(Invitrogen) was used in this project, which binds to the unfolded/denatured 
protein after being heated using a qPCR machine (StepOneTM Real time PCR) 
and results were analysed using PROTEIN THERMAL SHIFTTM software, 
version 1.0 (Applied Biosystem, UK).  
Buffer-stability was determined in the same experiment and was assessed on 24 
buffers in duplicates. The reaction mixture was as follows: 
For 24 wells a master mix was prepared on ice, with a total volume of 450 µl 
containing:  
Protein     up to 0.133 mg/ml 
5,000 X SYPRO Orange     0.96 µl 
Water   up to 450 µl 
18 µl of the master mix was used in each well with 2 µl of the buffer screen or the 
studied compound (Vivoli, Novak et al. 2014). 
 
2.2.3.10.4. Protein parameter determination: 
Protein characteristics were analyzed using the online program ProtParam tool, 
http://expasy.org/tools/protparam.html. This facility helps calculating various 
protein characteristic parameters such as the iso-electric point of the protein pI, 
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its theoretical stability, estimated half-life, extinction coefficient, in addition to its 
theoretical molecular weight. All analyses are based on the provided amino acid 
sequence of the protein. 
2.2.3.10.5. Analytical ultra-centrifugation: 
The analytical ultra-centrifugation (AUC) experiment was conducted using 
facilities at the Research Complex at Harwell (RCH), Oxford.  
Analytical ultra-centrifugation enables detecting the molecular weight and the 
shape of macromolecules. Velocity sedimentation (VS) gives an idea about the 
shape and mass of the macromolecules studied while equilibrium sedimentation 
(ES) only provides the mass of the macromolecule (Cole, Lary et al. 2008). 
In analytical ultra–centrifugation the movement of a molecule in a solution is 
detected under the application of high speed produced by centrifugal forces. AUC 
establishes a balance between the sedimentation of the molecule under the 
centrifugal forces and the diffusion of the material in the other direction. 
Ultimately, a point is reached where there is no migration of material in the unit 
cell. 
This detected movement is measured, recorded and analyzed using software 
integrated in the system that helps controlling the entire experiment from 
initialization, running, and data collection. Data analysis software analyses the 
data and provides information about the hydrodynamic and thermodynamics of 
the macromolecule calculating parameters such as sedimentation and diffusion 
coefficients, and provides an estimate of the heterogeneity of the sample. 
The RCH facility offers the use of the Beckman Coulter ProteomeLab XL-1 
Protein Characterization System, which has an AN-60 Ti rotor that rotates up to 
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60,000 x rpm (about 290,000 x g). This high speed is used in sedimentation 
velocity (SV) experiments while lower speeds are used when performing 
sedimentation equilibrium (SE) experiments. This system comprises two 
integrated detection systems: Rayleigh Interference and Scanning UV/Visible 
optics equipped with a CCD camera with a high resolution (2048 X 96 pixels). 
The detection rate is conducted at a high scanning rate of roughly once every 5 
seconds.  
The other system used is Windows-user interface software that allows initiating 
the experiment, and also recording and analyzing the data and calculating the 
parameters reflecting the hydrodynamics and thermodynamics properties of the 
macromolecules. 
The AUC machine was operated by Professor David Scott (University of Oxford) 
at the Research Complex at Harwell (RCH). To conduct this experiment, three 
different concentrations of the protein were used: 1, 0.2 and 0.05 mg/ml of the 
protein using 400 µl of each sample. The protein was analysed by analytical 
centrifugation at 40,000 rpm speed generating about 129,000 X g. Each protein 
sample was centrifuged in a separate well, after being calibrated versus water. 
The procedure was conducted at 4°C using the rotor mentioned above, and AUC 
parameters were computed using the integrated software. 
2.2.3.10.6. Crystallization work  
2.2.3.10.6.1. Initial crystal trials 
Proteins were purified using different purification methods as explained in section 
2.2.3.3. Purified proteins were initially concentrated using Amicon® Ultra Millipore 
filters with varied cut-offs according to the protein’s molecular weight. A final 
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concentration of about 12 mg/ml was generally used to conduct the initial 
crystallization trials. Before starting crystallization a pre-crystallization test Kit 
(PCT™, Hampton Research) was used according to the manufacturer’s 
instructions. The pre-crystallization kit gives an idea of the concentrations to be 
used for setting crystallization dishes, and thus saving time and money.  In this 
experiment if a precipitate forms, it indicates that the protein is too concentrated 
and therefore likely that the screen will result in many amorphous precipitates. 
On the other hand, if the PCT kit produces clear drops (no precipitate at all) this 
would likely also be the case in the actual crystal screen. A set of screens were 
used in this project from different companies as mentioned in 2.1.2.3.2.7. The 
protein under study was pelleted by centrifugation at 12,000 X g for about 20 
minutes. A total of 50 µl was used for each screen. An automated robot was used 
in a high-throughput crystallization pipeline in Oxford Protein Production Facility 
(OPPF) at the University of Oxford. This Hydra instrument allows for loading 96-
well Greiner plates with both the screen blocks and the protein solution using 
nanolitre-scale droplets (usually 100 nl protein/100 nl screen). These are 
subsequently kept in a Formulatrix storage and imaging system at 21°C. Plates 
are checked at automatically at regular intervals via a remote web-interface 
facility equipping stereo-microscopes with Pixera imaging cameras. 
2.2.3.10.6.2. Crystal harvesting and X-ray data collection 
Remotely captured images of the crystal screens were regularly checked for any 
crystal formation. Crystals generally take between several hours to several weeks 
to form. Once detected, a crystal was left and repeatedly checked for further 
growth. Once it reached a satisfactory size, the crystal was harvested by the help 
of my colleague Dr. Michail Isupov in our Biocatalysis Centre in Exeter. The 
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crystal was harvested using a cryoprotectant prepared according to the 
conditions that the crystal grew in. Harvested crystals were subsequently stored 
in liquid nitrogen until sent to the Diamond Light Synchrotron Radiation Source 
(www.diamond.ac.uk) where data collection took place using beamlines I03 and 
I04-1 with the help of Dr. Isupov who assisted in data collection and analysis. 
 
2.2.3.10.6.3. Crystallization optimization  
Optimization steps were performed on the conditions that produced crystals with 
good diffraction potential after X-ray exposure for obtaining a better resolution. 
The optimization was performed using Hampton 96 well plates micro-batch 
utilizing an Oryx 6 automated crystallization robot (Douglas research, UK). This 
system contains a programme that helps setting an optimization screen with 
varying buffer, precipitant, or protein concentrations. 
 
2.2.3.10.7. Enzyme activity assay 
All enzyme activities were performed on gel filtration (GF) purified proteins in 
biological and technical triplicates. Details of activity assay are described in the 
main Blastocystis enolase biochemical characterization chapter.  
2.2.3.10.8. Homology modelling  
Homology modelling was used to predict the 3D structure of a protein with known 
sequence based on comparison with another protein with a solved 3D structure 
(the template protein). Homology modelling allows the prediction of possible 
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function of the studied protein in addition to possibly identifying the binding site, 
provided that residues of conserved pocket are intact. 
2.2.3.10.8.1. Template selection  
The template protein is chosen after performing a BLASTP search against the 
PDB database using the amino acid sequence of the protein of interest as the 
query sequence. The template should usually share more than 30% similarity 
with the studied protein and ideally would be a protein with a solved structure.  
2.2.3.10.8.2. Target -template alignment  
After selecting the most suitable (identical) sequence, multiple alignment analysis 
is performed using ClustalW (Larkin, Blackshields et al. 2007). Alignments are 
manually inspected to remove gaps and make sure known important residues are 
aligned.  
 
2.2.3.10.8.3. Model building and inspection  
Model building was conducted using the automated server at 
https://www.ebi.ac.uk/thornton-srv/databases/pdbsum/Generate.html. The 
quality of the model was checked and confirmed by superimposing the model 
structure on the template structure using PyMOL (http://www.pymol.org) and by 
manually inspecting the model (especially the active site). 
 
 
 
    
 
116 
 
 
 
Chapter 3. Bioinformatic  analysis of the Blastocystis glycolytic 
enzyme enolase  
The development of genomics and bioinformatics was a boon for the field of 
biology and molecular biology. Understanding the genomic potentials and 
capacities of an organism will enable a defined understanding of the metabolism 
and physiology of a pathogen. This knowledge has the potential to make a 
profound difference in drug development and therapeutics in order to possibly 
eradicate those pathogens. An important part of this process is to understand the 
critical proteins/enzymes that play important roles in the pathogen’s metabolism. 
In this chapter, an initial in silico analysis was initiated in order to predict several 
structural and functional characteristics of Blastocystis enolase, a key glycolytic 
enzyme. Several publically available tools were utilised in this study, using the 
amino acid sequences of the protein and other proteins from different organisms. 
Bioinformatics analyses and structural modelling methods were used.  This 
included identifying signature motifs of the enolase super family, checking for 
possible targeting signals, identifying a suitable homolog with a solved crystal 
structure to build a 3D model, predicting protein domains, etc. Phylogenetic 
analysis was performed on the Blastocystis enolase sequence to assess its 
possible evolutionary path.  
    
 
117 
 
3.1. Enolase super family  
Blastocystis enolase belongs to the enolase super family. This is a highly diverse 
and broad super family containing over 8,000 species from members of all 
domains of life. Blastocystis enolase sequence was run on Pfam database, this 
came back with two Pfam domains: enolase N (which is the N-terminal domain) 
and enolase C (which is the C-terminal domain) (see Fig. 3.1)(Gerlt, Babbitt et al. 
2012). 
 
Figure 3. 1 Predicted domain structure of Blastocystis enolase by Pfam. Showing Blastocystis 
enolase to belong to the enolase super family, which consists of two main Pfam domains: Enolase 
N; the N terminal domain and Enolase C; the C terminal TIM barrel domain. 
 
3.2. Pre-sequence and signature motif  
The DNA sequence encoding enolase has an open reading frame of 1350 
nucleotides, indicating that Blastocystis enolase is composed of 449 amino acids 
with predicted molecular mass of 48 kDa and predicted iso-electric point (PI) of 
6.56. 
Blastocystis enolase homologues were found using BLAST in the NCBI 
database. A BLASTP search of the translated Blastocystis enolase gene 
sequence was performed using the NCBI’s web interface using the non-
redundant protein sequence data base to identify possible homologues. An initial 
BLAST search of Blastocystis enolase sequences showed the high abundance 
of this protein in the tree of life, specifically Plantae. Homologues of Blastocystis 
enolase were identified in this research using a representative of each main group 
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including; Plantae (Malus domestica), Excavates (Trypanosome rangeli), Fungi 
(Rhizopus delemar), Amoebozoa (Entamoeba histolytica), Chromaveloata 
(Aphanomyces astaci), Animalia (Echinostoma caproni) as well as in Archaea 
(Archeon) and Bacteria (Clostridium and Escherichia coli (Dannelly and Reeves 
1988)). Blastocystis enolase exhibited high identity to previously characterized 
enolases from the previously mentioned groups in accordance with the fact that 
this is an essential enzyme and a highly conserved protein participating in several 
vital processes specifically glycolysis (Piast, Kustrzeba-Wojcicka et al. 2005). 
The multiple sequence alignment included homologues with similarities of at least 
60% except for bacteria and amoeba which was 57, and 58% respectively. 
Selected sequences and the Blastocystis query sequence were aligned using 
ClustalW (Larkin, Blackshields et al. 2007). The alignment shows that the primary 
structure conservation is not restricted to specific parts of the enolase sequence; 
it extends from N- to C-terminus, with highest similarity at the C-terminal, Figure 
3.1. 
This protein and its homologous share two conserved domains or two families; 
Enolase N forming the N terminus domain and enolase C forming the C terminus 
domain forming the TIM barrel domain. Enolase N is found at the N-terminus of 
the catalytic TIM-barrel like domain in enolase and other enzymes. Enolase C is 
found in enzymes that adopt TIM barrel fold. 
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Figure 3. 2 Multiple alignment of deduced amino acid sequences of Blastocystis enolase with 
proteins from taxonomically diverse organisms. It shows strict identity indication highly conserved 
regions identical residues are indicated with identical colours. The figure definitely shows no 
differences between conserved groups. The organisms studied in this alignment and their accession 
numbers were as follows: Homo sapiens (BAD96912.1); Clostridium (WP_010294244.1); Malus 
domestica (XP_008391739.1); Aphanomyces astaci (XP_009829255.1); Archeon (KHO45292.1); 
Echinostoma caproni (ABI26619.1); Rhizopus delemar (EIE87278.1); Entamoeba histolytica 
(XP_649161.1); Trypanosome rangeli ESL052 19.1). 
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Blastocystis MLS--RLSTT SFK-ALTRAA STITAVNART VLDSRGNPTV EVDVTTQDG- TFRASVPSGA STGIHEALEL RDGGKA-YNG KGVTKAVNNV KTIIGPHICG Blastocystis
Aphanomyces astaci MLSQQRAVTK ALRHTQARFA STIKKVHARE IIDSRGNPTV EVDLTTEQG- LFRASVPSGA STGIHEAVEL RDGGKR-YLG KGVIQAVNNV KNIIGPKLEG Aphanomyces astaci
archaeon ---------- ---------M AKIRSVHARE ILDSRGNPTV EVELTSTDG- YVVAMVPSGA STGIHEALEL RDGGKR-YNG RGVLKAVKNI NTIIAPLIKG archaeon 
Entamoeba histolytica ---------- ---------- MSIQKVHARE ILDSRGNPTI EVEITTGKG- MFRSCVPSGA STGVHEAVEL RDGDKKRYGG KGVLKAVENV NTIIGPALLG Entamoeba histolytica 
Echinostoma caproni ---------- ---------- MAIKSIHARQ IFDSRGNPTV EVDVTTAKG- LFRAAVPSGA STGVHEALEL RDGPPG-YMG KGVLKAVSNV NNQIAPGLLK Echinostoma caproni
Clostridium ---------- ------MKQY VEIIDVYARQ ILDSRAFPTV EVEVTLDDGT VGRAAVPSGA STGMFEAVEL RDGDKAVYNG KGVLKAVDNV NEIIAEELVG Clostridium
Homo sapiens ---------- ---------- MSILKIHARE IFDSRGNPTV EVDLFTSKG- LFRAAVPSGA STGIYEALEL RDNDKTRYMG KGVSKAVEHI NKTIAPALVS Homo sapiens
Malus domestica ---------- ---------M ATIQSVKARQ IFDSRGNPTV EVDIILSDGT LARAAVPSGA STGVYEALEL RDGGKD-YLG KGVSKAVNNV NTIIGPALIG Malus domestica
Rhizopus delemar ---------- ---------M STVTKVHARQ IFDSRGNPTV EVEVTTAKG- VFRAAVPSGA STGIHEALEL RDGDKSQYMG KGVTKAVNNV NSVIAPALIE Rhizopus delemar 
Trypanosoma rangeli ---------- ---------- MTIQKVHGRE VLDSRGNPTV EVEVTTELG- VFRSIVPSGA STGVHEACEL RDDDKRRYLG KGCLHAVKNV NDVLAPALVG Trypanosoma rangeli 
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Blastocystis MDV--TDIYA IDDLMFQ-LD GTKN-----K GKLGANAILG TSLACVKAGA AAQKIPLYKF FADMAGKDK- FVLPVPSMNV INGGKHAGNA LAFQEFMLMP Blastocystis
Aphanomyces astaci MDP--TNQSE IDLLMKQ-LD GTDN-----K GNLGANAILG VSLAVAKAGA RAKSIPLFQH FADLSGNDK- LVLPVPSFNV INGGSHAGNQ LAFQEFMILP Aphanomyces astaci
archaeon KDP--AEQKS IDELMIK-KD GTKN-----K SKLGANAILG VSLAVCRAGA LARDKPLYLH IAGLAEPPR- PVLPVPFFNV INGGRHAGNK LDVQEYMIAP archaeon 
Entamoeba histolytica KNV--LNQAE LDEMMIK-LD GTNN-----K GKLGANAILG CSMSICRAAA AEKGLPLYKY LAELTGHKE- MTMPVPCFNV INGGAHAGNA LAMQEFMICP Entamoeba histolytica 
Echinostoma caproni CGIPVTDQAG IDNFMLQ-LD GTPN-----K EKLGANAILG VSLAVCKAGA AEKGLPLYKY IASLAGNND- VVMPVPSFNV INGGSHAGNK LAMQEFMIMP Echinostoma caproni
Clostridium MNV--FDQVA IDKLMIE-LD GTKN-----K GKLGANAMLG VSLACAKAAA ESLGLGLYQY IGGVN--AK- -VLPVPMMNI LNGGKHADNN VDLQEFMIMP Clostridium
Homo sapiens KKLNVTEQEK IDKLMIE-MD GTEN-----K SKFGANAILG VSLAVCKAGA VEKGVPLYRH IADLAGNSE- VILPVPAFNV INGGSHAGNK LAMQEFMILP Homo sapiens
Malus domestica KDP--SEQTA IDNFMVQQLD GTVNEWGWCK QKLGANAILA VSLAVAKAGA SVKKVPLYKH IANLAGNKN- LVLPVPAFNV INGGSHAGNK LAMQEFMILP Malus domestica
Rhizopus delemar SKIPVTEQKA IDEFLIE-LD GTPN-----K GKLGANAILG VSLAVAKAAA GDKGVPLYVH FADLAGSKKP FVLPVPAFNV INGGSHAGNK LAMQEFMILP Rhizopus delemar 
Trypanosoma rangeli KDE--LQQAT LDQLMRD-LD GTAN-----K SRLGANAILG CSMAISKAAA ARKGIPLYRY LAELAGSKE- IRLPVPCFNV INGGKHAGNA LPFQEFMIAP Trypanosoma rangeli 
210 220 230 240 250 260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis VGAKSFSEAM QIGCEVYHSL KSVIKKRYGL DATNVGDEGG FAPSIKSNIE GLDILSEAIE KAGYAK--EV RIAMDCAASE FYT-QDGYYD LMFKQGG--G Blastocystis
Aphanomyces astaci TGAESFSEAM VMGCEVYHHL KGVIKKKYGQ DATNVGDEGG FAPNIQSNHE GVELLMLAIE KAGYTG--KI GIGMDVASSE FYT-ESKHYD LNFKNPG--S Aphanomyces astaci
archaeon LGAKTFAEAL RMGAETYHTL KGIIQEKYGK NAINVGDEGG FAPPLDHIEE PLKLLVEAIK KAGFAG--KI KIAMDAAASE FYVEKKKCYN LQGKDVD--- archaeon 
Entamoeba histolytica TGATNFHEAL RMAAETYQCL KVVIKAKYGQ DATNVGDEGG FAPNVSGARE ALDLLVEAIA KAGYTG--KI EIAMDCAASE FYNEETKKYD LGKKIPADKK Entamoeba histolytica 
Echinostoma caproni TGASSFAEAM KIGSEVYHHL KAVIKGKYGL DACNVGDEGG FAPNIQDNLE GLELLRTAIE KAGYTG--KV KIAMDSAASE FYK-EGK-YD LDFKNPK--S Echinostoma caproni
Clostridium VGAKSFSEAL RMCAEVYHTL KSILKEKG-- LGTGVGDEGG FAPNLASNEE AIKVIMEAIE KAGYKAGEEI FLALDPASSE FFE--DGKYN LSGEGRI--- Clostridium
Homo sapiens VGAANFREAM RIGAEVYHNL KNVIKERYGK DATNVGDEGG FAPNILENKE GLELLKTAIG KAGYTD--KV VIGMDVAASE FFR-SGK-YD LDFKSP---D Homo sapiens
Malus domestica IGASSFKEAM KMGVEVYHNL KSVIKKKYGQ DATNVGDEGG FAPNIQENRE GLELLKTAIE KAGYTG--KV VIGMDVAASE FYG-SDKTYD LNFKEEK--N Malus domestica
Rhizopus delemar TGAKSFKEAM KIGSEVYHNL QSVIKAKYGL DATNVGDEGG FAPNIQKNEE GLDLLVQAIE KAGYTG--KV KIGMDCAASE FYK-DGK-YD LDFKNPN--S Rhizopus delemar 
Trypanosoma rangeli VKASSFSEAL RMGSEVYHAL KSIIKKKYGQ DAVNVGDEGG FAPPITDINE PLPILMEAIE QAGHKG--KF AICMDCAASE TYDENKKQYN LTFKSPN--- Trypanosoma rangeli 
310 320 330 340 350 360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis MKK---SKEQ MTELYIKLVK DYPIVSIEDP FEQDDWAAYA LLREKIGKDV QIVGDDLLVT NPARIAEAIQ KKACNALLLK VNQIGSVTES VQACLDSQAA Blastocystis
Aphanomyces astaci KEAP-LTGEQ LGQLYKDLAK EFPIISIEDP FDQDDWEHYS AFTAAIGTDV QVVGDDLLCT NPTRIAKAVG IKACNALLLK VNQIGSVSES IQAVKDAKAA Aphanomyces astaci
archaeon -------SLE LADIYKYLVK TYPIISIEDP FSEDDWESFY VLTKSIGKKV QIVGDDLTVT NPERLQRAIT QKSATALLLK VNQIGTVTES LQAAAMCKGH archaeon 
Entamoeba histolytica DPSLVKDVDG LIAEYVDYGK HYPIASIEDP FAEDDWAAWN KFT-VEHGNF QIVGDDLLVT NPARVQMAMD KNACNSVLIK VNQIGTLTET FKTIKMAQEK Entamoeba histolytica 
Echinostoma caproni PASSWISSDA MADVYKKMMS TYPIVSIEDP FDQDDWPAWT KLTGECK--I QIVGDDLTVT NPLRVQKAID QKACNCLLLK VNQIGSVTES IQACKMAQSA Echinostoma caproni
Clostridium -----LTPEE MADYYVELAN KYPIISIEDG MAEEDWEGWK HLTDKIGDKV QLVGDDLFVT NTERLAMGFE KEVANSILIK LNQIGTLTET INAIEMASRK Clostridium
Homo sapiens DPSRYISPDQ LADLYKSFIK DYPVVSIEDP FDQDDWGAWQ KFTASAG--I QVVGDDLTVT NPKRIAKAVN EKSCNCLLLK VNQIGSVTES LQACKLAQAN Homo sapiens
Malus domestica DGSQKISGNA LKDLYKSFAS EYPIVSIEDP FDQDDWEHYA KMTAEVGEKI QIVGDDLLVT NPKRVEKAIK EKSCNALLLK VNQIGSVTES IEAVRMSKKA Malus domestica
Rhizopus delemar DQSKWIDGKE LTALYSSFAS KYPIVSIEDA FDQDDWEAWT HLNETSD--F QLVGDDLLVT NPKRIATAIE KKSCNALLLK VNQIGTLTES IQAAKDSQAA Rhizopus delemar 
Trypanosoma rangeli --ATWVTAKQ LGETYAKWVS EYPIVSIEDP YDQDDFEGFA GITEVLKGKA QVVGDDLTVT NVARIKMAIE KKACNSLLLK INQIGTITEA IDASKLCMAN Trypanosoma rangeli 
410 420 430 440 450 460 470
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ....|....| ...
Blastocystis GWGVMVSHRS GETEDNYIAD LAVGLCSGQI KTGAPCRSER LAKYNQLLRI EESLGSKAVY AGLN-FRTPD RC-                               Blastocystis
Aphanomyces astaci GWGVMTSHRS GETEDSYIAD LAVGLSTGQI KTGAPCRSER LAKYNQLLRI EEMLGRSAVY AGKH-FRNPH EA-                               Aphanomyces astaci
archaeon GWNVMVSHRS GETEDSFIAD LVVGLGCGQL KSGAPCRSER VAKYNQLIRI EEQLGKKAVY GGKR------ ---                               archaeon 
Entamoeba histolytica GWGVMASHRS GETEDTFIAD LVVGLNCKQI KTGAPCRSER LCKYNQLMRI EEELGN-IPY AGKN-WRNST A--                               Entamoeba histolytica 
Echinostoma caproni GWGVMVSHRS GETEDNFIAD LVVGLRTGQI KTGAPCRSER LAKYNQLLRI EEDLGSAAKY AGEN-FRRP- ---                               Echinostoma caproni
Clostridium GYTAVVSHRS GETEDTTIAD LVVAMNAGQI KTGAPARSER VAKYNQLLRI EEELGDMAEY RGMNSFYNIK R--                               Clostridium
Homo sapiens GWGVMVSHRS GETEDTFIAD LVVGLCTGQI KTGAPCRSER LAKYNQLLRI EEELGSKAKF AGRN-FRNPL AK-                               Homo sapiens
Malus domestica GWGVMTSHRS GETEDTFIAD LAVGLATGQI KTGAPCRSER LAKYNQLLRI EEELGAEAVY AGAK-FRVPV EPY                               Malus domestica
Rhizopus delemar GWGVMVSHRS GETEDTTIAD LVVGLRTGQI KTGAPCRSER LAKYNQLLRI EEELGENCIY AGEN-FRNAH EL-                               Rhizopus delemar 
Trypanosoma rangeli GWSVMVSHRS GETEDTYIAD LVVGLGSGQI KTGAPCRGER TAKLNQLLRI EEELG---AH AKFG-FPAWA ---                               Trypanosoma rangeli 
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3.2.1. Enolase pre-sequence analysis  
A more detailed BLAST search was performed using more representatives of 
several groups of life.  All sequences that lacked an obvious start at their amino-
terminus were excluded manually. Aligned sequences were inspected by eye and 
sequences containing aberrant sequence regions that were highly divergent and 
ambiguously aligned positions were removed manually before the subsequent 
phylogenetic analysis.  
Although there is no consensus sequence for mitochondrial targeting signals, the 
N-terminal amino acids usually shows a bias in distribution forming a kind of a 
pattern that was related to a mitochondrial targeting signal. This pattern seems 
to be associated with cleavage of precursor protein by a certain protease. In 
literature, the mitochondrial targeting peptides (mTP) were found to be rich in 
basic, hydrophobic and hydroxylated residues and they lack acidic amino acids. 
Using those features helped in building predictions for the mitochondrial targeting 
sequence (von Heijne 1986). Possible targeting signals in this project were 
detected using the following four programmes; Mitoprot (Claros 1995), Predator 
(Small, Peeters et al. 2004), TargetP (Emanuelsson, Brunak et al.), and iPSORT 
(Bannai, Tamada et al. 2002) as indicated in Table 3.1 which shows the prediction 
signal with cleavage site and sequence when applicable. Each sequence was 
checked for possible targeting signals and Figure 3.2 shows the N-terminal region 
of several enolase proteins which indicate a possible mitochondrial targeting 
signal. Sequences with predicted mitochondrial targeting signal were rich in basic 
residues with no acidic amino acids at all.  
It is suggested that a kind of sequence specificity might be available for 
mitochondrial targeting peptides. This was found to be true as the mitochondrial 
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targeting signals were later found to be sharing the following features: argenine 
rich in position -2, -3, -10 and -11 in relation to the cleavage site, or at least a 
small and neutral residue close to the cleavage site, for the cleavage to occur 
(Nielsen, Engelbrecht et al. 1996). Another feature was found for mTPs, which 
was a bias towards having hydrophobic residues in position -8 that have arginine 
in position -10 of the mitochondrial targeting peptide (mTP) (Gavel and von Heijne 
1990).  
In this particular project, those predicted targeting signals followed the description 
expected of having a net positively charged mitochondrial targeting residues, with 
a length between 17-70 (typically 30), enriched with arginine residues specially 
at the cleavage sites R-2, R-3, R-10, apart from few who had different localization 
of the arginine residues, Figure 3.3. And as mentioned in Heijne et al analysis of 
the mTP, the R-10 had the conserved R-X (F-I-L), and it was isoleucine (I) in this 
instance. A similar alignment was made between Blastocystis and members of 
the stramenopiles group, Figure 3.4.  Those spotted patterns around the cleavage 
site, could be an indicator of a single protease responsible for the cleavage of 
mTP in R-2 and R-3, as well as the first cleavage of R-10 (Gavel and von Heijne 
1990). 
Analysis of the targeting signal in this project suggests that the Blastocystis 
enolase possibly contains a mitochondrial targeting signal with high support 
values. It seems that stramenopiles in general also contain a mitochondrial 
targeting signal on their enolase which is quite interesting finding. Most 
stramenopiles With the exception of Saprolegnia parasitica, Plasmopara halstedii 
and Aureococcus anophagefferens, seem to contain these pre-sequences as 
well. Those studied expressed high tendency for targeting the mitochondria with 
    
 
122 
 
a signal prediction of 0.93 and more, except for Phaeodactylum tricornutum which 
had a value of 0.65 for signalling the mitochondria.   
 
Figure 3. 3 Analysis of the N-terminal region of Blastocystis enolase in comparison to other 
organisms, indicating a possible mitochondrial targeting signal depending on Mitoprot (Claros 
1995). Targeting signals were predicted using four programs; MitoProt, Prodeator, iPSORT, and 
TargetP. The predicted targeting signals are underlined in the figure in black colour. The figure 
shows no targeting signal for bacteria; Clostridum (WP_010294244.1|) and other organisms used 
have the following accession numbers respectively. Blastocystis of the study, Aureococcus 
anophagefferens (EGB09778.1), Ectocarpus siliculosus (CBJ32586.1), Trichomonas vaginalis 
(EAY10059.1), Allomyces macrogynus (KNE63834.1), Ectocarpus siliculosus (CBN78148.1), 
Phaeodactylum tricornutum (EEC42834.1), Aphanomyces astaci (ETV81397.1), Aphanomyces 
invadans (ETV95487.1), Phytophthora parasitica (ETO77406.1), Saprolegnia diclina (EQC41869.1), 
Hammondia hammondi (KEP66655.1), Toxoplasma gondi (EPR64867.1), Tetrahymena thermophila 
(EAR94453.1), Ichthyophthirius multifiliis (EGR28782.1), Oxytricha trifallax (EJY82089.1), 
Paramecium tetraurelia (CAK85009.1), Acanthamoeba castellanii (ELR15398.1), Dictyostelium 
fasciculatum (EGG24313.1), Entamoeba invadens (BAN40624.1), Arabis alpine (KFK32725.1). 
 
 
Figure 3. 4 Sequence alignment of the amino terminal region of enolases from stramenopiles. The 
underlined sequence represents the predicted targeting signal of Blastocystis sp.  Accession 
numbers from top to bottom; Blastocystis (KNB43609.1), Aphanomyces astaci (ETV81397.1), 
Ectocarpus siliculosus (CBJ32586.1), Saprolegnia diclina (EQC41869.1), Aphanomyces invadans 
(ETV95487.1), Nannochloropsis gaditana (EWM28602.1), Phytophthora parasitica (ETO77406.1), 
Albugo candida (CCI42145.1), Thalassiosira pseudonana (EED92063.1), Phaeodactylum tricornutum 
(EEC42834.1), Aureococcus anophagefferens (EGB09778.1). 
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These finding that enolase is targeting the mitochondria is quite interesting and 
is in accordance with Liaud et al (2000). In their study they demonstrated that 
some glycolytic proteins of stramenopiles are targeting the mitochondria, in 
addition to Takishita et al work that mentioned the same hypothesis (Liaud, 
Lichtle et al. 2000, Nakayama, Ishida et al. 2013). Another interesting remark in 
this project is the finding that Blastocystis enolase targeting signal was 
significantly shorter (16 amino acid) than other mitochondrial targeting signals 
detected. The same remark was noticed in stramenopiles’ putative mitochondrial 
targeting sequences, though not as short as Blastocystis enolase targeting signal 
sequence.  
Previous studies have mentioned the short mitochondrial targeting signal such as 
those found on the Trichomonas vaginalis hydrogenosomal proteins which 
ranged between 5-14 amino acids (Bradley, Lahti et al. 1997). Those studies have 
indicated to the possibility that these short signals might need further assistance 
by other internal signals (Burri and Keeling 2007). According to Keeling and Burri 
(2007) pre-sequences are generally larger in yeast and mammals and can be as 
big as 20-80 amino acids, while they were reported to be shorter in parasites such 
as T. vaginalis (5-14 amino acids) and (20-30 amino acids) in fungal 
hydrogenosomes such as Neocallimastix frontalis (vanderGiezen, Rechinger et 
al. 1997). 
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Table 3. 1 Possible mitochondrial targeting signal on enolase sequences from several organisms. 
Prediction performed using TargetP (http://ipsort.hgc.jp/), Mitoprot (Claros 1995), iPsort (Nielsen, 
Engelbrecht et al. 1996, Emanuelsson, Nielsen et al. 2000) and Predator 
(https://urgi.versailles.inra.fr/predot ar/predotar.html). 
Organism  TargetP  MitoProt probability/ 
targeting signal 
iPsort Predotar 
Blastocystis hominis 0.831 0.9829 
MLSRVSAISLKSFTRA 
MLSRV SAISL KSFTR 
AASTI TAVNA RQVLD 
0.82 
Aphanomyces astaci 0.823  
 
0.9849 
MLSQQRAVTKALRHTQARF
ASTIKKVHAREIIDSRGNP 
MLSQQ RAVTK ALRHT 
QARFA STIKK VHARE 
0,50 
Ectocarpus 
siliciolocus  
0.908 0.9871 
MLSTMSSAAVRASRPVLAR
NMSAITAVNGRYIIDSRGNP 
MLSTMSSAAVRASRPVL
ARNMSAITAVNGR 
0.57 
Saprolegnia diclina 0.791 
 
0.9913 
MQAARPTASTLQRRFASTIK
KVHAREIIDSRGNP 
MQAAR PTAST LQRRF 
ASTIK KVHAR EIIDS 
0,16 
Aphanomyces 
invadans 
0.828 
 
0.9930 
MLSQQRAVTKLLRQTQTRF
ASTIKKVHAREIIDSRGNP 
MLSQQ RAVTK LLRQT 
QTRFA STIKK VHARE 
0,57 
Nannochloropsis 
gaditana 
0.912 
 
0.9615 
MLFTLSLKKPALAAGRLSAA
RAASTITAIKGRQIIDSRGNP 
MLFTL SLKKP ALAAG 
RLSAA RAAST ITAIK 
0,94 
Phytophthora 
parasitica 
0.922 
 
0.9970 
MLARTSALRRAATTATGAVR
NASTIQSIHAREIIDSRGNP 
 
MLART SALRR AATTA 
TGAVR NASTI QSIHA 
0,71 
Plasmopara halstedii 0.246 
 
0.1958 
MVSILSIKARQIFDSRGNP 
No signal or mts 0,37 
Phaeodactylum 
tricornutum 
mTP  
0.287   
SP 
0.777 
 
0.6506 
MLFKPSTLLALFAVAGTTLAF
APRSTTTSLTSTTRGSASSS
VTTLAMSGITGVLAREILDSR
GNP 
Signal peptide, not 
mitochondrial 
MLFKP STLLA LFAVA 
GTTLA FAPRS TTTSL 
0.99   
ER 
0.21 mit 
Aureococcus 
anophagefferens 
0.082  
 
Not predictable 
0.1038 
No No mit 
No ER 
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3.2.2. Blastocystis enolase signature motif and amino acid 
discrepancies analysis 
A BLAST search of the Pubmed database with the deduced amino acid sequence 
of Blastocystis enolase revealed a strong identity with the homologous genes of 
several organisms representing the tree of life. The organisms and their 
accession number according to GeneBank database were as follows; 
Trypanosoma rangeli (ESL05219.1), Aphanomyces astaci (XP_009829255.1), 
Archaeon (KHO45292.1d), Entamoeba histolytica (XP_649161.1), Echinostoma 
caproni (ABI26619.1), Clostridium (WP_010294244.1), Homo sapiens 
(BAD96912.1), Malus domestica (XP_008391739.1), Rhizopus delemar 
(EIE87278.1), Leishmania mexicana (XP_003873490.1). Functional domain and 
key sites were estimated in two ways, either by comparing the amino acid 
sequence with already studied protein of different organisms, or by using 
automated servers that predicted the function based on the amino acid sequence 
of the query protein as well, like the new tool offered by embl-ebi, InterProScan 
(http://www.ebi.ac.uk/InterProScan/).  
By analysing the aligned sequences it was noticed that the primary sequence 
revealed the conservation of several structural features of enolase. Most 
importantly, Blastocystis enolase sequence included the four potential Mg2+ 
binding sites, which were in Blastocystis enolase as follows: Ser 57, Asp 259, Glu 
306, Asp 333. Those residues were indicated to by black arrowheads in Figure 
3.5. Mg2+ is a divalent cation important for activating the enzyme, and works as 
its natural cofactor. Residues for potential substrate binding site which are crucial 
for enzyme activity were all located and indicated in the same figure with black 
star at (His 172, Glu 224, Lys 358, His 386, Arg 387, Ser 388). Those four metal 
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binding residues and the six substrate binding residues are important for enzyme 
function and dimerization of enolase, and were reported in other studies (Gan, 
Zhao et al. 2010, Carabarin-Lima, Rodriguez-Morales et al. 2014). This 
comparison reveals that residues responsible for both substrate and metal 
binding are invariably present in Blastocystis enolase sequence and other 
sequences as well. 
Moreover, enolase signature was predicted at the C-terminus amino acid 
sequence covering the region 355-368 (LLLKVNQIGSVTES) as predicted by 
PROSITE for motif scan detection tool. Enolase signature was underlined in Fig 
3.5. In Blastocystis enolase deduced sequence, a characteristic enolase family 
fingerprint motif was also detected at 385-393 (SHRSGETED) (located at the C-
terminal of the protein sequence), and this was clearly highly conserved in the 
organisms studied in this research and in other organisms studied to date 
(Quinones, Pena et al. 2007). A plasminogen-binding site which was previously 
detected in Leishmania mexicana was not conserved in Blastocystis enolase 
sequence (not included in this search), while it appeared in Trypanosoma rangeli 
sequence included in this project search (TYDENKKQY). This indicates that no 
plasminogen-binding activity is expected in Blastocystis enolase. Blastocystis 
enolase amino acid sequence was submitted to Uniprot server and the 
annotations revealed by its Blast search are summarized in Table 3.2. 
http://www.uniprot.org/blast/.  
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Table 3. 2. Special features in Blastocystis enolase sequence as annotated by Uniprot server, 
http://www.uniprot.org/blast/. The table shows the important regions in the protein sequence for its 
activity and classification. 
Feature key Position(s) Length Residue  Description  
Function  
Binding site  171-171 1 K Substrate  
Binding site 181-181 1 E Substrate  
Active site  224-224 1 E Proton donor  
Binding site 306-306 1 E Substrate 
Binding site 333-333 1 D Substrate 
Active site 358-358 1 K Proton acceptor 
Binding site 409-409 1 K Substrate 
Family and domains  
Region  385-388 4  SHRS Substrate binding  
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10 20 30 40 50
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis MLS--RLSTT SFK-ALTRAA STITAVNART VLDSRGNPTV EVDVTTQDG-
Trypanosoma rangeli ---------- ---------- MTIQKVHGRE VLDSRGNPTV EVEVTTELG-
Aphanomyces astaci MLSQQRAVTK ALRHTQARFA STIKKVHARE IIDSRGNPTV EVDLTTEQG-
archaeon ---------- ---------M AKIRSVHARE ILDSRGNPTV EVELTSTDG-
Entamoeba histolytica ---------- ---------- MSIQKVHARE ILDSRGNPTI EVEITTGKG-
Echinostoma caproni ---------- ---------- MAIKSIHARQ IFDSRGNPTV EVDVTTAKG-
Clostridium ---------- ------MKQY VEIIDVYARQ ILDSRAFPTV EVEVTLDDGT
Homo sapiens ---------- ---------- MSILKIHARE IFDSRGNPTV EVDLFTSKG-
Malus domestica ---------- ---------M ATIQSVKARQ IFDSRGNPTV EVDIILSDGT
Rhizopus delemar ---------- ---------M STVTKVHARQ IFDSRGNPTV EVEVTTAKG-
Leishmania mexicana ---------- ---------- MPIQKVHARE VLDSRGNPTV EVELMTEAG-
60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis TFRASVPSGA STGIHEALEL RDGGKA-YNG KGVTKAVNNV KTIIGPHICG
Trypanosoma rangeli VFRSIVPSGA STGVHEACEL RDDDKRRYLG KGCLHAVKNV NDVLAPALVG
Aphanomyces astaci LFRASVPSGA STGIHEAVEL RDGGKR-YLG KGVIQAVNNV KNIIGPKLEG
archaeon YVVAMVPSGA STGIHEALEL RDGGKR-YNG RGVLKAVKNI NTIIAPLIKG
Entamoeba histolytica MFRSCVPSGA STGVHEAVEL RDGDKKRYGG KGVLKAVENV NTIIGPALLG
Echinostoma caproni LFRAAVPSGA STGVHEALEL RDGPPG-YMG KGVLKAVSNV NNQIAPGLLK
Clostridium VGRAAVPSGA STGMFEAVEL RDGDKAVYNG KGVLKAVDNV NEIIAEELVG
Homo sapiens LFRAAVPSGA STGIYEALEL RDNDKTRYMG KGVSKAVEHI NKTIAPALVS
Malus domestica LARAAVPSGA STGVYEALEL RDGGKD-YLG KGVSKAVNNV NTIIGPALIG
Rhizopus delemar VFRAAVPSGA STGIHEALEL RDGDKSQYMG KGVTKAVNNV NSVIAPALIE
Leishmania mexicana VFRSAVPSGA STGVHEACEL RDGEKARYCG AGCMQAVKNV NEILAPALVG
110 120 130 140 150
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis MDV--TDIYA IDDLMFQ-LD GTKN-----K GKLGANAILG TSLACVKAGA
Trypanosoma rangeli KDE--LQQAT LDQLMRD-LD GTAN-----K SRLGANAILG CSMAISKAAA
Aphanomyces astaci MDP--TNQSE IDLLMKQ-LD GTDN-----K GNLGANAILG VSLAVAKAGA
archaeon KDP--AEQKS IDELMIK-KD GTKN-----K SKLGANAILG VSLAVCRAGA
Entamoeba histolytica KNV--LNQAE LDEMMIK-LD GTNN-----K GKLGANAILG CSMSICRAAA
Echinostoma caproni CGIPVTDQAG IDNFMLQ-LD GTPN-----K EKLGANAILG VSLAVCKAGA
Clostridium MNV--FDQVA IDKLMIE-LD GTKN-----K GKLGANAMLG VSLACAKAAA
Homo sapiens KKLNVTEQEK IDKLMIE-MD GTEN-----K SKFGANAILG VSLAVCKAGA
Malus domestica KDP--SEQTA IDNFMVQQLD GTVNEWGWCK QKLGANAILA VSLAVAKAGA
Rhizopus delemar SKIPVTEQKA IDEFLIE-LD GTPN-----K GKLGANAILG VSLAVAKAAA
Leishmania mexicana KDE--SDQAG LDKMMCE-LD GTKN-----K SKLGANAILG CSMAISKAAA
160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis AAQKIPLYKF FADMAGKDK- FVLPVPSMNV INGGKHAGNA LAFQEFMLMP
Trypanosoma rangeli ARKGIPLYRY LAELAGSKE- IRLPVPCFNV INGGKHAGNA LPFQEFMIAP
Aphanomyces astaci RAKSIPLFQH FADLSGNDK- LVLPVPSFNV INGGSHAGNQ LAFQEFMILP
archaeon LARDKPLYLH IAGLAEPPR- PVLPVPFFNV INGGRHAGNK LDVQEYMIAP
Entamoeba histolytica AEKGLPLYKY LAELTGHKE- MTMPVPCFNV INGGAHAGNA LAMQEFMICP
Echinostoma caproni AEKGLPLYKY IASLAGNND- VVMPVPSFNV INGGSHAGNK LAMQEFMIMP
Clostridium ESLGLGLYQY IGGVN--AK- -VLPVPMMNI LNGGKHADNN VDLQEFMIMP
Homo sapiens VEKGVPLYRH IADLAGNSE- VILPVPAFNV INGGSHAGNK LAMQEFMILP
Malus domestica SVKKVPLYKH IANLAGNKN- LVLPVPAFNV INGGSHAGNK LAMQEFMILP
Rhizopus delemar GDKGVPLYVH FADLAGSKKP FVLPVPAFNV INGGSHAGNK LAMQEFMILP
Leishmania mexicana AKAGVPLYRY IAALAGTKD- IRLPVPCFNV INGGKHAGNV LPFQEFMIAP
210 220 230 240 250
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis VGAKSFSEAM QIGCEVYHSL KSVIKKRYGL DATNVGDEGG FAPSIKSNIE
Trypanosoma rangeli VKASSFSEAL RMGSEVYHAL KSIIKKKYGQ DAVNVGDEGG FAPPITDINE
Aphanomyces astaci TGAESFSEAM VMGCEVYHHL KGVIKKKYGQ DATNVGDEGG FAPNIQSNHE
archaeon LGAKTFAEAL RMGAETYHTL KGIIQEKYGK NAINVGDEGG FAPPLDHIEE
Entamoeba histolytica TGATNFHEAL RMAAETYQCL KVVIKAKYGQ DATNVGDEGG FAPNVSGARE
Echinostoma caproni TGASSFAEAM KIGSEVYHHL KAVIKGKYGL DACNVGDEGG FAPNIQDNLE
Clostridium VGAKSFSEAL RMCAEVYHTL KSILKEKG-- LGTGVGDEGG FAPNLASNEE
Homo sapiens VGAANFREAM RIGAEVYHNL KNVIKERYGK DATNVGDEGG FAPNILENKE
Malus domestica IGASSFKEAM KMGVEVYHNL KSVIKKKYGQ DATNVGDEGG FAPNIQENRE
Rhizopus delemar TGAKSFKEAM KIGSEVYHNL QSVIKAKYGL DATNVGDEGG FAPNIQKNEE
Leishmania mexicana TKATSFREAL RMGSEVYHAL KVIIKNKYGQ DAVNVGDEGG FAPPIKHIDE
260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis GLDILSEAIE KAGYAK--EV RIAMDCAASE FYT-QDGYYD LMFKQGG-GM
Trypanosoma rangeli PLPILMEAIE QAGHKG--KF AICMDCAASE TYDENKKQYN LTFKSPN---
Aphanomyces astaci GVELLMLAIE KAGYTG--KI GIGMDVASSE FYT-ESKHYD LNFKNPG--S
archaeon PLKLLVEAIK KAGFAG--KI KIAMDAAASE FYVEKKKCYN LQGKDVD---
Entamoeba histolytica ALDLLVEAIA KAGYTG--KI EIAMDCAASE FYNEETKKYD LGKKIPADKK
Echinostoma caproni GLELLRTAIE KAGYTG--KV KIAMDSAASE FYK-EGK-YD LDFKNPK--S
Clostridium AIKVIMEAIE KAGYKAGEEI FLALDPASSE FFE--DGKYN LSGEGRI---
Homo sapiens GLELLKTAIG KAGYTD--KV VIGMDVAASE FFR-SGK-YD LDFKSP---D
Malus domestica GLELLKTAIE KAGYTG--KV VIGMDVAASE FYG-SDKTYD LNFKEEK--N
Rhizopus delemar GLDLLVQAIE KAGYTG--KV KIGMDCAASE FYK-DGK-YD LDFKNPN--S
Leishmania mexicana PLPILMEAIE KAGHKN--KF AICMDCAASE AYDAERKMYN LTFKNPE---
310 320 330 340 350
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis KK----SKEQ MTELYIKLVK DYPIVSIEDP FEQDDWAAYA LLREKIGKDV
Trypanosoma rangeli --ATWVTAKQ LGETYAKWVS EYPIVSIEDP YDQDDFEGFA GITEVLKGKA
Aphanomyces astaci KEAP-LTGEQ LGQLYKDLAK EFPIISIEDP FDQDDWEHYS AFTAAIGTDV
archaeon -------SLE LADIYKYLVK TYPIISIEDP FSEDDWESFY VLTKSIGKKV
Entamoeba histolytica DPSLVKDVDG LIAEYVDYGK HYPIASIEDP FAEDDWAAWN KFT-VEHGNF
Echinostoma caproni PASSWISSDA MADVYKKMMS TYPIVSIEDP FDQDDWPAWT KLTGECK--I
Clostridium -----LTPEE MADYYVELAN KYPIISIEDG MAEEDWEGWK HLTDKIGDKV
Homo sapiens DPSRYISPDQ LADLYKSFIK DYPVVSIEDP FDQDDWGAWQ KFTASAG--I
Malus domestica DGSQKISGNA LKDLYKSFAS EYPIVSIEDP FDQDDWEHYA KMTAEVGEKI
Rhizopus delemar DQSKWIDGKE LTALYSSFAS KYPIVSIEDA FDQDDWEAWT HLNETSD--F
Leishmania mexicana --PTYVSAAE LQATYERWVS EYPLVSIEDP FAEDNFDEFS AITKALAGRA
360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis QIVGDDLLVT NPARIAEAIQ KKACNALLLK VNQIGSVTES VQACLDSQAA
Trypanosoma rangeli QVVGDDLTVT NVARIKMAIE KKACNSLLLK INQIGTITEA IDASKLCMAN
Aphanomyces astaci QVVGDDLLCT NPTRIAKAVG IKACNALLLK VNQIGSVSES IQAVKDAKAA
archaeon QIVGDDLTVT NPERLQRAIT QKSATALLLK VNQIGTVTES LQAAAMCKGH
Entamoeba histolytica QIVGDDLLVT NPARVQMAMD KNACNSVLIK VNQIGTLTET FKTIKMAQEK
Echinostoma caproni QIVGDDLTVT NPLRVQKAID QKACNCLLLK VNQIGSVTES IQACKMAQSA
Clostridium QLVGDDLFVT NTERLAMGFE KEVANSILIK LNQIGTLTET INAIEMASRK
Homo sapiens QVVGDDLTVT NPKRIAKAVN EKSCNCLLLK VNQIGSVTES LQACKLAQAN
Malus domestica QIVGDDLLVT NPKRVEKAIK EKSCNALLLK VNQIGSVTES IEAVRMSKKA
Rhizopus delemar QLVGDDLLVT NPKRIATAIE KKSCNALLLK VNQIGTLTES IQAAKDSQAA
Leishmania mexicana QIVGDDLTVT NVERVRMAIE KSACNSLLLK INQIGTISES IAAAKLCMEN
410 420 430 440 450
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis GWGVMVSHRS GETEDNYIAD LAVGLCSGQI KTGAPCRSER LAKYNQLLRI
Trypanosoma rangeli GWSVMVSHRS GETEDTYIAD LVVGLGSGQI KTGAPCRGER TAKLNQLLRI
Aphanomyces astaci GWGVMTSHRS GETEDSYIAD LAVGLSTGQI KTGAPCRSER LAKYNQLLRI
archaeon GWNVMVSHRS GETEDSFIAD LVVGLGCGQL KSGAPCRSER VAKYNQLIRI
Entamoeba histolytica GWGVMASHRS GETEDTFIAD LVVGLNCKQI KTGAPCRSER LCKYNQLMRI
Echinostoma caproni GWGVMVSHRS GETEDNFIAD LVVGLRTGQI KTGAPCRSER LAKYNQLLRI
Clostridium GYTAVVSHRS GETEDTTIAD LVVAMNAGQI KTGAPARSER VAKYNQLLRI
Homo sapiens GWGVMVSHRS GETEDTFIAD LVVGLCTGQI KTGAPCRSER LAKYNQLLRI
Malus domestica GWGVMTSHRS GETEDTFIAD LAVGLATGQI KTGAPCRSER LAKYNQLLRI
Rhizopus delemar GWGVMVSHRS GETEDTTIAD LVVGLRTGQI KTGAPCRSER LAKYNQLLRI
Leishmania mexicana GWSVMVSHRS GETEDTYIAD LSVGLGTGQI KTGAPCRGER TAKLNQLLRI
460 470
....|....| ....|....| ...
Blastocystis EESLGSKAVY AGLN-FRTPD RC-
Trypanosoma rangeli EEELG---AH AKFG-FPAWA ---
Aphanomyces astaci EEMLGRSAVY AGKH-FRNPH EA-
archaeon EEQLGKKAVY GGKR------ ---
Entamoeba histolytica EEELGN-IPY AGKN-WRNST A--
Echinostoma caproni EEDLGSAAKY AGEN-FRRP- ---
Clostridium EEELGDMAEY RGMNSFYNIK R--
Homo sapiens EEELGSKAKF AGRN-FRNPL AK-
Malus domestica EEELGAEAVY AGAK-FRVPV EPY
Rhizopus delemar EEELGENCIY AGEN-FRNAH EL-
Leishmania mexicana EEEIG---SA AAYG-FPGWA ---
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10 20 30 40 50
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis MLS--RLSTT SFK-ALTRAA STITAVNART VLDSRGNPTV EVDVTTQDG-
Trypanosoma rangeli ---------- ---------- MTIQKVHGRE VLDSRGNPTV EVEVTTELG-
Aphanomyces astaci MLSQQRAVTK ALRHTQARFA STIKKVHARE IIDSRGNPTV EVDLTTEQG-
archaeon ---------- ---------M AKIRSVHARE ILDSRGNPTV EVELTSTDG-
Entamoeba histolytica ---------- ---------- MSIQKVHARE ILDSRGNPTI EVEITTGKG-
Echinostoma caproni ---------- ---------- MAIKSIHARQ IFDSRGNPTV EVDVTTAKG-
Clostridium ---------- ------MKQY VEIIDVYARQ ILDSRAFPTV EVEVTLDDGT
Homo sapiens ---------- ---------- MSILKIHARE IFDSRGNPTV EVDLFTSKG-
Malus domestica ---------- ---------M ATIQSVKARQ IFDSRGNPTV EVDIILSDGT
Rhizopus delemar ---------- ---------M STVTKVHARQ IFDSRGNPTV EVEVTTAKG-
Leishmania mexicana ---------- ---------- MPIQKVHARE VLDSRGNPTV EVELMTEAG-
60 70 80 90 100
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis TFRASVPSGA STGIHEALEL RDGGKA-YNG KGVTKAVNNV KTIIGPHICG
Trypanosoma rangeli VFRSIVPSGA STGVHEACEL RDDDKRRYLG KGCLHAVKNV NDVLAPALVG
Aphanomyces astaci LFRASVPSGA STGIHEAVEL RDGGKR-YLG KGVIQAVNNV KNIIGPKLEG
archaeon YVVAMVPSGA STGIHEALEL RDGGKR-YNG RGVLKAVKNI NTIIAPLIKG
Entamoeba histolytica MFRSCVPSGA STGVHEAVEL RDGDKKRYGG KGVLKAVENV NTIIGPALLG
Echinostoma caproni LFRAAVPSGA STGVHEALEL RDGPPG-YMG KGVLKAVSNV NNQIAPGLLK
Clostridium VGRAAVPSGA STGMFEAVEL RDGDKAVYNG KGVLKAVDNV NEIIAEELVG
Homo sapiens LFRAAVPSGA STGIYEALEL RDNDKTRYMG KGVSKAVEHI NKTIAPALVS
Malus domestica LARAAVPSGA STGVYEALEL RDGGKD-YLG KGVSKAVNNV NTIIGPALIG
Rhizopus delemar VFRAAVPSGA STGIHEALEL RDGDKSQYMG KGVTKAVNNV NSVIAPALIE
Leishmania mexicana VFRSAVPSGA STGVHEACEL RDGEKARYCG AGCMQAVKNV NEILAPALVG
110 120 130 140 150
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis MDV--TDIYA IDDLMFQ-LD GTKN-----K GKLGANAILG TSLACVKAGA
Trypanosoma rangeli KDE--LQQAT LDQLMRD-LD GTAN-----K SRLGANAILG CSMAISKAAA
Aphanomyces astaci MDP--TNQSE IDLLMKQ-LD GTDN-----K GNLGANAILG VSLAVAKAGA
archaeon KDP--AEQKS IDELMIK-KD GTKN-----K SKLGANAILG VSLAVCRAGA
Entamoeba histolytica KNV--LNQAE LDEMMIK-LD GTNN-----K GKLGANAILG CSMSICRAAA
Echinostoma caproni CGIPVTDQAG IDNFMLQ-LD GTPN-----K EKLGANAILG VSLAVCKAGA
Clostridium MNV--FDQVA IDKLMIE-LD GTKN-----K GKLGANAMLG VSLACAKAAA
Homo sapiens KKLNVTEQEK IDKLMIE-MD GTEN-----K SKFGANAILG VSLAVCKAGA
Malus domestica KDP--SEQTA IDNFMVQQLD GTVNEWGWCK QKLGANAILA VSLAVAKAGA
Rhizopus delemar SKIPVTEQKA IDEFLIE-LD GTPN-----K GKLGANAILG VSLAVAKAAA
Leishmania mexicana KDE--SDQAG LDKMMCE-LD GTKN-----K SKLGANAILG CSMAISKAAA
160 170 180 190 200
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis AAQKIPLYKF FADMAGKDK- FVLPVPSMNV INGGKHAGNA LAFQEFMLMP
Trypanosoma rangeli ARKGIPLYRY LAELAGSKE- IRLPVPCFNV INGGKHAGNA LPFQEFMIAP
Aphanomyces astaci RAKSIPLFQH FADLSGNDK- LVLPVPSFNV INGGSHAGNQ LAFQEFMILP
archaeon LARDKPLYLH IAGLAEPPR- PVLPVPFFNV INGGRHAGNK LDVQEYMIAP
Entamoeba histolytica AEKGLPLYKY LAELTGHKE- MTMPVPCFNV INGGAHAGNA LAMQEFMICP
Echinostoma caproni AEKGLPLYKY IASLAGNND- VVMPVPSFNV INGGSHAGNK LAMQEFMIMP
Clostridium ESLGLGLYQY IGGVN--AK- -VLPVPMMNI LNGGKHADNN VDLQEFMIMP
Homo sapiens VEKGVPLYRH IADLAGNSE- VILPVPAFNV INGGSHAGNK LAMQEFMILP
Malus domestica SVKKVPLYKH IANLAGNKN- LVLPVPAFNV INGGSHAGNK LAMQEFMILP
Rhizopus delemar GDKGVPLYVH FADLAGSKKP FVLPVPAFNV INGGSHAGNK LAMQEFMILP
Leishmania mexicana AKAGVPLYRY IAALAGTKD- IRLPVPCFNV INGGKHAGNV LPFQEFMIAP
210 220 230 240 250
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis VGAKSFSEAM QIGCEVYHSL KSVIKKRYGL DATNVGDEGG FAPSIKSNIE
Trypanosoma rangeli VKASSFSEAL RMGSEVYHAL KSIIKKKYGQ DAVNVGDEGG FAPPITDINE
Aphanomyces astaci TGAESFSEAM VMGCEVYHHL KGVIKKKYGQ DATNVGDEGG FAPNIQSNHE
archaeon LGAKTFAEAL RMGAETYHTL KGIIQEKYGK NAINVGDEGG FAPPLDHIEE
Entamoeba histolytica TGATNFHEAL RMAAETYQCL KVVIKAKYGQ DATNVGDEGG FAPNVSGARE
Echinostoma caproni TGASSFAEAM KIGSEVYHHL KAVIKGKYGL DACNVGDEGG FAPNIQDNLE
Clostridium VGAKSFSEAL RMCAEVYHTL KSILKEKG-- LGTGVGDEGG FAPNLASNEE
Homo sapiens VGAANFREAM RIGAEVYHNL KNVIKERYGK DATNVGDEGG FAPNILENKE
Malus domestica IGASSFKEAM KMGVEVYHNL KSVIKKKYGQ DATNVGDEGG FAPNIQENRE
Rhizopus delemar TGAKSFKEAM KIGSEVYHNL QSVIKAKYGL DATNVGDEGG FAPNIQKNEE
Leishmania mexicana TKATSFREAL RMGSEVYHAL KVIIKNKYGQ DAVNVGDEGG FAPPIKHIDE
260 270 280 290 300
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis GLDILSEAIE KAGYAK--EV RIAMDCAASE FYT-QDGYYD LMFKQGG-GM
Trypanosoma rangeli PLPILMEAIE QAGHKG--KF AICMDCAASE TYDENKKQYN LTFKSPN---
Aphanomyces astaci GVELLMLAIE KAGYTG--KI GIGMDVASSE FYT-ESKHYD LNFKNPG--S
archaeon PLKLLVEAIK KAGFAG--KI KIAMDAAASE FYVEKKKCYN LQGKDVD---
Entamoeba histolytica ALDLLVEAIA KAGYTG--KI EIAMDCAASE FYNEETKKYD LGKKIPADKK
Echinostoma caproni GLELLRTAIE KAGYTG--KV KIAMDSAASE FYK-EGK-YD LDFKNPK--S
Clostridium AIKVIMEAIE KAGYKAGEEI FLALDPASSE FFE--DGKYN LSGEGRI---
Homo sapiens GLELLKTAIG KAGYTD--KV VIGMDVAASE FFR-SGK-YD LDFKSP---D
Malus domestica GLELLKTAIE KAGYTG--KV VIGMDVAASE FYG-SDKTYD LNFKEEK--N
Rhizopus delemar GLDLLVQAIE KAGYTG--KV KIGMDCAASE FYK-DGK-YD LDFKNPN--S
Leishmania mexicana PLPILMEAIE KAGHKN--KF AICMDCAASE AYDAERKMYN LTFKNPE---
310 320 330 340 350
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis KK----SKEQ MTELYIKLVK DYPIVSIEDP FEQDDWAAYA LLREKIGKDV
Trypanosoma rangeli --ATWVTAKQ LGETYAKWVS EYPIVSIEDP YDQDDFEGFA GITEVLKGKA
Aphanomyces astaci KEAP-LTGEQ LGQLYKDLAK EFPIISIEDP FDQDDWEHYS AFTAAIGTDV
archaeon -------SLE LADIYKYLVK TYPIISIEDP FSEDDWESFY VLTKSIGKKV
Entamoeba histolytica DPSLVKDVDG LIAEYVDYGK HYPIASIEDP FAEDDWAAWN KFT-VEHGNF
Echinostoma caproni PASSWISSDA MADVYKKMMS TYPIVSIEDP FDQDDWPAWT KLTGECK--I
Clostridium -----LTPEE MADYYVELAN KYPIISIEDG MAEEDWEGWK HLTDKIGDKV
Homo sapiens DPSRYISPDQ LADLYKSFIK DYPVVSIEDP FDQDDWGAWQ KFTASAG--I
Malus domestica DGSQKISGNA LKDLYKSFAS EYPIVSIEDP FDQDDWEHYA KMTAEVGEKI
Rhizopus delemar DQSKWIDGKE LTALYSSFAS KYPIVSIEDA FDQDDWEAWT HLNETSD--F
Leishmania mexicana --PTYVSAAE LQATYERWVS EYPLVSIEDP FAEDNFDEFS AITKALAGRA
360 370 380 390 400
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis QIVGDDLLVT NPARIAEAIQ KKACNALLLK VNQIGSVTES VQACLDSQAA
Trypanosoma rangeli QVVGDDLTVT NVARIKMAIE KKACNSLLLK INQIGTITEA IDASKLCMAN
Aphanomyces astaci QVVGDDLLCT NPTRIAKAVG IKACNALLLK VNQIGSVSES IQAVKDAKAA
archaeon QIVGDDLTVT NPERLQRAIT QKSATALLLK VNQIGTVTES LQAAAMCKGH
Entamoeba histolytica QIVGDDLLVT NPARVQMAMD KNACNSVLIK VNQIGTLTET FKTIKMAQEK
Echinostoma caproni QIVGDDLTVT NPLRVQKAID QKACNCLLLK VNQIGSVTES IQACKMAQSA
Clostridium QLVGDDLFVT NTERLAMGFE KEVANSILIK LNQIGTLTET INAIEMASRK
Homo sapiens QVVGDDLTVT NPKRIAKAVN EKSCNCLLLK VNQIGSVTES LQACKLAQAN
Malus domestica QIVGDDLLVT NPKRVEKAIK EKSCNALLLK VNQIGSVTES IEAVRMSKKA
Rhizopus delemar QLVGDDLLVT NPKRIATAIE KKSCNALLLK VNQIGTLTES IQAAKDSQAA
Leishmania mexicana QIVGDDLTVT NVERVRMAIE KSACNSLLLK INQIGTISES IAAAKLCMEN
410 420 430 440 450
....|....| ....|....| ....|....| ....|....| ....|....|
Blastocystis GWGVMVSHRS GETEDNYIAD LAVGLCSGQI KTGAPCRSER LAKYNQLLRI
Trypanosoma rangeli GWSVMVSHRS GETEDTYIAD LVVGLGSGQI KTGAPCRGER TAKLNQLLRI
Aphanomyces astaci GWGVMTSHRS GETEDSYIAD LAVGLSTGQI KTGAPCRSER LAKYNQLLRI
archaeon GWNVMVSHRS GETEDSFIAD LVVGLGCGQL KSGAPCRSER VAKYNQLIRI
Entamoeba histolytica GWGVMASHRS GETEDTFIAD LVVGLNCKQI KTGAPCRSER LCKYNQLMRI
Echinostoma caproni GWGVMVSHRS GETEDNFIAD LVVGLRTGQI KTGAPCRSER LAKYNQLLRI
Clostridium GYTAVVSHRS GETEDTTIAD LVVAMNAGQI KTGAPARSER VAKYNQLLRI
Homo sapiens GWGVMVSHRS GETEDTFIAD LVVGLCTGQI KTGAPCRSER LAKYNQLLRI
Malus domestica GWGVMTSHRS GETEDTFIAD LAVGLATGQI KTGAPCRSER LAKYNQLLRI
Rhizopus delemar GWGVMVSHRS GETEDTTIAD LVVGLRTGQI KTGAPCRSER LAKYNQLLRI
Leishmania mexicana GWSVMVSHRS GETEDTYIAD LSVGLGTGQI KTGAPCRGER TAKLNQLLRI
460 470
....|....| ....|....| ...
Blastocystis EESLGSKAVY AGLN-FRTPD RC-
Trypanosoma rangeli EEELG---AH AKFG-FPAWA ---
Aphanomyces astaci EEMLGRSAVY AGKH-FRNPH EA-
archaeon EEQLGKKAVY GGKR------ ---
Entamoeba histolytica EEELGN-IPY AGKN-WRNST A--
Echinostoma caproni EEDLGSAAKY AGEN-FRRP- ---
Clostridium EEELGDMAEY RGMNSFYNIK R--
Homo sapiens EEELGSKAKF AGRN-FRNPL AK-
Malus domestica EEELGAEAVY AGAK-FRVPV EPY
Rhizopus delemar EEELGENCIY AGEN-FRNAH EL-
Leishmania mexicana EEEIG---SA AAYG-FPGWA ---
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Figure 3. 5 Alignment of the amino acid sequences of the enolases. Trypanosoma rangeli 
(ESL05219.1), Aphanomyces astaci (XP_009829255.1), Archaeon (KHO45292.1d), Entamoeba 
histolytica (XP_649161.1), Echinostoma caproni (ABI26619.1), Clostridium (WP_010294244.1), Homo 
sapiens (BAD96912.1), Malus domestica (XP_008391739.1), Rhizopus delemar (EIE87278.1), 
Leishmania mexicana (XP_003873490.1). Brackets show GeneBank accession numbers. The dashed 
lines demonstrate gaps introduced between sequences. Residues indicating Mg2+ binding sites are 
shown in black arrowheads, residues forming  the enolase signature motif are underlined, while 
residues motif for substrate binding are indicated with a black star. The enolase fingerprint motif is 
boxed. Coloured amino acids indicate conservative amino acid regions. The letters below the 
alignment mark residues involved in binding to the phosphate (P), carboxyl (C) group of substrate, 
and in metal binding (M).  
 
3.3. Homology modelling   
Function of proteins can be inferred in most of the times from the protein 
structure, although the relationship between function and fold is complicated. 
Some cases one fold of protein can perform several functions, while in other 
cases; it is found that one function can be achieved by several folds. The 
complexity of fold-function relation necessitates different approaches. This gave 
way to inspecting special sites, motifs, signatures, and other conserved residues 
(Jones and Thornton 2004). Homology modelling is a method used to predict the 
three dimensional structure of a protein of known sequence by modelling it on a 
known 3D structure of a related protein sequence (template sequence). This will 
give an insight of a probable function of the studied protein in light with an already 
assigned structure. Finding a homologous protein is only feasible with templates 
of 30% or more similarity. Modelling the protein will allow us to assess the function 
of the protein and its binding sites of study in comparison to the known structure 
of the template. 
Structures of enolases from different species were available from protein data 
bank (PDB) (http://blast.ncbi.nlm.nih.gov/Blast.cgi) seeking potential template- 
homologues proteins for model construction. The template protein used to build 
a 3D structure model for enolase was chosen as described in 2.2.3.10.8.1, a 
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multiple sequence alignment between the target and the template protein was 
run using pair-wise sequence alignment tool which allows manipulation of the 
sequences parameters such as gaps, which will help avoiding errors.  
 The model built using the template chosen (3UCD) and the SwissModel server 
(http://swissmodel.expasy.org/interactive) came with the model protein shown in 
Fig 3.6 as a dimer. The structure was built as described in both 2.2.3.10.8.2 and 
2.2.3.10.8.3. The chosen model was human neuron specific gamma enolase 
(hNSE) (PDB 3UCD) (Qin, Chai et al. 2012) which shares 64.24% identity with 
Blastocystis enolase protein sequence and belongs to Homo sapiens. The 
quality of the model was checked by superimposing the model protein with the 
template chosen using PyMol program and inspecting the active sites manually 
and visually. The query protein and the template both have a conserved active 
sites and binding sites. Both proteins (the model and the template) have 
virtually the same overall topology with nearly identical secondary structural 
elements (Figure 3.7). The overall structure of the model was found to be highly 
conserved when compared to the template 3UCD in regards to the enolase 
signature motif, enolase family motif, Figure 3.8, and figure 3.9. tow loops were 
found to take different position between the template and the model. Those 
loops were covering the region 259-266 in each subunit, see Figure 3.10. 
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Figure 3. 6 Cartoon representation of the modelled overall structure of Blastocystis enolase, shown 
as a dimer. The model was built using the neuron human enolase protein template (hNSE) (3UCD) 
as a template. Molecule is seen looking down the twofold axis. A greater portion of the polypeptide 
backbone adopts α-helical conformation. The two monomers are shown in hot pink. The image was 
generated using PyMOL (http://www.pymol.org).  
 
 
Figure 3. 7 Blastocystis enolase model aligned with the template human neuron specific enolase 
(hNSE) (PDB 3UCD), showing almost identical overall topology between the two proteins. The image 
was created using PyMOL. 
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Figure 3. 8 A close up in Blastocystis enolase model structure built using human neuron specific 
enolase (hNSE) (PDB 3UCD) as a template showing the highly conserved enolase signature motif 
covering the amino acid region (355-368) (LLLKVNQIGSVTES). This was made using PyMol. 
 
 
Figure 3. 9 A close up in Blastocystis enolase model structure built using human neuron specific 
enolase (hNSE) (PDB 3UCD) as a template. It shows the highly conserved enolase finger print region 
covering amino acids (385-393) (SHRSGETED). This was made using PyMol. 
 
 
 
Figure 3. 10 A close up in Blastocystis enolase model structure built using human neuron specific 
enolase (hNSE) (PDB 3UCD) as a template. It shows a loop converted from the template orientation, 
covering amino acids (259-266), an area which was responsible for asymmetry between the unit 
interfaces in (hNSE) structure. This was made using PyMol.  
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3.4. Phylogentic relationships of Blastocystis enolase and other 
enolases 
In order to confirm the previous results of the mitochondrial targeting nature of 
Blastocystis enolase phylogenetic analyses including extended sampling were 
conducted. Sequences previously used in signature motif and mitochondrial 
targeting signal analyses were analysed by phylogenetic reconstructions.   
3.4.1. Sequence alignment and phylogenetic analysis.      
Two sets of enolase sequence data were constructed. The first set comprised a 
large sample of protein sequences (87) that included enolase protein sequences 
from all super-groups, the second set of sequences was only an expanded 
stramen opiles searches. A detailed list of organisms used to execute this 
phylogenetic analysis can be found in Table 3. 3. 
Table 3. 3 Taxa used in large‐scale Blastocystis enolase protein phylogeny including accession 
numbers, and the super-groups.   
Subgroup  Name of organism Accession number  
  Stramenopiles 
 Blastocystis hominis (XP_012894576.1) 
 Aphanomyces astaci  (XP_009829255.1) 
 Ectocarpus siliculosus  (CBJ32586.1) 
 Saprolegnia diclina  (XP_008604438.1) 
 Phytophthora parasitica  (ETO77406.1) 
 Apodachlya brachynema  (AAR97547.1) 
 Saprolegnia parasitica  (XP_012196295.1) 
 Plasmopara halstedii  (CEG45103.1) 
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 Phaeodactylum tricornutum  (XP_002185511.1) 
 Aureococcus anophagefferens  (XP_009035814.1) 
 Aphanomyces invadans  (XP_008875680.1) 
 Nannochloropsis gaditana  (EWM28602.1) 
Amoebozoa 
 Acanthamoeba castellanii (XP_004337411.1) 
 Dictyostelium fasciculatum  (XP_004362164.1) 
 Polysphondylium pallidum  (EFA79459.1) 
 Entamoeba invadens  (BAN40624.1) 
Plantaea 
Chromophytes Arabis alpine  (KFK32725.1) 
 Phaseolus vulgaris  (XP_007162849.1) 
 Algae Chondrus crispus  (XP_005716244.1) 
 Galdieria sulphuraria  (XP_005706995.1) 
 Cyanidioschyzon merolae  (XP_005536545.1) 
 Prionitis lanceolata  (AAL05461.1) 
 Mastocarpus papillatus  (AAL05459.1) 
Plantae  Solanum pennellii  (XP_015088120.1) 
 Nicotiana tabacum  (ACR56690.1) 
 Selaginella moellendorffii  (XP_002984551.1) 
 Glycine max  (KRG96124.1) 
 Oryza sativa  (NP_001049556.1) 
 Phaseolus vulgaris  (XP_007162849.1) 
The  Opisthokonta 
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 Animalia   Clonorchis sinensis  (GAA51601.1) 
 Echinostoma caproni  (ABI26619.1) 
 Fasciola hepatica  (CAK47550.1) 
 Lingula anatine  (XP_013386675.1) 
 Taenia solium  (AHB59732.1) 
 Hydra vulgaris  (XP_012564321.1) 
 Echinococcus granulosus  (ACY30465.1) 
 Ictalurus punctatus  (NP_001187631.1) 
 homo sapiens  (BAD96912.1) 
Choanoflagellata Salpingoeca rosetta (XP_004994770.1) 
Fungi  Rhizopus delemar (EIE87278.1) 
 Mucor circinelloides  (EPB85979.1 
 Parasitella parasitica (CEP19658.1) 
 Lichtheimia ramose  (CDS14531.1) 
 Conidiobolus lamprauges  (ALX18691.1) 
 Allomyces macrogynus  (KNE63834.1) 
 Blastocladiella emersonii  (ABK34894.1) 
 Neocallimastix frontalis  (AFJ73493.1) 
 Mortierella verticillata  (KFH71943.1) 
 Rozella allomycis  (EPZ33681.1) 
Opisthokonta Opisthorchis viverrini  )XP_009174927.1( 
 Rhizopus delemar  (EIE80761.1) 
 Echinostoma caproni  (CAK47551.3 
 Lichtheimia corymbifera  (CDH56669.1) 
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The  Excavata 
Diplomonads Spironucleus salmonicida  (EST42221.1) 
 Giardia lamblia (EFO60949.1) 
 Hexamita inflate (AAD45328.1) 
 Hexamita inflate  (AAD45329.1) 
Heterolopbosea Naegleria gruberi  (XP_002680773.1) 
Kinetoplastides Trypanosoma congolense  (CCC93490.1) 
 Bodo saltans  (CUG84387.1) 
 Trypanosoma cruzi  )EKF32804.1(  
 Angomonas deanei   (EPY25410.1) 
 Strigomonas culicis  (EPY28299.1) 
 Leptomonas pyrrhocoris  (KPA77322.1) 
 Leishmania panamensis  (XP_010697345.1)    
Parabasalids Trichomonas vaginalis    (XP_001322282.1) 
 Pseudotrichonympha grassii  (BAF48677.1) 
 Trichomonas vaginalis  (XP_001315627.1) 
Chromalveolates 
Apecomplexa Plasmodium falciparum  (XP_001347440.1) 
 Gregarina niphandrodes  (XP_011131468.1) 
 Babesia bigemina  (XP_012768952.1) 
 Theileria annulata  Ankara(XP_953341.1)  
 Babesia bovis  (XP_001611923.1)  
 Hammondia hammondi  (XP_008882278.1) 
 Toxoplasma gondii (XP_002365578.1)  
    
 
138 
 
 Eimeria tenella (XP_013229351.1)  
 Toxoplasma gondii (XP_002365579.1)  
 Cryptosporidium parvum Iowa  (XP_626138.1) 
Ciliata Paramecium tetraurelia  (XP_001452406.1) 
 Tetrahymena thermophila  (XP_001014643.1)  
 Ichthyophthirius multifiliis  (XP_004030018.1)  
 
 Oxytricha trifallax  (EJY82089.1) 
Diatoms Thalassiosira pseudonana  (XP_002290311.1) 
Oomycetes Aphanomyces astaci  (XP_009829255.1) 
Plants and higher 
plants  
Solanum pennellii (XP_015088120.1( 
Phayophytes  Aureococcus anophagefferens  (XP_009035814.1) 
 Ectocarpus siliculosus  (CBJ32586.1) 
 
Initially, database searches (BLASTp) over a wide taxonomic spectrum were 
performed using Blastocystis enolase protein sequence.  Blastocystis enolase 
was aligned with other enolase sequences retrieved from NCBI data bank. The 
sequences were picked, aligned and manually refined by eye then aligned using 
MUSCLE (Edgar 2004). MUSCLE will detect any sequence repetitions and gaps 
and will remove them automatically. Regions of gaps or those that 
are not clearly alignable  in  all  sequences  were  excluded  from  the  phylogen
etic  analysis  by  masking  the  alignment  manually.  A phylogenetic tree is then 
constructed using those edited sequences.  
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The enolase phylogenies were calculated using the maximum likelihood (ML) 
approaches with the PhyML programme using (phylogeny.fr) web server tools 
(Castresana 2000, Chevenet, Brun et al. 2006, Dereeper, Guignon et al. 2008, 
Dereeper, Audic et al. 2010). Blastocystis enolase phylogeny was additionally 
analysed using the Bayesian analysis program MrBayes (Huelsenbeck and 
Ronquist 2001, Ronquist, Teslenko et al. 2012) on the same web server 
(phylogeny.fr). Bootstrap  re-
sampling  was  performed  on  ML  trees  with  100  replications  for  all  data  se
ts.  Phylogenetic reconstruction of Blastocystis 
enolase using MrBayes were run using a mixed amino acid. One hundred 
thousand generations were calculated and trees sampled every 100 generation. 
The model stabilised rapidly and 250 trees were discarded as burnin.   
 
3.4.1.1. Placing of Blastocystis enolase in the kingdom of life 
The large scale phylogenetic reconstruction reveals a wide diversity within the 
enolase family and a general distribution within tight systematic groups. The tree 
generated from amino acid sequences of enolase (see Figure 3.11), clearly 
showed that Blastocystis enolase is clustering with other members of 
chromalveolates and particularly stramenopiles forming a monophylum  with a 
high bootstrap value of 95%. It showed a group that clusters with organisms of 
high mitochondrial targeting signal of over 95% probability to target the 
mitochondria. Other organisms have also grouped together with high bootstrap 
value such as Plantae (98%), and Opisthokonta (89%). Another interesting value 
was the notice of a weekly supported relationship between Amoebozoa and all of 
the following (Plantae, Stramenopile and Opisthokonta), while those themselves 
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(Plantae, Stramenopile and Opisthokonta) showed a strongly supported 
relationship demonstrated by a bootstrap value of 87% between themselves. A 
far relationship was found between Bacteria and Chromalveolates, although 
strongly supported with a root bootstrap of 100% and showed that Blastocystis 
enolase is evolved after bacteria. This might explain the relationship between the 
mitochondrial targeting sequence found in Blastocystis and other members of 
Stramenopiles, and the fact that this mitochondria might be of a bacterial 
ancestor.  
 
Figure 3. 11 Relationship of Blastocystis enolase among Eukaryotes and Prokaryotes as determined 
by phylogenetic analysis of protein sequence. Shown is a protein maximum-likelihood topology 
constructed by the PhyML program. Bootstrap values and posterior probability values were 
calculated using PhyML and MrBayes. Phylogenetic reconstruction using maximum-likelihood (and: 
neighbouring-joining or parsimony analyses) shows that Blastocystis enolase is embedded within 
the Stramenopila lineages. The dataset contained 11 from all super-groups of Eukaryotes and 
Prokaryotes. Numbers at nodes are bootstrap P-values (≥50%).  A complete list of taxa and their 
accession numbers can be found in Table 3.3.   
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Figure 3. 12 Phylogenetic tree (Maximum-likelihood and confirmed by MrBayes) of Blastocystis 
enolase and enolases from Stramenopila group. Numbers at nodes are bootstrap P-values (≥50%). 
A complete list of taxa and their accession numbers can be found in Table 3.3. 
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3.5. Conclusion  
The conducted comparison of Blastocystis enolase amino-acid sequences, 
demonstrated a high degree of amino acid conservation in enolases. This was 
the case when compared to representative members of the kingdom of life. It is 
highly conserved with respect to residues implicated in substrate binding and 
catalysis active site. The enzyme was also predicted to be a dimer as reported in 
other enolases, apart from cases where some bacterial enolases had shown 
octameric enolase (Karbassi, Quiros et al. 2010).  
Of the features that were spotted in some enolases was its plasminogen binding 
activity (Vanegas, Quinones et al. 2007), which was not conserved in this 
instance. 
A special finding was that Blastocystis enolase posses a mitochondrial targeting 
signal, which is unusual as glycolysis is canonically taking place in the cytosol. 
This is an interesting finding as it might imply a special role for enolase being 
targeted to the mitochondria.  
This analysis has shown that Blastocystis enolase is like other enolases, a highly 
conserved enzyme, apart from its unusual mitochondrial targeting signal. More 
work is to be done to unravel the possible role of this unusual localization in this 
organism.   
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Chapter 4. Biochemical characterization of enolase 
4.1. General background (introduction) 
 Enolase (EC 4.2.1.11), also called (phosphopyruvate hydratase or 2-phospho-
D- glycerate hydrolase) is a glycolytic enzyme that belongs to the Enolase family 
(PF03952) (including both the Enolase N and Enolase C family) and mediates 
the reversible conversion of 2-phosphoglycerate (2-PG) into 
phosphoenolpyruvate (PEP). It requires magnesium as a cofactor, which helps in 
catalysis and for stabilizing the dimer protein (Castillo-Romero, Davids et al. 
2012). It is one of the most abundant enzymes expressed in the cytosol of a wide 
range of organisms (Castillo-Romero, Davids et al. , Brewer and Collins 1980, 
Dannelly, Duclos et al. 1989, Bjerkehagen, Fossa et al. 1994, Agarwal, 
Hammerschmidt et al. 2012, Azapagasi, Alehan et al. 2012, Bae, Kim et al. 2012, 
Bruna, Carolina et al. 2012, Chen, Yuan et al. 2012). It participates in many roles 
and functions, from biological to pathophysiological. It is well known through its 
role in glycolysis. However, it is also involved in tissue invasion in brain tumors 
(Liu 2007) and in parasite virulence by facilitating invasiveness of the host (Wang, 
Chen et al. 2011). It was also been found to be involved with cyst formation in 
Naegleria fowleri (Chavez-Munguia, Segovia-Gamboa et al. 2011). 
Multifunctional proteins such as enolase behave differently depending on their 
cellular location, so-called moonlighting where the protein has variant non-
enzymatic functions in different hosts and different tissues (Collingridge, Brown 
et al. 2010).  In vertebrates, there are three isoforms called α, β, and γ of this 
enzyme, and these are tissue specific. While α isoform can be found in most 
tissues (but mainly in the liver), the β isoform is principally found in muscle tissue. 
The γ isoform is neuron specific. All these forms of enolase are found as a 
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homodimers. Heterodimer forms also do exist, for example αβ and βγ (Keller, 
Scarna et al. 1981, Joseph, Cruz-Sanchez et al. 1996, Liu 2007). However, 
enolase generally exists as a homodimer. The molecular mass of the monomers 
ranges from 22 kDa, as in Streptococcus rattus FA-1 (Huther, Psarros et al. 
1990), to 45 kDa in Streptococcus. pyogenes forming an ocatameric enolase of 
450 kDa (Karbassi, Quiros et al. 2010).  
Enolase is a highly conserved protein that belongs to the enolase super family. It 
contains two conserved domains; the N terminal enolase domain and the C 
terminal enolase domain. Enolase can be divided into clusters according to 
sequence similarity with a BLASTP E value <10-90 corresponding to > 35% 
sequence identity (Gerlt, Babbitt et al. 2012). The amino terminal (Enolase N) 
domain covers the amino acid residues 3-131, and the carboxy terminal domain 
(Enolase C) ( which adopt a TIM barrel fold that contains metal binding site) 
covers amino acid residues 143-431, (Asuncion, Blankenfeldt et al. 2002). See 
chapter 3 for a more detailed discussion. 
In this chapter, I will discuss the cloning, purification and the biochemical 
characterization of the recombinant Blastocystis enolase to further study its 
activity and localization into Blastocystis cells for understanding the possible role 
of this enzyme in the parasite cells. 
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4.2. Recombinant Blastocystis Enolase was successfully cloned and 
over-expressed in E. coli 
4.2.1. Cloning and amplification of recombinant Blastocystis enolase  
The gene encoding Blastocystis enolase was amplified from Blastocystis ST4 
genomic DNA (Figure 4.1) using primers EnoF and EnoR mentioned in Table 2.2. 
A mix of enzymes was used in the PCR reaction including proofreading Pfu DNA 
polymerase and Taq polymerase to minimize any chance of introducing 
mutations during amplification. The PCR product was incorporated in cloning 
vector pGEM-T-Easy and subsequently transformed into E. coli cells. This 
construct was confirmed by the DNA sequencing facility at MWG-Eurofins using 
M13F and M13R primers of pGEM-T-Easy plasmid referred to in Figure 2.3. 
 
Figure 4. 1 Agarose gel electrophoresis analysis of PCR-amplified enolase, from Blastocystis ST4. 
The gel shows a band of the amplified Blastocystis enolase gene with an expected size of 1.3 kb. 
DNA HyperLadder I is on the left of the PCR product. Sizes of relevant marker are indicated in kb 
(Bioline).  
The Blastocystis enolase was amplified using PCR primers containing NdeI, and 
BamHI restriction sites, mentioned in Table 2.2 for directional cloning into the 
gene expression plasmid pET-14b to incorporate an N-terminal His-tag for a later 
affinity purification step. The gene was directly cloned into this expression vector; 
Figure 4.2 is an agarose gel of the amplified Blastocystis enolase gene with the 
1  
1.5 
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new restriction sites, and Figure 4.3 a schematic representation of the final 
construct.  
The construct was validated through DNA sequencing using the MWG-Eurofins 
sequencing facility (Germany). Three strains of E.coli cells were used to express 
this gene: Rosetta2 (DE3) pLyS (Novagen) and BL21 pLysY (Bioline) and Arctic 
Express cells (Agilent Technologies). Rosetta cells were initially used and 
showed a high expression level of enolase. However, most of the recombinant 
Blastocystis enolase was present in inclusion bodies, and therefore not soluble. 
Insoluble protein cannot be used for downstream experiment such as activity 
assay. Therefore the Blastocystis enolase gene was transformed into BL21 cells. 
This resulted in good expression levels in the soluble fraction which was 
subsequently used for downstream experiments. 
 
Figure 4. 2 Agarose gel electrophoresis analysis of PCR-amplified Blastocystis enolase with added 
NdeI, BamHI restriction sites. The gel shows a band of the expected size 1.46 kb. DNA HyperLadder 
I is on the left side lane of the PCR product. The sizes of the gene of interest and the relevant 
reference DNA are indicated next to the band. 
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Figure 4. 3 Schematic representation of Blastocystis enolase-pET-14b construct of 5,968 kb size with 
the restriction sites added. The map shows the location of the gene under the influence of T7 RNA 
polymerase promoter, and showing the ampicillin resistance marker (AmpR). 
4.2.2. Recombinant Blastocystis enolase is deposited in the inclusion bodies of E. 
coli Rosetta cells but soluble in BL21 and Arctic Express cells. 
Analytical-scale expression experiments were performed to determine which E. 
coli strain would produce the highest level of soluble protein. Strains included: 
BL21, Rosetta 2 and Arctic Express cells. Various parameters were tested to 
identify optimal expression conditions. Induction times ranged between 2, 4, 5, 
overnight and 48 hours.  Growth temperature tested over 10, 18 or 37°C, and 
cultures were induced using different concentration of IPTG (1 µM-1 mM). 
Different growth media (LB and ZYM-5052) were tested as well, (for media 
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composition see section 2.1.1.2). Finally expression trials varied between IPTG 
inductions and auto-induction technique. 
The Blastocystis enolase pET-14b construct was initially transferred into E. coli 
Rosetta cells which resulted in a high amount of the protein ending up in inclusion 
bodies. A possible explanation might be that the prokaryotic machinery might 
have difficulty folding the eukaryotic polypeptide chain and depositing this 
unfolded or partially folded protein into the inclusion bodies. These are formed by 
insoluble protein exposing their hydrophobic regions (Sabate, de Groot et al. 
2010, Upadhyay, Murmu et al. 2012) 
However, transferring the construct into E. coli Arctic Express cells and induction 
at the lower 10°C for 24 hours (after growing for 3-4 of hours at 37°C to boost 
initial biomass) resulted in very low levels of recombinant protein.   
A final trial was performed by using the auto-induction technique which depends 
on the fact that the expression strain will grow to a high density until inhibiting 
factors, such as glucose, are depleted from the medium. After that has happened, 
the lactose will automatically induce the expression of the gene in what is called 
auto-induction (Studier 2005). The protein produced using this method gave a 
high yield in comparison to the other over-expression conditions. This was 
achieved by growing an overnight culture at 37°C, which was subsequently used 
to inoculate a 500 ml culture of ZYM-5052 and incubated at 37°C for a period of 
2-3 hours or until the OD was less than 1. The culture was subsequently 
incubated at 20 °C with shaking at 220 rpm for 24 - 48 hours. This method gave 
a yield about 10 times higher than traditional expression experiments (OD ̴ 7-10) 
and it can sometimes reach an OD of 20. Figure 4.5 gives examples of the main 
    
 
149 
 
expression trials at different conditions discussed above and shown on 12% SDS 
gels. 
4.3. Identification of recombinant Blastocystis enolase by mass 
spectrometry 
In order to identify the produced protein, a mass spectrometry analysis was 
performed, for proteomic analysis, by sending a gel slice of the putative 
recombinant Blastocystis enolase, to the protein sequencing facility at the 
University of Exeter Biosciences, by Dr. Hannah Florance. Protein sample that 
was sent for analysis was of insoluble enolase found in inclusion bodies as seen 
in 4.2.2 paragraph. The resulting mass spectrometry data (Figure 4.4) was 
checked against the protein of interest and clearly showed a very good hit. 69 
spectral files were submitted to search and 67 were classed as hits. All hits were 
attributable to Blastocystis enolase, with 64% coverage of the whole protein. The 
mass spectrometry data also confirmed that there is no contamination from other 
proteins in the sample which indicated that there was no need to search against 
the non-redundant species database. See Figure 4.4 for detailed proteomics data 
of the purified recombinant Blastocystis enolase protein. 
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Figure 4. 4 Identification of recombinant enolase Blastocystis by mass spectrometry. Matched 
peptides are shown in red.   
 
4.4. Blastocystis enolase expression and purification 
The E. coli BL21 pLysY cells harbouring His-tagged recombinant Blastocystis 
enolase in the pET-14b were plated on LB plates containing a final concentration 
of 100 µg/ml ampicillin and grown overnight at 37°C. A single colony was picked 
to inoculate a 10 ml LB media containing 100µg/ml ampicillin and incubated 
overnight at 37°C in a 200 rpm shaking incubator. The 10 ml overnight culture 
was then used to inoculate 500 ml ZYM-5052 media, which was either grown at 
37°C for a few hours until growth had visually started and then transferred to 20°C 
overnight, or was incubated at 20°C for 48 hours. Cells were harvested at 6000 
g for 30 minutes and lysed following the protocol described in methods 2.2.3.2. 
A nickel affinity column (NAC) was equilibrated using 5 x column volume of NAC 
buffer A described in Table 2.6, with a flow rate of 1 ml/min. The crude soluble 
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clarified cell extract was loaded onto the column via an injection into the 
“Superloop”. The unbound protein was washed off using buffer A and the bound 
protein was eluted using 5 x column volumes of buffer B, (see Table 2.6), using 
a step gradient up to 100% buffer B. Eluted fractions were all collected. Fractions 
containing protein gave absorbance at 280 nm. Figure 4.6 represents the elution 
profile of Blastocystis enolase purified by NAC. Fractions containing the 
recombinant protein were analysed by 12% SDS-PAGE showing the protein of 
interest with a purity of about 95%, see Figure 4.7.  
The fractions representing the putative Blastocystis enolase were pooled in one 
fraction and concentrated to final volumes between 1-5 ml using Amicon® Ultra 
Millipore filters, with a 30 kDa cut-off value. The concentrated fractions were 
loaded manually on a previously equilibrated GF column using 1.5 x column 
volume of GF buffer at a flow rate of a 1 ml/min. Fractions were collected and 
absorbance measured at 280 nm. Figure 4.8 represents the elution profile of the 
Blastocystis enolase on GF column. The peak containing the Blastocystis 
enolase was also checked on 12% SDS-PAGE, (Figure 4.9). The recombinant 
Blastocystis enolase protein showed a high purity up to about 99 % and was used 
for all subsequent experiments.  
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Figure 4. 5 Expression trials for Blastocystis enolase in different cell lines under several conditions.  A) Blastocystis enolase cloned into pET-14b in E. coli Arctic Express cells was induced 
using: a) 100 mM IPTG for 24 h at 10°C. Lane 1: uninduced fraction, 2: total cell lysate, 3: insoluble fraction, 4: soluble fraction. b) 1 mM IPTG for 24 h at 10°C where the lanes 1-3 represent 
the empty vector and lanes 4-6 represent enolase construct, both constructs lanes are in the following sequence: uniduced, insoluble soluble.  c) 400 mM IPTG for 24 h at 10°C where the 
lanes 1-3 represent Blastocystis enolase construct and lanes 4-6 represent the empty vector, both constructs lanes are in the following sequence: uniduced, insoluble soluble.  B) Blastocystis  
enolase cloned in pET-14b  in E. coli  Bl21 cells, which were induced at 37°C for 4 h using: d) 1 mM IPTG, where lanes 1-4 represent the empty vector while lanes from 5-8 represent the 
Blastocystis  enolase construct in E. coli  BL21, e) 400 mM IPTG . Lanes 1-4 represent the enolase construct in E. coli BL21 while lanes 5-8 represent the empty vector and f) 10 mM IPTG where 
lanes 1-4 represent the Blastocystis enolase construct in E. coli BL21 and lanes from 5-8 represents the empty vector while lanes 9-12 show the expression of Blastocystis enolase construct 
in Bl21 using 100 mM IPTG. The lanes pattern of lanes 1-4, 5-8, 9-12 all are in the following sequence: uninduced, induced, insoluble, soluble consecutively. C) Blastocystis enolase constructs 
in E. coli BL21 autoinduced at 20°C for 48 h.  g) The expression pattern of autoinduced Blastocystis enolase construct (1-3) compared to the empty pET-14b vector (4-6). Lanes 1-3 and 4-6 are 
as follows consecutively: uniduced, insoluble, soluble.  h) Blastocystis enolase purification with different imidazole concentrations from (10 - 500 mM) after being autoinduced compared to 
i) autoinduced empty vector construct purified also using nickel affinity column.  Lanes 1-6 in h and i are the elution gradient flow throw, 25 mM, 50 mM, 100 mM, 250 mM and 500 mM 
respectively D) Blastocystis enolase construct in pET-14b in E. coli Rosetta2 cells induced with 1mM IPTG over night at 18°C. Where lane 1: uniduced fraction. Lane 2: insoluble, lane 3: soluble, 
lane 4: flow through, 5-10 imidazole concentration gradient from 10-500 mM. MWm: molecular weight marker. Molecular weights are indicated in kDa on the left of all the previous gels.                          
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Figure 4. 6 Elution profile of Blastocystis enolase from a HisTrap column (GE Healthcare). 10 ml 
fractions were collected across the entire elution. The A280 trace is seen in blue. The y-axis 
represents the absorbance at 280 nm. The x-axis shows elution volumes. Protein was loaded on the 
column from 0-40 ml. Fraction from 45-60 ml represent eluted protein and the bar represents protein 
analysed by SDS-PAGE (Figure 4.7).  
 
Figure 4. 7 Coomassie-stained SDS-PAGE gel of recombinant Blastocystis enolase purified by His-
trap column. Fractions represent (47-60) ml, (see Fig. 4.6). The protein bands representing enolase 
(~48kDa) shows a large amount of protein with purity of more than 95%. Lane 1 shows the molecular 
weight marker (Fermentas Spectra Multicolor Broad Range). Molecular weights are indicated in kDa 
on the left. 
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Figure 4. 8 Elution profile of Blastocystis enolase from a Superdex 200 gel filtration (GF) 
chromatography column. The A280 trace is seen in blue, and Blastocystis enolase eluted in the 
fractions between 60-80 ml, and the bar represents protein fractions analysed by SDS-PAGE (Figure 
4.8). The x axis represents the absorbance of the protein at 280 nm. The Y axis shows the elution 
volumes of the protein. The peak at about 40 ml represents high molecular weight and aggregated 
protein, which elutes in the void volume. The peak at about 65 ml represents the eluted target protein, 
Blastocystis enolase. See Fig 4.9. 
 
 
Figure 4. 9 Coomassie-stained SDS-PAGE gel of gel filtrated Blastocystis enolase. Fractions 
representing 60 to 80 ml eluted protein from Superdex 200 (gel filtration) GF chromatography 
column, (see Fig 4.8). Lane 1 shows the molecular weight marker used from (Fermentas Spectra 
Multicolor Broad Range). Molecular weights are indicated in kDa on the left. 
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 4.5. Biochemical characterization 
4.5.1. Molecular weight determination 
4.5.1.1. Analytical gel filtration 
In order to determine the experimental molecular weight of the recombinant 
native protein. The affinity-purified recombinant Blastocystis enolase (Figure 4.7) 
was pooled and analysed on a Superdex 200 Hiload GF chromatography column 
which has a separation range for molecules of molecular weight between 10-600 
kDa. The recombinant Blastocystis enolase monomer has a theoretical molecular 
weight, as estimated by ExPasy, of 48 kDa.  
The Superdex 200 GF chromatography column can be used to estimate the 
size and oligomeric status of native proteins. Blastocystis enolase purification 
was performed in triplicate and the molecular weight was determined using the 
gel filtration standard curve shown in Appendix 2. Blastocystis enolase was 
eluted with an elution volume Ve of 68.37 ml. This was used to calculate the 
molecular weight using the equation 4.1. After applying the trend line equation 
of the calibration curve, the calculated molecular weight for Blastocystis enolase 
was 74.13 kDa. The eluted fractions were analysed on both a 12% SDS-PAGE 
gel confirming the size of a monomer of the protein, and on a native gel to 
estimate the native molecular weight of the protein. All calculations were based 
on triplicate experiments.  
The experimental results differ from the theoretical value and is closer in size to 
a dimer of a protein. The discrepancies between the expected theoretical 
molecular weight and the measured experimental molecular weight might be 
due to experimental errors, or to factors that the calculating programs do not 
take in consideration while calculating. The molecular weight as measured by 
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gel filtration was reproducible (performed in triplicate). The possibility of a 
difference in protein shape between a standard protein and the Blastocystis 
enolase might have contributed to a deviation from the ideal gel filtration 
behaviour. Protein travel in gel filtration columns not only according to their 
molecular weight but also according to their volume and size. Hence, a possible 
difference in the shape might result in an unexpected size estimation.  
To be able to determine the molecular composition of the Blastocystis enolase, 
additional experiments were performed. Dynamic light scattering and native gel 
electrophoresis was performed to get a better understanding of the nature of the 
native protein. 
 
Measure:   Kav = 
 
 
Figure 4. 10 Elution profile of Blastocystis enolase analysed on an analytical Superdex 75 GF 
chromatography column in triplicate. The single peak obtained represents Blastocystis enolase. The 
y axis represents the absorbance at 280 nm. The x axis shows elution volumes in ml. 
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4.5.1.2. Immunodetection using a heterologous antibody  
The purified recombinant Blastocystis enolase was immuno detected in a step 
used to prove identity of the purified protein described previously. The protein 
was loaded and electrophoresed on a 12% SDS gel and transferred to 
nitrocellulose membrane as previously detailed in chapter 2, section 2.2.3.7. The 
transferred proteins were detected using two different antibodies. The first one 
was a His tag antibody (Qiagene) targeting histidine residues on the recombinant 
protein. The antibody against this affinity tag was used in a concentration of 
1:1,000 followed by the secondary antibody (1:5,000). Figure 4.11/A shows a 
band corresponding to the calculated theoretical size (̴ 48 kDa) of Blastocystis 
enolase.  
A heterologous polyclonal antibody against Trypansosoma brucei enolase was 
also used (kind gift from Prof. Julius Lukeš, Czech Republic). This heterologous 
antibody was used in a concentration of 1:1,000 for the primary antibody and 
1:5,000 for the secondary antibody. Immuno-detection using the anti-enolase 
antibody also showed a band of 48 kDa, the expected size of enolase, see Figure 
4.11/B. 
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Figure 4. 11 Western blot  of Blastocystis total protein lysate and recombinant Blastocystis enolase 
with anti- histidine monoclonal antibodies and anti- enolase antibodies. A: only one band 
corresponding to enolase probed with His Abs as the predicted molecular weight is about 48 kDa. 
Lane 1: molecular weight marker, (Fermentas Spectra Multicolor Broad Range). Lane 2: Gel filtrated 
purified recombinant Blastocystis enolase purified enolase. B: Western blot of Blastocystis enolase 
using monoclonal enolase antibodies (raised against Trypanosoma brucei, kindly donated by Dr. 
Julius Lukeš, Czech Republic) showing lane 1 of a molecular weight corresponding to Blastocystis 
enolase, Lane 2: Blastocystis total cell lysate, lane 3: Blastocystis enolase.  
 
4.5.1.3. Oligomeric status determination of the native enolase 
Blastocystis enolase purified using GF column was analysed by native gel 
electrophoresis using native condition as described in methods 2.2.3.5. This gel 
allows the determination of the molecular weight and also oligomeric status of 
native protein electrophoresed alongside a set of six standard native proteins 
mentioned in Table 2.13 (Olga Randelj 2007). Blastocystis enolase was analysed 
on 12% Clear Native Polyacrylamide Gel Electrophoresis (CN-PAGE) and Blue 
Native – PAGE (BN-PAGE) for about 3 hour or until the running front reached the 
front side of the gel, of 100 V at 4°C to avoid denaturing the protein due to the 
heat produced by the running current (Figure 4.12 A/B). This gel showed a band 
below the 100 kDa marker, in agreement with the dimeric status of enolase found 
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in the literature (Lee, Kang et al. 2006). The band produced by the native gel was 
cut out and analysed on SDS gel in a technique called 2D electrophoresis, (Figure 
4.13). The SDS gel produced a band corresponding to the expected size of 
Blastocystis enolase. This band was tested using western blot analysis with anti-
His antibodies (Figure 4.14).  
                                                                       
Figure 4. 12 Native gels of gel filtration – purified Blastocystis enolase. A. Blue native (BN) gel where 
the bands from 1 - 6 represents the following standard proteins: 1: Thyroglobuline (660 kDa), 2: 
Appoferritine (440 kDa), 3: Beta amylase (200 kDa), 4: Alcohol dehydrogenase (150 kDa), 5: Albumin 
(66 kDa), 6: carbonic anhydrase (30 kDa). B. Clear native (CN) gel.  The native gel (CN and BN/PAGE) 
of recombinant Blastocystis enolase alongside 6 protein standard the lanes from 1-6 as in  A. The 
big arrows in the figure refers to the corresponding expected enolase band. 
 
Figure 4. 13 Second dimension SDS-PAGE representing a strip cut from blue native gel PAGE of 
expected recombinant Blastocystis enolase band. The red arrow shows the band representing the 
expected enolase with a molecular weight of about 48 kDa. Molecular weights are indicated in kDa 
on the left. 
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Figure 4. 14 Western blot analysis of the predicted Blastocystis enolase from native PAGE. Anti – 
His antibody was used to decorate the protein.  
4.5.1.4. Size distribution profile using Dynamic Light Scattering (DLS) 
The Blastocystis recombinant enolase was analysed using dynamic light 
scattering (DLS) as described in methods, chapter 2, section 2.2.3.9.2 after being 
centrifuged for 20 min at 16,000 X g at 4°C. The analyses was repeated for about 
10 measurements and each measurement had a total of  10 acquisitions with 20 
seconds each acquisition time recorded at room temperature using DynamPro 
Titan (Wyatt Technology Corporation) and the analysis programme DYNAMICS 
(protein solution, USA). Table 4.1 shows the medium measurements for 
recombinant Blastocystis enolase sample parameters such as intensity, 
diameter, and molecular weight. The mean molecular weight of recombinant 
Blastocystis enolase 77.99 ±1.3 kDa is in agreement with the analytical column 
results. The Pd value was 0.2 ± 0.3 nm, where any value below 0.1 indicates a 
sample near-monodisperse. The percentage of polydispersity is also < 20% 
which also indicates a monodisperse sample.  
These results suggest the presence of a Heterologous bimodal sample 
comprising of two peaks which mean that there are two different species with a 
difference of five times or more in their parameters. The first peak is considered 
to be negligible due to the very low percentage of mass (0%), where any value of 
less than 1% of the relative amount of the value of the peak, is considered 
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negligible. The second peak is composed of two pins, and the intensity of the pin 
close to the expected size of the Blastocystis enolase is 97.9% resulting in a 
molecular weight of 79 kDa. The other bin intensity comprises only 2.1% of the 
mass (see Figure 4.16). The presence of a single sharp peak as shown in Figure 
4.15 indicates the presence of a homogenous species in the tested solution. This 
is confirmed by Figure 4.16 which shows the presence of 2 species; however one 
of these is a very low molecular weight molecule which is likely to be a salt as the 
intensity is only 2.1% of the whole solution, while the main molecule of 77.99 kDa 
makes 97.9 % of the solution composition.  
Table 4. 1 Dynamic light scattering parameters obtained from 10 measurements and each 
measurement is a mean of 10 readings. R: diameter of the scattered molecule, Pd: Poly dispersity, 
MW-R is the molecular weight measured in kDa. 
Item  Time (s)  Temp (C)  Intensity (Cnt/s)  R (nm)  Pd (nm)  %Pd  MW-R (kDa)  
Measurement 1  200  18  109123  3.8  0.1  3.3  76  
Measurement 2  409  18  108058  3.8  0.2  5.3  77  
Measurement 3  629  18  108015  3.9  0.9  22.4  79  
Measurement 4  833  18  107007  3.8  0.9  22.3  78  
Measurement 5  1037  18  105749  3.8  0.2  5.5  78  
Measurement 6  1239  18  107264  3.9  0.2  4.2  80  
Measurement 7  1441  18  106161  3.8  0.9  22.5  77  
Measurement 8  1698  18  102997  3.8  0.1  3.2  75  
Measurement 9  1902  18  103438  3.8  0.1  2  77  
Measurement 10  2104  18  103426  3.8  0.3  8.7  78  
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Figure 4. 15  Size distribution (by intensity) of Blastocystis enolase. The sharp peak indicates the 
presence of a single species component with no evidence of aggregation.  
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Figure 4. 16 A Heterologous bimodal size distribution histogram (regularization graph) of the gel 
filtration- purified Blastocystis enolase. A total of two distinct populations were detected. The graph 
displays the distribution of particle size from a regularization analysis of the data selected. The 
observed mass peaks from dynamic light scattering on recombinant Blastocystis enolase protein 
shows a total of two peaks, and the second peak comprises of two bins. The intensity of the scattered 
light of the second peak was 97.9% with a molecular weight of 79 kDa along with small molecules of 
2.1% intensity. The first peak is considered negligible in these results. The results table summary 
under the histogram shows an estimated relative amount of mass (concentration) (% mass) of 100% 
of the second peak. The x axis represents the discrete particle size in nm. The y axis represents the 
relative amount of light scattered by each bin (% intensity). 
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4.5.2. Fluorescent-based thermal shift assay (DFS: differential scanning 
fluorimetry)  
The thermal stability of a protein in a solution is influenced by several factors such 
as buffer identity, pH capacities, ligands, metal-ions, salts and concentrations. 
Any change in these components will result in changes in the protein melting 
temperature, Tm. To screen for the optimal condition at which Blastocystis 
enolase shows the highest stability, the protein is made in contact with a 
fluorescent dye such as SyprOrange®, which is quenched in the solution. By 
exposing the protein to increasing temperatures, it will undergo thermal unfolding, 
whereby the hydrophobic sites will be exposed. The dye becomes unquenched 
by attaching to the hydrophobic sites of the protein. The procedure is performed 
using StepOne™ Real-time PCR and the results are analyzed using PROTEIN 
THERMAL SHIFT ™ software, version 1.0 (applied Biosystems, UK). 
Temperature will be plotted against the fluorescence signal obtained. The 
midpoint temperature towards protein unfolding represents the Tm which is the 
optimal temperature at which the protein is stable. Figure 4.17 represents the 
calculated melting temperature of the Blastocystis enolase. Thermal stability 
assays were done in duplicates.   
In this project a screen of different buffers at different pH values was used. A list 
of all the buffers used in this experiment is listed in Table 2.7. A thermoFluor® 
instrument was programmed to increase the temperature from 25°C to 94°C by 
1°C/min. Fluorescence was measured using a CCD camera. A comparison 
between the melting temperatures of the protein in different buffers at different 
pHs and different salt concentrations was performed and can be seen in Figure 
4.18. Blastocystis enolase showed the highest stability in HEPES buffers and 
even more when HEPES was combined with glycerol. This is reassuring as 
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HEPES1 was used for enolase purification in GF columns. The stability of 
enolase was also reasonably good with imidazole, which is used in NAC. An 
increase in stability was noticed with increasing ionic strength. See for example 
the case of HEPES with varied concentrations of sodium chloride and glycerol. 
In the case of a complicated buffer mix, the stability of the protein in HEPES and 
gly 1 was the highest. Some additives such as glycerol are known to enhance the 
stability of the protein by forming glycerol – water bonds, these bonds form a coat 
around the protein molecule.  Also as glycerol is a poly-hydric alcohol, this 
decreases the rupturing nature of hydrogen bonds in addition to the hydrating 
effect of glycerol on the molecule’s surface. However, a decrease in stability was 
noticed when the glycerol percentage was doubled to 40% in the buffer 
composition. A similar effect was reported when the salt concentration was 
increased up to 2 M. (Gekko and Timasheff 1981).  
 
Figure 4. 17  Thermal shift stability assay of Blastocystis enolase.  The optimal melting temperature 
of Blastocystis enolase is 65.91°C.  The x axis shows the melting temperature of the protein-buffer 
mix. The Y axis shows the fluorescence signal detected. 
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Figure 4. 18  The stability of Blastocystis enolase versus buffer composition, and salt addition. 
Variations in protein melting temperature with different buffer’s composition and varying pHs. 
Buffers names in this experiment are shown in abbreviation detailed in Table 2.7. 
 
4.6. Activity assay and kinetic parameters  
The principle reaction for detecting recombinant Blastocystis enolase activity is 
explained in Figure 4.19 where enolase mediates the 9th reaction of glycolysis 
and catalyses the reverse reaction of 2-phosphoglycerate into 
phosphoenolpyruvate. Pyruvate kinase then converts phosphoenolpyruvate into 
pyruvate, a three carbon molecule, with the production of ATP. NADH should 
then be re-oxidized to NAD and this happens in the mitochondria in aerobic 
conditions, while in anaerobic conditions pyruvate is reduced to form lactic acid 
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in animal cells. In yeast, the reduction of pyruvate in anaerobic conditions results 
in carbon dioxide and methanol instead of lactic acid.  
Recombinant Blastocystis enolase activity was determined 
spectrophotometrically by measuring the conversion of NADH+ into NAD+ (the 
reduction of absorption at A340 nm). Enzyme kinetics was determined by carrying 
out the standard enolase assay (Bergmeyer 1965, Florian Muller 2012), and 
measuring the continuous rate changes over a period of 5 minutes for each 
measurement. Main measurements were carried out at 25°C (Section 2.3.8.2).  
 
Figure 4. 19  Schematic representation of recombinant Blastocystis enolase assay in which one 
molecule of NADPH+ is oxidised into NAD+. 2-phosphoglycerate is converted into 
phosphoenolpyruvate (PEP) in the presence of enolase, thereafter it is converted by pyruvate kinase 
into pyruvate producing one molecule of ATP. Pyruvate is then reduced into lactate by lactate 
dehydrogenase. NADPH+ absorbance is monitored at 340 nm.   
  
Recombinant Blastocystis enolase activity detection was performed at 25°C at 
increasing substrate concentrations while the enzyme concentration was fixed 
using 0.05 units in all reactions, see Figure 4.20. The increased substrate 
concentration was accompanied by an increase of the velocity of the reaction, 
suggesting the presence of a genuine enolase activity. The velocity of the 
reaction reached a plateau at about 56 mM of the substrate concentration. 
According to the Michaelis-Menten plot, the maximum velocity of the recombinant 
2-Phosphoglycerate + H2O                PEP                  Pyruvate + ATP 
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Blastocystis enolase was 0.03808 mmol/min, as calculated by SigmaPlot while 
the Km value was calculated as 16.8 mM. Km gives an idea about the affinity of 
the enzyme to its substrate, the higher Km value the lower the affinity of the protein 
to the substrate. It is clear from the calculated Michaelis-Menten value that 
recombinant Blastocystis enolase has a low affinity for its substrate in comparison 
to other previously studied enolases (Merkulova, Lucas et al. 1997, Quinones, 
Pena et al. 2007, Yang, Qiu et al. 2010). Table 4.2 shows examples of enolases 
purified for other organisms, showing a high Km of 16.8 mM for Blastocystis 
recombinant enolase while it is 0.078 ± 1.1 mM in mouse muscle-specific enolase 
(Merkulova, Lucas et al. 1997), 1.99 mM in Schistosoma japonicum, 0.08 mM in 
Leishmania mexicana (it has to be noted that this study used a different assays 
method)  (Quinones, Pena et al. 2007), A similar low affinity of the enzyme for its 
substrate of 7.2 mM can be seen for Ricinus communis (Miernyk and Dennis 
1984) and the highest 43 µM in Oryctolagus cuniculus (Yang, Qiu et al. 2010). 
One possible explanation about these data discrepancies from literature could be 
attributed to the odd point in the data shown in Figure 4.20. Deleting this point 
might lead to changing the kinetics to fit with enolase kinetics reported in other 
organisms. 
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Table 4. 2 Michaelis-Menten constant value for different organisms including Blastocystis sp4 (this 
study)  
Organism  Km  value (mM) Study 
Blastocystis sp 4 16.8 This study 
Leishmania mexicana 0.08  Quinones, Pena. 2007 
Schistosoma japonicum  1.99 Yang, Qiu. 2010 
Mouse muscle 0.078 Merkulova, Lucas. 1997 
Ricinus communis 7.2 Miernyk, 1984 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. 20 Steady state kinetics of recombinant soluble Blastocystis enolase showing an increase 
in the reaction rate with increasing substrate concentration, reaching a plateau at about 56 mM 2- 
glycerophosphate. X-axis: substrate concentration (2GP: 2-phosphoglycerate), Y-axis: rate of 
reaction in m.mol/min/mg. 0.5 mg/ml of enolase was used in this assay. Error bars show standard 
deviated calculated from duplicate measurements.  
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Figure 4. 21 Rate of the recombinant Blastocystis enolase activity reaction and its dependence on 
protein concentration. Protein concentrations varied between 0-4 mg/ml. X axis shows the enolase 
concentration in mg/ml. Y axis shows the rate of the reaction in mg.ml-1 .sec-1 
 
Figure 4. 22 Recombinant Blastocystis enolase activity using varied substrate concentration which 
varied from 1 mM to 100 mM. The substrate concentration is coloured varied. The X axis shows the 
protein concentration in mM. The Y axis shows the time consumed by the protein in sec. 
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When comparing the effect of substrate concentration on the reaction rate, it was 
noticed that the reaction was faster with substrate concentrations such as 20 and 
56 mM, while it was almost unnoticed when using low concentration as 1 mM. 
The higher substrate concentration of 100 mM resulted in a very low rate as well 
(see Figure 4.21/ Figure 4.22). 
4.7. Summary   
Here I have shown that the Blastocystis enolase was successfully cloned into 
different expression systems, of which E.coli BL21 gave the best yield when 
autoinduced at 20°C for 48h. Cloning into E.coli Rosetta2 cells gave a high yield 
of recombinant Blastocystis enolase as well, but this was deposited in inclusion 
bodies, which suggests unfavourable conditions that forced the protein to target 
the inclusion bodies. Blastocystis enolase was purified using two basic columns. 
A nickel affinity column, utilising a His tag flanked on the N-terminus on the 
recombinant protein. This column resulted in a high purity of the protein of about 
95%. A SEC column resulted in a final purity of about 99%.  
The recombinant protein Blastocystis enolase identity was checked using both 
His tag and a heterologous enolase specific antibodies from Trypanosoma 
brucei.  
The recombinant Blastocystis enolase was shown to be a homodimer after using 
mass spectrometry, native gel electrophoresis, analytical gel filtration and 
dynamic light scattering experiments, in accordance with previously published 
data for other enolases. The calculated theoretical molecular weight is 48 kDa, 
while the measurements were about 74 kDa according to analytical gel filtration, 
and 78 kDa according to dynamic light scattering. Those data suggest a monomer 
of about 37 kDa. This difference between the theoretical and calculated molecular 
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weight could be attributed to experimental errors, or to possible differences in the 
shape of the protein standards used for generating the standard curve of gel 
filtration. Other methods are advised to be used for the calculation of the 
molecular weight of enolase. Since gel filtration and native gel do not give a 
precise value due to the nature of the experiment, and same for dynamic light 
scattering. The addition of more steps is recommended such as using analytical 
ultra-centrifuge, which is more precise, but less approachable due to the need for 
specialist equipment and also because it is more time consuming (approximate 
4 hours compared to 10-20 minutes using dynamic light scattering). Analytical 
ultra-centrifugation not only gives a precise number of the protein’s molecular 
weight, but it can also give an idea about the oligomeric status of the protein. 
Another method that could be used is size exclusion chromatography-multi angle 
laser scattering (SEC –MALS) which is a combination of light scattering and gel 
filtration. 
The kinetics parameters; Vmax and Km of the soluble recombinant Blastocystis 
enolase were lower than those of previously studied enolases in different 
organism and show a low affinity to the substrate.  This high Km relative to the 
physiological concentration of the substrate indicates that the protein is not 
normally saturated with the substrate and its activity depends highly on the 
substrate concentration and hence the product depends on substrate availability. 
The high Km value gives an indication of low affinity of the enolase to its substrate 
2-phosphoglycerate. Which means that the product is more readily available in 
the environment. A study performed by Liu et al was looking to characterize 
proteins depending on their Kinetic modelling, has referred to 
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to enolase, GAPDH and PGK as critical enzymes in system biology, i.e. their 
deletion will influence the metabolic system robustness (Li and Liu 2012). This 
means that any change of these enzymes would make a systemic biology impact 
on distant areas and exert a persistent impact on system structure. Therefore, 
enolase has a system-level role on the physiology not only the local effect studied 
by the protein’s biochemical and biophysical properties. 
Therefore and from what was mentioned above, the unusual value of enolase Km 
compared to other enolases could suggest that Blastocystis enolase exhibits 
different biochemical properties than enolase studied in other organisms, shown 
by a low affinity to its substrate. In an attempt to explain this, several theories 
might be utilised to achieve this; first it was shown in chapter 3 that enolase may 
localize differently than other text book enolases. It showed to localize to the 
mitochondria and not the cytosol of the cells. This might indicate a different role 
played by Blastocystis enolase, falling into the moonlighting group of proteins 
which exhibits several other functions that the protein might play. Being a 
moonlighting protein might mean that the gene coding for Blastocystis enolase is 
a duplicated gene of the ancestral enolase gene. This might result in two 
possibilities; either that the duplicated copy gene has lost its original function 
through what is called loss-of-function mutation which means that they both share 
the same sequence but the other copy is un-functional, otherwise it had adapted 
a new function. This process of losing functionality might take millions of years 
after having the duplicated gene and before losing the function. Or it might have 
lost its functionality, and is in the process of gene resurrection which happens 
due to stressful new environmental changes that challenges the organism, in an 
event known as gene conversion (Koch 1972). But this not likely to be correct 
since the Blastocystis enolase had shown activity as a glycolytic protein.   
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The other suggestion is that the Blastocystis enolase gene is duplicated gene 
that could be still functional but performing other functions, such as other 
moonlighting enolases reported in literature. And here we face two scenarios; the 
gene might become a paralog gene adopting a new function forming what is 
called a neofunctionalisation where one copy retains the main function and the 
other copy adapts a new function, which would be the moonlighting phenomenon. 
Or that the paralog copy goes in what called quantitative subfunctionalisation 
where both copies retain part of the function and hence the ancestral function is 
partitioned between the two paralogs (Espinosa-Cantu, Ascencio et al. 2015).  
On the other hand, and looking at the data points in Figure 4.20, an odd point is 
protruding out of the curve. This point might be the reason behind different 
kinetics of Blastocystis enolase of the study compared to other enolases. 
Further work is to be performed to find the possible role of enolase in Blastocystis 
virulence, and find the impact of its localization to the mitochondria on its role. 
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Chapter 5. In silico characterisation of recombinant Blastocystis 
TPI-GAPDH fusion protein  
Glycolysis is an important process that offers energy supply to all living cells. Text 
books always refer to glycolysis process to be a cytosolic process, with some 
exceptions as in trypanosomatids (Trypanosome spp and Leishmania spp) 
whose glycolysis only take place in peroxisomes like organelles called 
glycosomes.   
However in a paper published 2000 by Liaud et all, a non-canonical localization 
of glycolytic proteins was reported in diatoms (Liaud, Lichtle et al. 2000). They 
showed the presence of unusual glycolytic protein TPI-GAPDH to possess a 
mitochondrial targeting signal. They had also reported the presence of other 
glycolytic enzymes, not only TPI-GAPDH, and basically a tendency to be those 
taking place in the second half of the glycolytic pathway, i.e. the payoff phase.  
Later in 2012 another group published an in silico analysis of the glycolytic 
proteins and they showed that this phenomenon is spreading to a wide group of 
organisms that belong to Stramenopiles (Nakayama, Ishida et al. 2013).  
In Blastocystis, a similar event was found, and an unusual glycolytic protein TPI-
GAPDH was also found to be fused in one gene, with a possible targeting to the 
mitochondria. 
Hence, it is sought in this project to analyse the Blastocystis TPI-GAPDH 
sequence, and find where this protein localizes in the living system, giving an 
insight about the evolutionary relation of this protein and other mitochondrial 
protein reported as well. 
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5.1. Individual proteins super families  
The Blastocystis TPI-GAPDH fusion protein is composed of two proteins coded 
on one gene and being translated as a 603 amino acid protein, and assembled 
in the mitochondria as a tetramere. No isoformes were found in Blastocystis 
cytosol as a stand-alone proteins, either TPI or GAPDH, making it the only 
version of those two glycolytic proteins. For this, a separate investigation of those 
two proteins is done to find how conserved are those proteins, and if they kept 
their active sites and residues. 
To perform this, Blastocystis TPI-GAPDH fusion protein sequence was used as 
a query search against all main group of living system, including prokaryotes and 
eukaryotes. Due to the speciality of this sequence, the search always came back 
with a mix of both TPI and GAPDH results. Therefore, the results were separated 
into those two. 
5.1.1. TPI super family 
Performing an NCBI protein search using Blastocystis TPI-GAPDH fusion protein 
as a query came back with results from all members in the living kingdom, since 
it is a widely abundant protein.  
Triosephosphate isomerase belongs to the (βα) 8 barrel enzyme family (TIM 
barrel family), a wide group of enzymes performing several functions. This 
enzyme doesn’t need a metal ion or co-factor for its catalysis, its catalysis is acid-
base catalysis, which means special residues are responsible for the catalytic 
reaction to happen (Nagano, Orengo et al. 2002). The TIM barrel family has 
remarkable residues important for the proteins activity. When comparing the 
sequence of Blastocystis TPI-GAPDH fusion protein with other TPI proteins, it 
was found that the fusion protein has kept all TIM barrel special sequences and 
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active site. Three residues are important for the catalytic activity, and the fourth 
is important for the right orientation of the lysine residue in the active site 
(Knobeloch, Schmidt et al. 2010).The four residues [the substrate binding 
aspargine (N) and lysine (K) in addition to the Histidine (H) and glutamic acid (E)] 
playing an important role in substrate binding and active site catalysis were found 
to be conserved in all the search proteins, see Figure 5.1. Another important 
feature, loop 6 connecting β strand 6 with α helix 6 and forming a lid that covers 
the active site residues during the catalytic reaction, taking the sequence 
AYEPIWAIGTG which is important in protein activity was also highly conserved 
in Blastocystis and the other search organisms, Figure 5.1. Organisms used in 
this search are all mentioned in Figure 5.1 with their corresponding accession 
numbers or PDB codes when available. 
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Figure 5. 1 Comparison of the amino acid sequences of triosephosphate isomerase part of the 
Blastocystis TPI-GAPDH fusion protein with various organisms. The asterisks refer to the amino 
acids playing important role in protein activity. Region in box refers to the amino acid sequence 
covering the flexible loop region. Accession numbers or PDB codes are as follows from top to 
bottom: EFA82625.1, XP_004357462.1, BAN38145.1, XP_004333360.1, pdb|4BI7|A, EST45141.1, 
XP_001320336.1, pdb|4Z0J|A, EJY68394.1, CDW88838.1, KRX01127.1, XP_001008794.2, 
XP_002295570.1, XP_002181761.1, CBJ32973.1, NP_000356.1, XP_005706061.1, XP_005538108.1 and 
YP_008965787.1.                   
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5.1.2. GAPDH super family  
Same search was performed using Blastocystis TPI-GAPDH fusion protein 
sequence on NCBI server against representatives of members of the living 
system. The result came back with mixed TPI and GAPDH due to the nature of 
the query. For this reason, only results containing the stand alone GAPDH protein 
were chosen to perform the comparison. 
Protein sequences were aligned using ClustalW multiple alignment (Larkin, 
Blackshields et al. 2007). The alignment was investigated by eye, and vaguely 
aligned regions were excluded. The alignment showed that GAPDH region of the 
fusion protein is highly conserved among other species and Blastocystis. The 
main regions detected were two. The first one is the active site region taking the 
amino acid sequence (ASCTTNCL). This sequence covers the active site of 
GAPDH, and it was conserved as Figure 5.2 shows. Another important feature in 
GAPDH sequence is a signature motif indicating the protein binding ability. 
GAPDH Rossmann fold can either bind the cofactor NAD+ or NADP+ to its active 
site, in what is called dual co-substrate specificity. A consensus N-terminal 
sequence, which is Glycine-rich phosphate binding loop, was found to play an 
important role in the determination of cofactor binding. It takes the following 
sequence GXGXXGX. Replacing Glycine with alanine will change the binding 
from NAD+ to NADP+  (Hanukoglu 2015). In the Blastocystis TPI-GAPDH fusion 
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protein it was clear that the cofactor is NAD+, see Figure 5.3. 
 
Figure 5. 2 The actives site region of Blastocystis TPI-GAPDH and other glycolytic GAPDH proteins 
from different species. The residues in the box show the sequence motif indicative of loop 6 area. 
The organism’s accession number or PDB codes are as follows from top to bottom. Query protein,  
XP_012894401.1, XP_008620095.1, XP_008861346.1, ETO79873.1, BAN38604.1, EFO63427.1, PDB 
4LSM, XP_003865363.1, PDB 3STH, EUD71497.1, XP_001445566.1, XP_002290129.1, 
XP_002177670.1, AAU81890.1, CBJ32822.1, CAA25833.1, GAQ46613.1, BAJ90709.1, AMT91855.1, 
XP_005537058.1, XP_005704189.1, WP_004033988.1 and CZT56408.1.         
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Figure 5. 3 Conserved region in Blastocystis TPI-GAPDH and other glycolytic GAPDH proteins from 
different species. The residues in the box show the GXGXXGX sequence motif indicative of GAPDH 
binding NAD+. The organism’s accession number or PDB codes are as follows from top to bottom. 
Query protein,  XP_012894401.1, XP_008620095.1, XP_008861346.1, ETO79873.1, BAN38604.1, 
EFO63427.1, PDB 4LSM, XP_003865363.1, PDB 3STH, EUD71497.1, XP_001445566.1, 
XP_002290129.1, XP_002177670.1, AAU81890.1, CBJ32822.1, CAA25833.1, GAQ46613.1, 
BAJ90709.1, AMT91855.1, XP_005537058.1, XP_005704189.1, WP_004033988.1 and CZT56408.1.                
  
5.2. In silico characterization of Blastocystis TPI-GAPDH; pre-
sequence and signature motif  
5.2.1. TPI-GAPDH Pre-sequence analysis  
The Blastocystis TPI-GAPDH fusion protein is composed of an intact moiety of 
TPI at its N-terminal, attached with a small hinge region with a complete intact 
GAPDH moiety. TPI’s C-terminal is attached to GAPDH’S N-terminal 
immediately. And the whole fusion protein has an N-terminal which is a targeting 
signal. Liaud et al has shown that this protein has a mitochondrial targeting signal 
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in diatoms, and they proved it with electron microscopy experiments. In their 
papers, (Liaud, Lichtle et al. 2000) and (Nakayama, Ishida et al.) both 
hypothesized that this is widely spread in the Stramenopiles. Nakayama et al 
have referred to the presence of these mitochondrial proteins in several other 
glycolytic proteins, including the second half of glycolysis pathway. 
To test this hypothesis in Blastocystis and since it only possess the fused version 
of the protein, the targeting signal of Blastocystis TPI-GAPDH and same proteins 
of several groups were evaluated.  
A BLAST search was performed using Blastocystis TPI-GAPDH fusion protein, 
and was divided into two groups as mentioned before in 5.1.1. and 5.1.2. 
sections.  
This search resulted in three groups; proteins representing TPI stand-alone 
version only, protein representing GAPDH stand-alone version only, and the third 
group was limited to the organisms which showed a fusion protein as the protein 
of query. 
The mitochondrial targeting signal was evaluated in each group using four 
predicting programs; MitoProt (Claros 1995), iPSORT (Bannai, Tamada et al. 
2002), Predotar (Small, Peeters et al. 2004)  and TargetP (Emanuelsson, Brunak 
et al. 2007). Only those organisms whose protein showed to be targeting the 
mitochondria in at least three out of the four programs, with a high value (> 0.7%) 
were considered to be mitochondrial localized proteins to avoid false positive 
results. 
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The group containing TPI proteins only had shown that only Blastocystis TPI-
GAPDH is targeting the mitochondria. The rest were all negative for targeting the 
mitochondria.  
On the other hand, the search results representing GAPDH proteins had shown 
almost a similar result; proteins that belong to the Chromalveolates were all 
positive towards having a mitochondrial targeting signal, with a high support 
value. Inspecting those sequences by eye revealed that those proteins were all 
a full version of the fusion protein, and not only GAPDH as the NCBI blast search 
showed. In addition to the full TPI-GAPDH proteins, were unusual localization 
reported in Homo sapiens and members of diatoms as well including 
(Thalassiosira pseudonana, Phaeodactylum tricornutum, Odontella sinensis), 
Figure 5.4.  
The BLAST search using the fusion protein as a query resulted in a group of 
fusion proteins as well. Those proteins mostly belonged to the chromalveolates 
represented by diatoms, Oomycetesas, Ciliata and Phaeophytes, Figure 5.5. 
These results are in agreement with what was reported in Liaud paper, of spotting 
fusion protein of TPI-GAPDH in diatoms. It also supports the findings of 
Nakayama of a wider spread of the fusion protein in stramenopiles 
Those mitochondrial targeting signals were all basic, positive residues, rich in 
arginine residues specially at R-3 and R-2 from the cleavage site, short signals 
ranging between (12-22) which all in accordance with the mitochondrial targeting 
signal specifications as discussed in details in chapter 3, section 3.2.1. and in 
agreement with what was already published about these kind of signals (Gavel 
and von Heijne 1990, vanderGiezen, Rechinger et al. 1997).  
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Figure 5. 4 GAPDH protein sequence alignments using the Blastocystis TPI-GAPDH as query 
sequence on BLAST search, and representing members covering all groups of life. Mitochondrial 
targeting signals are underlined. Accession numbers and PDB codes are as follow from top to 
bottom: XP_012894401.1, XP_008620095.1, XP_008861346.1, ETO79873.1, BAN38604.1, EFO63427.1, 
4LSM, XP_003865363.1, PDB 3STH, EUD71497.1, XP_001445566.1, XP_002290129.1, 
XP_002177670.1, AAU81890.1, CBJ32822.1, CAA25833.1, GAQ46613.1, BAJ90709.1, AMT91855.1, 
XP_005537058.1, XP_005704189.1, WP_004033988.1 and CZT56408.1.                
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Figure 5. 5 Fusion protein aligned with other fusions using Blastocystis TPI-GAPDH as a query. 
Showing the wide spread of the fusion proteins in chromalveolates. The mitochondrial targeting 
signals are underlined. Accession numbers and PDB codes are as follow from top to bottom: 
XP_012894401.1, AAF34330.1, AAF34328.1, XP_002290574.1, XP_008620095.1, AAF44720.1, 
XP_008861346.1, ETO79873.1, CBJ30340.1, ABU96664.1, and ABU96661.1.      
 
5.3. Phylogentic relationships of Blastocystis TPI-GAPDH and 
other organisms 
Blastocystis TPI-GAPDH fusion protein was aligned with protein sequences of 
TPI and GAPDH proteins, separately, from a broad spectrum of eukaryotes and 
bacteria. Another alignment was also made between stramenopiles members for 
both proteins as well, and for the fusion proteins reported by the BLAST search. 
Highly diverged and vaguely aligned sequences were removed manually from the 
alignment before the phylogenetic analysis. A complete list of all organisms used 
in this analysis is found in. Each set of sequences was aligned using MUSCLE 
(Edgar 2004). MUSCLE will detect any sequence repetitions and gaps and will 
remove them automatically. Regions of gaps or those that 
are not clearly alignable  in  all  sequences  were  excluded  from  the  phylogen
etic  analyses  by  masking  the  alignment  manually.  A phylogenetic tree is then 
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constructed using those edited sequences. Each alignment was analyzed using 
PhyML (maximum likelihood).  
The phylogenetic search was divided into three groups in this part due to the 
nature of the sequences submitted and to the fact that the BLAST search return 
with a mixed results containing TPI proteins, GAPDH proteins, and a smaller 
group containing the fusion protein. 
Phylogeny tree constructed from either TPI or GAPDH only, were of a low support 
value. In the case of tree constructed using TPI protein results only, Figure 5.6 
shows that Blastocystis TPI-GAPDH fusion protein is not clustering in a group 
with other TPI protein-containing organisms, and that it is evolving earlier than 
the most neighbouring organisms.  
The same procedure was performed using BLAST results containing GAPDH 
only, and as Figure 5.7 demonstrating, Blastocystis TPI-GAPDH fusion protein is 
clustering in the same group with organisms belonging to the diatoms, 
oomycetes, and phaeophytes. Interestingly, it is found that Blastocystis TPI-
GAPDH is branching closely to eubactericae as well. Finally, the tree constructed 
using the fusion protein results only, showed clearly that the organisms containing 
this fusion belong to the chromalveolates and specially diatoms, oomycetes, 
ciliata and phaeophytes, with a very high support value, Figure 5.8. 
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Figure 5. 6 Relationship of Blastocystis TPI-GAPDH fusion protein among eukaryotes and prokaryotes 
as determined by phylogenetic analysis of protein sequence representing triosephosphate 
isomerase only. Shown is a protein maximum-likelihood topology constructed 
by the PhyML program. Bootstrap values and posterior probability values were 
calculated using PhyML. The dataset contained 29 from all super-groups of eukaryotes and 
prokaryotes. A complete list of taxa and their accession numbers can be found in Table 3.3.   
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Figure 5. 7 Relationship of Blastocystis TPI-GAPDH fusion protein among a group of organisms 
containing GAPDH protein only determined by phylogenetic analysis of protein sequence. 
Shown is a protein maximum-likelihood topology constructed by the PhyML program. The dataset 
contained 13 organisms. A complete list of taxa and their accession numbers can be found in 
Table 3.3.   
 
Figure 5. 8 Relationship of Blastocystis TPI-GAPDH fusion protein among a group of organisms 
containing the complete fusion protein only determined by phylogenetic analysis of protein 
sequence. Shown is a protein maximum-likelihood topology constructed by the PhyML program. 
The dataset contained 13 organisms. A complete list of taxa and their accession numbers can 
be found in Table 3.3.   
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5.4. Conclusion  
In silico analysis of the Blastocystis TPI-GAPDH fusion protein clearly shows a 
highly conserved protein in general. The sequences analysis of the two parts of 
the protein have presented the important features and signatures identifying both 
TIM barrel family, to which triosephospate isomerase (TPI) protein belongs to,  
and the same was noticed for the glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH) part of the fusion, which presented with the Rossmann fold with its 
features.  
Interestingly this unusual protein has shown a special targeting signal. Unlike all 
glycolytic enzymes, the fusion protein in this study had presented with a 
mitochondrial targeting peptide with a high support value. This targeting signal 
was found in other organisms containing the fusion protein as well. Those 
organisms belonged basically to the stramenopiles, which is quite an interesting 
finding. The same phenomenon was previously reported in the work of Liaud et 
al where they noticed the presence of the mitochondrial targeting signal in a group 
of diatoms (Liaud, Lichtle et al. 2000). 
Phylogenetic analysis was performed to find where this protein originates from 
and how did it evolved. Interestingly, the tree constructed using the fusion protein 
sequence only, has shown a clear bias of those proteins to belong to the 
stramenopiles as well. This has been reported before in the work of Nakayama 
et al, in their paper 2012, they reported a broad distribution of this unusual 
enzyme in stramenopiles as well.  
It is difficult to trace the origin of this fusion protein, since neither TPI nor GAPDH 
trees give a clear resolution of this idea. However and quite interestingly, 
Blastocystis TPI-GAPDH had been very close to the bacterial GAPDH in the tree 
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constructed using GAPDH sequences only. This suggests that they are closely 
related and they share the same origin. This notion supports the hypothesis that 
the modern-day mitochondria are originating from α-proteobacterial (Cavalier-
Smith 1987) that has lost a lot of its genes through evolution both gene loss and 
nuclear transfer (Martin, Hoffmeister et al. 2001). Many of those transferred 
genes encode proteins that target the mitochondria. However there is no strong 
proof that those enzymes studied so far are of α-proteobacterial ancestry, but the 
existence of those glycolytic enzymes targeting signal to the mitochondria and 
others indicated in (Nakayama, Ishida et al.) gives a large motivation to 
investigate this more in organisms and study the localization in vivo as well as in 
silico. 
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Chapter 6. Biochemical characterisation of the unusual TPI-
GAPDH fusion protein from Blastocystis 
6.1. General background (introduction) 
The conservation of energy is a vital process for all organisms, and several 
pathways are made for this purpose. The glycolysis pathway is one of the most 
common ways to conserve energy, and glycolytic proteins are one of the most 
ubiquitous enzymes in eukaryotes. This pathway usually takes place in the 
cytosol where its end product pyruvate is transferred to the mitochondria to be 
utilized in Krebs cycle. This scenario is quite common that it is presented in most 
of the text books when explaining the glycolytic process. However, some 
organisms have a different localization of their glycolysis pathway. 
Trypanosomes have special organelles called glycosomes which are micro body 
-like organelles containing glycolytic enzymes (Misset, Bos et al. 1986, Michels 
1988). These trypanosomal glycosomal-localized glycolytic enzymes have been 
reported to possess special properties that are not found in the cytosolic 
Trypanosomal enzymes, and not even in the enzymes of other organisms and 
that are not localized to a special compartment. This made these proteins 
interesting as potential targets for drug development targeting the glycosomal 
glycolytic proteins.   
Recently, another unusual glycolysis cellular localization was discovered, taking 
place in a group of eukaryotes called stramenopiles. It was suggested that at 
least the second half of the glycolytic enzymes are targeted to the mitochondria, 
which is the first unusual event reported in this context. Yet fewer researchers 
had drawn the attention to the presence of an unusual protein formed from the 
fusion of two consecutive proteins, TPI-GAPDH. Unlike what was previously 
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reported about glycolysis of the presence of fusions between non-consecutive 
enzymes like enolase and GAPDH (Takishita, Patron et al. 2005).  
Triosephosphate isomerase (TPI) is a widely studied enzyme and it is well known 
for its role in the catalysis of the isomerization between glyceraldehydes-3-
phosphate (GAP) and dihydroxyacetone phosphate (DHAP) which are formed 
from fructose 1, 6-bisphosphate that is produced by the aldolase enzyme. GAP 
is then utilized in the glycolysis pathway by glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) which is the following enzyme on this pathway. DHAP 
can be used in the production of glycerine phosphate in lipid synthesis. GAPDH 
utilizes the other product of the TPI reaction, GAP, as a substrate in the reversible 
reaction converting GAP to 1, 3-diphosphoglycerate. 
Both TPI and GAPDH are well studied enzymes. Although almost universal, they 
do show some degree of divergence in their sequences, making them interesting 
candidates for drug development studies.  
In this instance, it was reported that TPI and GAPDH, together form a fusion 
protein that is coded by one gene, where the C-terminal of TPI is upstream the 
N-terminal of GAPDH, with no stop codon at the end of TPI. This fusion protein 
was reported abundantly in protists and specifically stramenopiles such as 
diatoms, photosynthetic protists that have plastids to which the fusion protein is 
targeted (Liaud, Lichtle et al. 2000, Nakayama, Ishida et al.).  
Genomic studies in Blastocystis have shown the presence of a similar fusion 
containing TPI and GAPDH on the same open reading frame (ORF). This gene 
seems to have a mitochondrial targeting signal, which makes it an interesting 
subject to be investigated for two reasons: firstly because it defies the general 
notion that glycolysis is localised in the cytosol, and secondly because 
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Blastocystis is an anaerobic organism with mitochondria and mitochondrial 
glycolytic enzymes might suggest unexpected metabolic adaptations of this 
parasite which could perhaps be exploited as drug targets..  
The TPI-GAPDH fusion protein is not fully characterized yet, apart from a paper 
in 2000 that investigated its molecular weight and oligomeric status using 
molecular biology techniques (Liaud, Lichtle et al. 2000). In 2014 an MSc report 
was written at the University of Bedfordshire which looked into the kinetics of the 
recombinant Blastocystis TPI-GAPDH fusion protein (using clones provided by 
our group, the same as used in this study). That study somewhat inconclusive 
regarding the oligomeric status of the fusion protein (Evans 2014).  
We anticipate that the TPI-GAPDH fusion protein performs a function similar to 
the sum of the individual glycolytic enzymes. However, no conclusive data to 
support this notion currently exists. As TPI and GAPDH normally have different 
multimeric stoichiometries (TPI is normally a homodimer while GAPDH is a 
homotetramer), it would be interesting to understand the multimeric arrangement 
of this unusual enzyme. In addition, is there any benefit from having a fusion 
enzyme compared to having two individual enzymes?  
In this project I sought to characterize this unusual fusion protein biochemically 
and biophysically in order to address these questions. Any difference with the 
host enzymes would make the Blastocystis TPI-GAPDH fusion a potential 
candidate for drug development against Blastocystis in the future. 
Evans et al (2014) suggested from their preliminary size exclusion 
chromatography data that the fusion protein is composed of a dimer of TPI and a 
dimer of GAPDH (Evans 2014). On the other hand, Liaud et al suggested the 
fusion to be a tetramer of GAPDH and two dimers of TPI (Liaud, Lichtle et al. 
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2000). The work in this chapter was sought to biochemically characterize the 
Blastocystis fusion protein. In order to do this the protein needed to be purified to 
a high level. This might ultimately lead to being able to crystalize this unusual 
fusion and help to unravel the three-dimensional structure of this interesting 
fusion protein.   
6.2. Recombinant Blastocystis TPI-GAPDH was successfully cloned 
and over-expressed in Escherichia coli 
6.2.1. Cloning and amplification of Blastocystis TPI-GAPDH (B.TPI-GAPDH) 
The gene encoding the recombinant Blastocystis TPI-GAPDH fusion protein was 
previously cloned in pET-14b and stored in our group stocks. The gene was 
originally amplified using TPI-GAPDH pET F and TPI-GAPDH pET R primers 
mentioned in Table 2.2 which introduce NdeI and BamHI restriction sites. Cloning 
in these sites introduced an N-terminal His-tag and allows for expression under 
the control of the T7 promotor. The gene was amplified from clones of the 
previously stored construct (see Figure 6.1). A mix of enzymes was used in the 
PCR reaction including proofreading Pfu DNA polymerase and Taq polymerases 
as mentioned in chapter 5, section 4.2.1. The gene construct was confirmed by 
the DNA sequencing facility at MWG - Eurofins using T7 and T7 term primers of 
the pET-14b plasmid referred to in Figure 2.4 and which sequence is mentioned 
in Table 2.11.  
Genes incorporated in pET-14b vector were transferred into several E. coli cell 
lines, including BL21, Arctic express and Rosetta2 cells to identify optimal protein 
production conditions. 
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Figure 6. 1 Agarose gel electrophoresis analysis of PCR-amplified TPI-GAPDH from Blastocystis 
ST4. Adding NdeI and BamHI restriction sites. The gel shows a band of the amplified recombinant 
Blastocystis TPI-GAPDH with an expected size of 1.86 kb. DNA HyperLadder I is on the left side lane 
of the PCR product. Sizes of relevant markers are indicated in kb (Bioline).  
 
 
Different cloning approaches were used at the Oxford Protein Production Facility 
laboratories in an attempt to examine the effects of changing the vector and 
amplification enzymes on the final protein product. New vectors and amplifying 
enzymes were tried. A new vector was tried to assess its impact on gene 
expression. The standard vector adopted by Oxford University/Oxford Protein 
Production Facility (OPPF) department is developed by them. These are pOPIN 
F 16417 and pOPIN E 16418. Primers used were kindly offered by the OPPF lab. 
The recombinant Blastocystis TPI-GAPDH gene was amplified using the Phusion 
Flash enzyme (Life Technologies) and the KOD Xtreme™ Hot Start DNA 
Polymerase (Merck Mellipore), as both give higher fidelity than the Phusion 
enzyme (Figure 6.2). Constructs made in pOPIN E and F were not further used 
afterwards in this project and only the recombinant fusion Blastocystis TPI-
GAPDH pET-14 construct in E. coli BL21 was used for downstream experiments.  
2  
1.5 
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Figure 6. 2 Agarose gel electrophoresis analysis of PCR-amplified Blastocystis TPI-GAPDH with 
pOPIN E and pOPIN F primers, using both Phusion flash (lane 1) and KOD Xtreme (lane 2) amplifying 
enzymes respectively. The gel shows a band of the expected size of 1.86 kb. DNA HyperLadder I 
(Bioline) is on the left side lane of the PCR product. The sizes of the relevant reference DNA are 
indicated next to the band. 
 
6.2.2. Recombinant Blastocystis TPI-GAPDH Expression trials; recombinant 
fusion protein TPI-GAPDH was soluble in all construct and in abundance in auto-
induced BL21 cells. 
In order to identify the optimal gene expression conditions that would result in 
maximum amounts of soluble protein, several parameters were varied. All 
Blastocystis TPI-GAPDH constructs were incorporated in the pET-14b vector. 
Several E. coli cell lines were used including BL21, Rosetta 2 and Arctic Express 
cells. Expression conditions have also been varied. The IPTG concentration has 
been varied and auto-induction has been used as well. In addition, incubation 
temperatures, media used, and time of induction have been changed. 
The TPI-GAPDH pET-14b construct was transferred into E. coli Rosetta, BL21 
and Arctic Express cells and induced at 37, 30, 25 and 18°C for Rosetta and 
BL21 E. coli cells and 10 °C for Arctic express E. coli cells. All of which gave a 
very low yield of the protein using different IPTG concentration of (1-400 mM). A 
few examples of the several expression trials conducted to find the most 
favourable conditions for gene expression and yield are shown in Figure 6.3.  
2 
1.5 
1
1 
2
2 
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As using various conditions of IPTG to induce protein did not result in satisfactory 
yields, auto-induction was used in the hope this would solve the poor yield 
obtained thus far. Interestingly, the gene was highly expressed under this 
condition (20°C, auto-induction for 48 hours in E. coli BL21 cells). This method 
depends on the role of lactose in the media that will induce the growth of cells to 
a much higher level than that achieved in normal induction over expression 
methods using IPTG. This role will start only after the high density media is 
depleted from the inhibiting factors, (Studier 2005). For further explanation of this 
approach please see chapter 4, section 4.2.2.  
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Figure 6. 3 Expression trials for Blastocystis TPI-GAPDH in E. coli cell lines under several conditions. A) TPI-GAPDH 
cloned into pET-14b in Bl21 E. coli, was induced at 37°C at different optical densities and different IPTG 
concentrations where:  
1) Gene expression induced with 1 mM IPTG at ODs values of 0.8 and 1 respectively. The lanes are as follows 
respectively: 1, 5. uninduced, 2, 6. induced cells cooled down for 4-5 hours for better folding of the protein (4+°c), 
3,7 insoluble and 4,8. Soluble fractions.   
2) Induction with 1 mM IPTG at ODs values of 0.4 and 0.6 respectively. The lanes are as follows respectively: 1, 5. 
uninduced, 2, 6. induced cells cooled down for 4-5 hours for better folding of the protein (4+ °c), 3, 7 insoluble and 
4, 8 soluble fractions.  
 3) Induction with 400 mM for 4 hours, where: 1: OD=1, 2: OD= 1.2, 3: OD= 1.3, 4: OD= 0.75, 5: OD= 1, 6: OD= 1.2, 7: 
OD= 1.3. Each number is composed of both insoluble and soluble fractions. 
B) TPI-GAPDH cloned in pET-14b in different cell lines:  
4) 400 mM IPTG at 30°C with different ODs: (0.6, 0.8. 1) respectively from 1-3 in B21, while 4 and 5 shows TPI-GAPDH 
pET-14b Rosetta2, 400 mM IPTG  at 30°C with different ODs: (0.6, 0.8) respectively, and finally 6 and 7 TPI-GAPDH 
pET-14b Arctic express at 10°C degrees for 36 h. at ODs: (0.6, 0.8) respectively 
 5) (1-3) TPI-GAPDH pET-14b E. coli BL21, (4-5): in E. coli Rosetta2 cells, (6-7) arctic express cells. Each two lanes 
represent Un-induced, soluble pattern respectively for the same condition. 
Molecular weights are indicated in kDa on the left. 
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A comparison of the expression levels of E. coli BL21 cells harbouring 
Blastocystis TPI-GAPDH pET-14b construct and using different expression 
methods including auto-induction in comparison with an empty vector is shown in 
Figure 6.4. It shows the difference in expression, with the highest level achieved 
using the auto-induction method. It also clearly shows the lack of expression in 
the empty vector. 
The gene induced via auto-induction resulted in a high level of protein compared 
to other methods used. The overnight culture was inoculated in 500 ml culture of 
ZYM-5052 (for composition see materials 2.1.1.2) and incubated at 37°C for a 
period of 4-5 hours or until the OD is less than 1, ideally 0.6-0.8. The culture is 
subsequently incubated at 20°C with shaking at 220 rpm for 24 - 48 hours. 
 
Figure 6. 4 SDS gel of several expression trials of Blastocystis TPI-GAPDH pET-14b construct in E. 
coli BL21. Lane1: molecular weight marker. Lanes 2-6: the same construct induced at different 
temperatures and with different IPTG concentration. Lanes 2-4: the same construct induced at 37°C 
with 400 mM IPTG, un-induced, induced total, soluble, consecutively. Lanes 5-7 induction with 400 
mM overnight at 30°C, where 5-7: un-induced, induced total, soluble consecutively. Lane 8 auto-
induction of Blastocystis TPI-GAPDH pET-14b construct in E. coli BL21. Lanes 9 auto-induced empty 
vector construct.  
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6.3. Blastocystis TPI-GAPDH expression and purification 
As mentioned above, the Blastocystis TPI-GAPDH gene gave a high expression 
yield when grown under auto-induction conditions. This method was used 
subsequently to carry out the rest of purification experiments of this chapter. 
Because the protein has a His-tag at the N-terminus, a nickel affinity column was 
the first step of the purification process. The recombinant Blastocystis TPI-
GAPDH protein was eluted from the nickel affinity column by elution using 
imidazole concentrations ranging from 10 - 500 mM, in 10 mM Tris–HCl. 
The clarified cell extract was applied to a 1 ml pre-equilibrated nickel column with 
3 X column volumes using a “super loop”. The protein was loaded by injecting 
the sample in the “super loop”. Any unbound protein was removed by applying 3 
X column volumes of nickel affinity column (NAC) buffer A mentioned in Table 
2.6. A gradient of NAC buffer B was applied ending with 100% of this buffer. This 
purification step was always followed by washing the column with 3 X 100% of 
NAC buffer B (Figure 6.5). Fractions were collected on a 96 well plate and the 
fractions were analysed by measuring the absorbance at 280 nm and by using 
SDS-PAGE as described in methods 2.2.3.4.  
Nickel affinity purification resulted in several additional bands in addition to a 
protein of the expected size (Fig. 6.6). To improve homogeneity, ion-exchange 
chromatography was attempted as well; both cationic and anionic affinity 
chromatography. Unfortunately, both resulted in a very low yield of protein. In 
addition, the purification steps were reversed to assess the effect on protein 
purification. So, ion exchange chromatography was performed first, followed by 
nickel affinity chromatography. This also resulted in poor yields unfortunately. 
Purification attempts using ion exchange chromatography (both cation as well as 
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anion chromatography) are shown in Figure 6.7. Unfortunately, protein yields 
were so poor that any significant protein was barely visible on SDS gels. No 
corresponding gels for ion exchange chromatography are shown. As a 
consequence, it was decided not to include ion exchange chromatography in 
further purification attempts. 
 
Figure 6. 5 Elution profile of Blastocystis TPI-GAPDH on a His-trap column (GE Healthcare). The A280 
trace is shown in blue. The y-axis represents the absorbance of the protein at 280 nm. The x-axis 
shows the elution volumes of the protein. Recombinant protein was loaded from 0-55 ml. Elution of 
the recombinant Blastocystis TPI-GAPDH occurred from 55-75 ml. 
 
Figure 6. 6 A Coomassie-stained SDS-PAGE gel of recombinant Blastocystis TPI-APDH purified by 
nickel affinity chromatography. The Blastocystis TPI-GAPDH pET-14b construct in E. coli BL21 was 
auto-induced at 20°C for 48 h and purified using a nickel column with 500 mM final concentration of 
imidazole. Lane 1 represents the molecular weight marker (MW) (Fermentas Spectra Multicolor Broad 
Range), FT: flow through of the total protein lysate incubated with nickel beads and washed with 
imidazole buffer. The last six lanes represent gradient concentration of imidazole from 10 mM-500 
mM. Molecular weights are indicated in kDa on the left. 
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The additional purification steps might have resulted in protein degradation. For 
this reason it was finally decided to restrict purification steps to nickel affinity 
chromatography followed by gel filtration chromatography.  
Initially, protein purification resulted in either aggregated or inactive protein.  
Phosphate buffer was therefore used in both nickel and gel filtration 
chromatography to aid protein stability. The use of phosphate buffer was inspired 
by the fact that this buffer is used in the activity assay of this protein. It was 
therefore reasonable to assume that the protein would be more stable in this 
buffer. The buffer used for nickel affinity chromatography was: 50 mM phosphate 
pH 7.5, 500 mM NaCl, 30 mM imidazole, 0.2% Tween 80.  
 
Different fractions containing the eluted protein from nickel affinity 
chromatography were pooled, concentrated and loaded onto a gel filtration 
column. This step is important to further purify the protein and to remove the 
imidazole buffer and exchange for a more suitable buffer for downstream 
analyses. Similar to nickel affinity chromatography, several buffers were tested 
for gel filtration chromatography. The most commonly used buffers (TRIS-HCl 
and HEPES) both resulted in a protein which showed a tendency to elute in the 
void volume (around 38.9 ml for the column used). This suggests the formation 
of aggregates of the protein. Protein aggregation was confirmed by performing 
activity assays which showed no activity indeed. In addition, thermal shift assays 
were performed on the eluted protein which indicated a miss-folded, aggregated 
or inactive form of the protein (shown later in paragraph 6.4.3).  
Other buffers which contained several additives we also tested for better protein 
stability. These additives were added either to prevent aggregation by keeping 
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the protein in solution, for example by using detergents, or to enhance the stability 
of the protein, by adding reducing or chelating agents. Detergents such as 
Glycine and Tween 80 were added to stabilize the protein and prevent 
aggregation by breaking protein-protein and protein- lipid interactions.  The 
detergents anti-aggregation effect is achieved by their surfactant property by 
disturbing the cell surface and hence allowing the proteins to be released in a 
soluble material (Johnson 2014). Here, a purification buffer mix of: 50 mM Tris 
/HCl (pH 7.8), 200 mM NaCl, 2 mM DTE, 1 mM EDTA, and 0.2 mM NAD was 
used (Liaud, Lichtle et al. 2000). This buffer mix helped stabilizing the protein, by 
using both a reducing agent (DTE) which protects the protein from damaging 
oxidative reactions, and a metal chelating agent (EDTA), which also helps in 
reducing oxidative processes, and chelates metal ions. However, unfortunately, 
no protein crystals formed in downstream crystallization experiments. 
Ultimately, changing the buffer used in both the nickel affinity and the gel filtration 
purification step from Tris-HCl to phosphate buffer resulted in improved 
purification and also helped in crystallizing the protein in further experiments. 
 
Therefore, the final buffer used in the gel filtration column was: 20 mM phosphate 
buffer with 200 mM NaCl, 1 mM of Tris (2-carboxyethyl) phosphine hydrochloride 
(TCEP) as a reducing agent, at a pH of 8.2. This resulted in a shift of the elution 
pattern of the protein from the void volume to about 60 ml elution volume, as 
shown in Figure 6.8 and 6.9. As mentioned above, these conditions also favoured 
crystal formation.  Using this buffer has resulted in a protein with a high purity of 
almost 95% (Fig. 6.10). In order to check whether the TPI-GAPDH fusion protein 
obtained using gel filtration chromatography is of a single oligomeric status, or is 
in equilibrium with other forms, an additional experiment was conducted. 
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Fractions containing the highest peak were collected and analyzed using another 
gel filtration chromatography step. This resulted in a single peak profile, 
suggesting that each peak shown in Figure 6.9 A consists of one single form of 
the fusion protein and that these are not in equilibrium with other forms. 
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Figure 6. 7 Ion exchange chromatography of recombinant Blastocystis TPI-GAPDH. Elution profiles representing purification trials of Blastocystis TPI-GAPDH 
using ion exchange (IEX) chromatography are shown. A: Elution profile of TPI-GAPDH starting from crude material and applied on a cation exchange column 
SP XL (GE Healthcare). Less than 10 ml fractions were collected across the entire elution. B: Elution profile of Blastocystis TPI-GAPDH from the SP XL (cation 
exchange column) (GE Healthcare) after nickel affinity chromatography. About 5 ml fractions were collected across the entire elution.  C: Elution profile of 
Blastocystis TPI-GAPDH from an anion exchange column from crude material. (The protein is presented in the low peak between 30-40ml). D: elution profile 
of the fusion protein using a QFF column after nickel affinity chromatography, showing very low yield of the protein with a peak around 10 ml. All protein 
resulting from these experiments did not result in any detectable band on SDS gels run afterwards. The A280 trace is shown in blue. The y-axis represents the 
absorbance of the protein at 280 nm. And x-axis shows the elution volumes of the protein in ml.  
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Figure 6. 8 Gel filtration chromatography of recombinant Blastocystis TPI-GAPDH. Elution profiles of Blastocystis TPI-GAPDH are shown from a Superdex 200 
gel filtration (GF) column using different buffers and detergents. A: Blastocystis TPI-GAPDH is eluted in the void volume using a Tris-HCl buffer. B: Blastocystis 
TPI-GAPDH also eluted in the void volume using a HEPES buffer. C: The Blastocystis TPI-GAPDH fusion protein elution profile shifted using a 50 mM Tris 
buffer with detergent (200 mM NaCl, 2 mM DTE, 1 mM EDTA, and 0.2 mM NAD+). D: Elution profile of TPI-GAPDH with a Tris buffer containing the co-factor 
NAD+. The A280 trace is shown in blue. The y-axis represents the absorbance of the protein at 280 nm. The x-axis shows the elution volumes of the protein in 
ml. 
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Figure 6. 9 A) Final purification of Blastocystis TPI-GAPDH using gel filtration size exclusion 
chromatography. Blastocystis TPI-GAPDH was eluted in phosphate buffer from a Superdex 200 gel 
filtration (GF) chromatography column. The A280 trace is shown in blue. The fusion protein is eluted 
in the fractions between 40 - 60 ml. Y axis represents the absorbance of the protein at 280 nm. X axis 
shows the elution volumes of the protein in ml. Peak at about 55 ml represents the eluted target 
protein. B) Elution profile of the purified Blastocystis TPI-GAPDH using the fractions collected from 
the highest peak to check if the gradient peak obtained in first purification is in equilibrium between 
different oligomeric state proteins. Showing a single peak, indicating that the peak in A is not an 
equilibrium between several oligomeric status proteins.  
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Figure 6. 10 Purified recombinant Blastocystis TPI-GAPDH. A Coomassie-stained SDS-PAGE gel of 
the Blastocystis TPI-GAPDH fusion protein obtained after gel filtration chromatography using a GF 
Superdex 200 gel filtration chromatography column. Blastocystis TPI-GAPDH protein bands 
correspond to all the fractions between 40 - 60 ml. The first lane represents the molecular weight 
marker. (Fermentas Spectra Multicolor Broad Range). Molecular weights are indicated in kDa on the 
left. 
 
6.4. Biochemical characterization 
6.4.1. Molecular weight determination 
6.4.1.1. Analytical GF 
Gel filtration chromatography is a method that can be used for purifying proteins 
but which can also be used as a tool for estimating the molecular weight of 
proteins when used in conjunction with reference proteins of known molecular 
weight. In order to determine the molecular weight of the recombinant 
Blastocystis TPI-GAPDH, the protein was loaded onto a HiLoad 16/60 Superdex 
200 gel filtration column and run as described in methods 2.2.3.3.3. To obtain the 
molecular weight of the native TPI-GAPDH, the protein was run in triplicate. A 
typical TPI-GAPDH elution profile is shown in Figure 6.11 and Figure 6.12. TPI-
GAPDH always eluted in the same pattern having three main adjacent peaks. For 
Figure 6.11, the first peak eluted at 37 ml, a second larger peak eluted at 47.80 
ml, the third main peak elutes around 55.67 ml, the fourth small peak eluted at 
78.12 ml and the last small peak eluted at 97.65 ml. The molecular weights were 
then calculated based on the calibration curve in Appendix 2, and using 38.92 ml 
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as a void volume of the used column. The following results are the estimated 
molecular weights of the peaks:  
 
Peak 1: VE = 37.00 ml               log Mw = 3.2   Mw = 1447.8 kDa 
Peak 2: VE = 47.80 ml  log Mw = 2.7   Mw = 508.2  kDa 
Peak 3: VE = 55.67 ml  log Mw = 2.4   Mw = 236 kDa 
Peak 4: VE = 78.12 ml  log Mw = 1.4   Mw = 26.9 kDa 
Peak 5: VE =97.65 ml  log Mw = 0.6   Mw = 4.7 kDa 
 
Based on the predicted molecular weight of a TPI-GAPDH monomer of 65 kDa, 
such an elution profile suggests the following. The very high molecular weight 
initial peak most likely represent aggregated proteins. The second peak of 508 
kDa is about eight times the molecular weight of the monomer which would 
suggest an octameric protein. Analysing this protein on SDS-PAGE shows a band 
corresponding to the expected molecular weight of the fusion protein indicating 
this high-molecular weight peak does indeed consist of TPI-GAPDH. The third 
peak would represent a tetramer of the fusion protein (~ 240 kDa) and this has 
also been confirmed by SDS-PAGE as above. The fourth peak might be a 
degraded fusion protein as it is corresponding to the molecular weight of 
triosephosphate isomerase alone (TPI Mw = 27 kDa). Finally, the last peak most 
likely represents small molecules that always tend to elute at the end of gel 
filtration chromatography runs. These are probably salts that are washed out at 
the end. 
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Figure 6. 11 Gel filtration chromatography of Blastocystis recombinant TPI-GAPDH. Elution profile for 
Blastocystis TPI-GAPDH run on HiLoad 16/60 Superdex 200 gel filtration chromatography column in 
triplicates, the single peak obtained represents Blastocystis TPI-GAPDH. The Y axis represents the 
absorbance of the protein at 280 nm. The X axis shows the elution volumes of the protein in ml. 
 
Figure 6. 12 Gel filtration chromatography of recombinant Blastocystis TPI-GAPDH. Elution profile of 
Blastocystis TPI-GAPDH on HiLoad 16/60 Superdex 200 gel filtration column and SDS-PAGE of the 
corresponding fractions. This work was repeated while at the Oxford protein production facility 
(OPPF) and confirmed work done previously.  
 
6.4.1.2. Immune-detection (Western Blotting) proved the identity of the purified 
protein to be TPI-GAPDH 
In order to confirm the identity of the protein purified in paragraph 6.3, an immune 
detection approach was used (see methods 2.2.3.7). The recombinant 
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Blastocystis TPI-GAPDH which was purified using gel filtration chromatography 
was used in a Western blotting experiment using two different antibodies: an anti-
His antibody (Qiagen) targeting histidine residues on the N-terminus of the 
recombinant protein, and using antibodies raised specifically against the protein 
in Blastocystis (unpublished work Dr. Matthew Rogers, University of Exeter). Both 
experiments identified a protein with a molecular weight of 65 kDa which is in 
agreement of the expected molecular weight of the recombinant TPI-GAPDH 
protein (see Figure 6.13). TPI-GAPDH antibodies were used in the following 
concentrations: 1:2,000 for the primary and 1:10,000 for the secondary 
antibodies. While it was 1:1,000 and 1:5,000 for primary and secondary 
antibodies when using Anti His Abs.  
           
Figure 6. 13 Western blot analysis detecting Blastocystis TPI-GAPDH protein. A. Western blot analysis 
using a homologous antibody rose in guinea pig against Blastocystis TPI-GAPDH protein. Only one 
band detected corresponding to the fusion protein probed with Anti-guinea pig TPI-GAPDH Abs 
corresponding to the predicted molecular weight of about 65 kDa. MW lane is the molecular weight 
marker (Fermentas Spectra Multicolor Broad Range). Lane 1: empty pET14b plasmid used as 
negative control. Lane 2:  represents the total cell lysate. Lanes 3 and 4 show gel filtration- 
chromatography purified TPI-GAPDH. B: Western blot analysis using anti-His antibodies targeting 
the His-tag introduced in Blastocystis TPI-GAPDH. This represents a sample of each of the three 
peaks obtained after purification, confirming the homo content of the 3 peaks which is the fusion 
protein TPI-GAPDH is. In B other bands appear which indicates a degradation and/or contamination 
with other proteins after purification. Antibody concentrations used: anti His: primary antibody: 
1:1,000 and secondary: 1:5,000. For anti-TPI-GAPDH: 1:2,000 for the primary and 1:10,000 for the 
secondary antibody. 
6.4.1.3 Oligomeric status determination of the native TPI-GAPDH 
The recombinant Blastocystis TPI-GAPDH fusion protein, purified by gel filtration 
chromatography, was analyzed using native gel electrophoresis to determine its 
oligomeric status. As this type of gel electrophoresis does not contain SDS, it 
Mw 1 2 3 4 
A 
B 
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allows for the determination of the molecular weight of proteins under native 
conditions. For details of this technique please see methods 2.2.3.5. In order to 
be able to determine the native molecular weight, the protein under study is 
analysed alongside a set of standard proteins mentioned previously in Table 2.13 
(except for Dextran). The Blastocystis TPI-GAPDH fusion protein was always 
located high up in the gel as can be seen in Figure 6.14. This suggests it is either 
aggregated or exists as a hexadecamer. The band corresponding to the purified 
TPI-GAPDH is close in size to 1048 kDa which is 16 x 65 kDa.  
To further analyse and confirm the native TPI-GAPDH fusion protein, the strip 
containing the TPI-GAPDH band was cut out of the native gel and analysed under 
reducing conditions on SDS-PAGE. This experiment confirmed the presence of 
the Blastocystis TPI-GAPDH fusion protein as a band of 65 kDa was observed 
on the Coomassie stained SDS-PAGE gel, see Figure 6.15.  
 
                       
Figure 6. 14 Native gel electrophoresis of Blastocystis TPI-GAPDH following gel filtration 
chromatography.  A: Blue native gel electrophoresis of TPI-GAPDH. The fusion protein is present in 
lanes 1-3. Protein standards located as follows: 4) Thyroglobulin (660 kDa), 5) appoferritin (440 kDa), 
6) beta amylase (200 kDa), 7) alcohol dehydrogenase (150 kDa), 8) albumin (66 kDa) 9) and carbonic 
anhydrase (30 kDa). B: Native gel electrophoresis of TPI-GAPDH alongside the native protein 
standard NativeMark™ (Life Technologies, see Figure 2.5). The protein marker is located in the last 
lane. Molecular weights are indicated in kDa. 
 
A B 
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Figure 6. 15 Second dimension SDS-PAGE following native gel electrophoresis. A strip was cut from 
a blue native gel containing TPI-GAPDH. The black arrow indicates the major band present 
representing the expected fusion protein with a molecular weight of about 65 kDa. Molecular weights 
are indicated in kDa on the left. 
 
Unfortunately, as can be seen from Figures 6.14 and 6.15, the oligomeric status 
of the purified fusion protein could not be properly determined. However, this 
experiment did confirm the identity of the high molecular weight protein to be the 
Blastocystis TPI-GAPDH fusion protein and that therefore this protein does seem 
to form a higher order oligomeric state. 
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6.4.1.4. Size distribution profile using Dynamic Light Scattering 
In order to determine the oligomeric state of the Blastocystis TPI-GAPDH protein, 
the gel filtration chromatography purified protein was centrifuged for 20 minutes 
at 4°C at 16,000 x g before being analysed on the dynamic light scattering 
machine as described in paragraph 2.2.3.9.2. Ten measurements were taken; 
each measurement had ten acquisition times of 20 seconds acquisition, recorded 
at room temperature using a DynamPro Titan (Wyatt Technology Corporation). 
Data was analysed using DYNAMICS (Protein Solution, USA).  
Unfortunately, the results of these experiments only suggested that there is a 
protein aggregation as a likely cause of the un-interpretable results. It is shown 
in Figure 6.16 that the protein always had some very high molecular weight 
components in the several thousand of kilo Daltons. This happened irrespective 
of the various purification trials conducted using different buffers, including the 
phosphate buffer (see section 6.2.2). Some of the results suggested degradation 
of the protein into its two building units as seen with the reported 38 kDa, 
representing a monomeric GAPDH, or the 78 kDa which is close to a dimeric 
GAPDH. The molecular weight of TPI alone is 28 kDa and it is normally found as 
a dimer (56 kDa). The molecular weight of GAPDH is 36.5 kDa and is naturally 
occurring as a tetramer (144 kDa). Table 6.1 represents some of those results.  
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Table 6. 1 Dynamic light scattering data of Blastocystis TPI-GAPDH. Data obtained from six 
measurements, each measurement is a mean of ten readings. R: diameter of the scattered 
molecule in nm, Pd: poly dispersity, MW-R is the molecular weight measured in kDa 
Item  Intensity (%) R (nm) Pd (nm) Pd  
(%) 
MW-R (kDa) 
Meas 1 53.3  0.2 0.0 16.4 78.836 
Meas 2 9.7 45442.2 0.0 10.1 265891000000 
Meas 3 95 0.1 0.0 28.3 0.012 
Meas 4 4 3.8 0.0 0.0 78.8364 
Meas 5 26.3 2.8 0.3 11.0 38.302 
Meas 6 7.4 3.1  0.5 17.1 47.700 
 
Nonetheless, DLS results when experimented on Blastocystis TPI-GAPDH 
showed a poly dispersity of the purified protein, and this indicates less 
homogeneity, Figure 6.16 shows examples of the results obtained from running 
the fusion protein on the DynamPro Titan machine.
 
Figure 6. 16  Dynamic light scattering analysis of the Blastocystis TPI-GAPDH fusion protein. The 
fusion protein shows varied intensities of several molecular weights ranging from very low as 0.005 
kDa of 51% intensity to 26% intensity of 38 kDa, with the presence of very large aggregated molecules 
of several thousand kDa with 18-21% intensity. X axis represents the measured diameter of the 
measured molecules. Y axis represents the percentage of the intensity of the molecule detected in 
the solution. 
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6.4.1.5. Analytical ultracentrifugation (AUC) 
A solute in a solution undergoes two forces, sedimentation and buoyant force. 
When using centrifugation, a solute starts precipitating at the bottom of the cell 
due to the gravitational effect resulting from the centrifuge forces. Hence, this 
would result in an increase of solute concentration near the bottom of the tube. 
This in turn will be opposed by another force, the distribution force which helps 
the solute to float (buoyant force). A final force is the frictional force resulting from 
the movement of the molecule in a solvent. After a certain time these forces will 
balance, resulting in a net force, which will help making the concentration of the 
solute the same in each part of the solution. Measuring concentration distribution 
after reaching equilibrium represents the sedimentation equilibrium (SE) (Cole, 
Lary et al. 2008). 
In the case of analytical ultra centrifugation, the sedimentation equilibrium 
represents the balance between those two already mentioned forces, the action 
of piling the molecules at the bottom of the cell due to gravity, and the diffusion 
of the molecule due to buoyant forces. Therefore, the concentration will be the 
same and it will only depend on the molecular weight of the solute. When we 
measure the concentration distribution after the balance has been reached,  we 
are measuring equilibrium sedimentation (Cole, Lary et al. 2008). Sedimentation 
equilibrium offers a very accurate way of measuring the molecular weight and 
consequently the oligomeric status of molecule in biological solution. 
This is the best method to determine the molecular weight of a substance, that 
no other method can surpass it, in accuracy and its wide coverage. Analytical 
ultra-centrifugation covers a wide range of molecular weights from few hundred 
Daltons to several hundred millions Daltons. Another factor that makes it superior 
to other methods such as dynamic light scattering (DLS) is the very small size 
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and concentration of the protein used in sedimentation equilibrium method (20–
120 µl) and (0.01-1 g/l) sequentially. As for the applicability sedimentation 
equilibrium can be used for any substance whose absorbance is different from 
the solvent it is found in. It could be used to detect both the purity and molecular 
weights of proteins, carbohydrates, nucleic acids, etc. Sedimentation equilibrium 
also gives an idea about the purity of the solution and the homogeneity of the 
molecules in it.  
In this project, analytical ultra-centrifugation was performed to precisely 
determine the molecular weight and the oligomeric status of the unusual TPI-
GAPDH fusion protein from Blastocystis. In addition to TPI-GAPDH, the purified 
Blastocystis GAPDH protein (details of this work is found in chapter 7) was also 
submitted to Oxford Protein Purification Facility. The results obtained from 
Blastocystis GAPDH will help elucidate whether this protein is found as a tetramer 
like most known GAPDH proteins studied (Jia, Linh le et al. 2011, Baker, Shi et 
al. 2014), or whether it is taking a different conformation as suggested in the MSc 
work by Evans et al (Evans 2014) that suggested that the Blastocystis GAPDH is 
a dimers. The sedimentation equilibrium experiment was performed using three 
different protein concentrations of each protein as explained in section 2.2.3.9.2. 
These were 1, 0.2 and 0.05 mg/ml of TPI-GAPDH in a total volume of 400 µl 
each. Each sample was loaded in a separate analytical cell cleaned properly with 
the gel filtration buffer used for purification and equilibrated against water, and 
centrifuged at the same run on Beckman Coulter ProteomeLab XL-I Protein 
Characterization System.  
The protein was run using an AN-60 Ti rotor (Beckman) at 40,000 X rpm 
generating about 128,793 X g at 4°C.  
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The data of the three concentrations were fitted to a range of models. The results 
indicate a homogeneous sample. These results also showed that Blastocystis 
TPI-GAPDH sediments at 9.89 S and this was consistent for all 3 concentrations 
used, demonstrating that it is larger and heavier than GAPDH on its own, which 
sedimented at 7.5 S (see Figure 6.17). The data also indicated the presence of 
some higher order aggregates in the sample with a very low degree. Most of the 
samples therefore appear to be homogeneous, i.e. they are a mono disperse 
species, see Table 6.2.  
Table 6. 2 Analytical ultra-centrifugation analyses of Blastocystis TPI-GAPDH. Data was 
obtained using three different protein concentrations as explained in the text.    
 Concentration (mg /ml) Percentage of signal 
% 
Molecular weight (kDa) 
0.05  65 186  
0.2 72 235  
1 79 260 
 
The signal obtained from analytical ultracentrifugation gave results varying in the 
expected molecular weight. The values ranged between 235-260 kDa forming 
72-79% of the signal obtained for each concentration measured (Table 6.2). A 
frictional ratios less than one is considered unrealistic in AUC results. The 
frictional ration obtained in this experiment was 1.49 and this corresponds to a 
tetramer. The molecular weight was calculated by fitting for the frictional ratio 
which resulted in ~160 kDa for GAPDH and ~240 kDa for the TPI-GAPDH fusion 
protein.  
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Figure 6. 17 Sedimentation equilibrium analytical ultracentrifugation of Blastocystis TPI-GAPDH. 
Distribution of sedimentation coefficient using three different concentrations of TPI-GAPDH. Size 
distribution profiles are shown in three different concentrations for the same protein, in: A:  1 mg/ml 
B:  0.2 mg/ml C: 0.05 mg/ml. D the 3 different concentrations aligned together and showing 
concentric peaks indicating the dominance of one form of the protein. X axis represents the 
sedimentation coefficient. Y axis represents concentration of the protein (thanks to Dr David Scott 
from the Oxford lab for experimental help, analyses and interpretation). 
 
6.4.1.5.1. Complementary work on triosephosphate isomerase (TPI) and Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) 
Because the fusion protein is composed of two units that are normally present as 
the separate proteins triosephosphate isomerase (TPI) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), it is important to study the components of 
this fusion protein. The main purpose of this part of the study was to determine 
the molecular weight and oligomeric state of the individual proteins comprising 
the building units of the fusion protein. To achieve this, both proteins were 
individually expressed from a construct of each gene in pET-14b vector in E. coli 
A B 
C D 
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BL21 cells. The constructs were all stored in the Dr van der Giezen group stocks 
and previously made by Dr Matthew Rogers. 
The Blastocystis artificially separated TPI and GAPDH genes were each cloned 
into E. coli BL21 cells in the pET-14b vector. The genes were expressed at 20°C 
using the auto-induction approach. They were thereafter over-expressed and the 
respective protein was subsequently purified using nickel affinity chromatography 
followed by gel filtration chromatography. Figure 6.18 A shows the purified 
recombinant Blastocystis GAPDH protein elution profile which was further 
analysed on SDS PAGE. Gel filtration chromatography resulted in a single large 
peak with very small shoulders, see Figure 6.18 A. When subsequently analysed 
on SDS PAGE, the recombinant GAPDH was clearly visible as a clear band of 
the expected size of 36 kDa (Figure 6.18 A). In addition, the purified recombinant 
GAPDH protein was analysed using AUC to determine its molecular weight and 
oligomeric state of about 160 kDa. AUC confirmed the presence of GAPDH in a 
tetrameric form (Figure 6.19).  
Similarly, the recombinant Blastocystis TPI was also expressed using auto-
induction. The crude cell lysate was subsequently processed using nickel affinity 
chromatography and gel filtration chromatography, successively. The GF elution 
profile of TPI, in addition to the SDS PAGE analyses indicate that the recombinant 
TPI is degraded (Figure 6.18 B). 
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Figure 6. 18 Purification of Blastocystis recombinant GAPDH and TPI. A. Elution profile of recombinant 
GAPDH during gel filtration chromatography. Inset shows SDS PAGE analysis of fractions taken 
from the elution profile indicated underneath the trace. Molecular weight marker indicated on the 
left. The marker used in OPPF is HiMark™ Pre-Stained Protein Standard. The red arrow indicates 
Blastocystis GAPDH of 36 kDa. B. Elution profile of recombinant TPI during gel filtration 
chromatography. Inset shows SDS PAGE analysis of fractions indicated underneath elution profile. 
 
A 
 
B 
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Figure 6. 19 Sedimentation equilibrium analytical ultracentrifugation of recombinant Blastocystis 
GAPDH. Distribution of sedimentation coefficient using three different concentrations of GAPDH. 
Size distribution profiles are shown in three different concentrations for the same protein A.  1 mg/ml 
B:  0.2 mg/ml C: 0.05 mg/ml. D the three different concentrations aligned together and showing a 
concentric peaks indicating the dominance of one form of the protein. X axis shows the 
sedimentation coefficient values. Y axis shows the protein concentration (thanks to Dr David Scott 
from the Oxford lab for experimental help, analyses and interpretation).  
 
 
 
A B 
C 
D 
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6.4.2. Fluorescent-based thermal shift assay (DSF: differential scanning 
fluorimetry) 
Differential scanning fluorimetry, or DSF, is a powerful technique to analyze 
protein stability in the presence of absence of ligands or other small molecules. 
It has played important roles in drug development. In addition, it can be used to 
provide information about the stability of a protein in different buffers. This can 
provide crucial information when choosing which buffer to use when purifying a 
protein. DSF is further explained in Materials and Methods 2.2.3.10.3. 
Here, the recombinant Blastocystis TPI-GAPDH fusion protein was analysed 
using differential scanning fluorimetry initially to check for buffer suitability. The 
protein was first purified using gel filtration chromatography as explained before 
and subsequently used for DSF analyses. Several different buffers were tested 
for this analyses and a full list of these buffers can be found in materials and 
methods Table 2.7.  
When the TPI-GADPH fusion protein was purified in a Tris-HCl buffer, a very high 
DSF signal was obtained suggesting that the protein is either inactive or 
aggregated (Figure 6.20 A). Changing the purification buffer to a phosphate buffer 
resulted in a much a lower DSF signal (Figure 6.20 B) which supports the 
assumption that the protein indeed behaves better when present in phosphate 
buffer. It was also noticed that using a phosphate buffer resulted in a moderate 
shift to a higher melting temperature (55.60°C) in comparison to the original Tris-
HCl buffer (49.92°C). This change in the melting temperature of 5.7°C suggests 
a better stability of the protein. 
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Changing the purification buffer from Tris-HCL to phosphate buffer was also 
accompanied by the addition of the ligand NAD+ to increase stability. This 
combination resulted in rather unusual results for the recombinant protein TPI-
GAPDH thermal shift profile. Usually in DSF experiments a simple denaturation 
profile is observed with a single peak indicating the optimal temperature at which 
the protein is stable. However, adding the ligand NAD+ resulted in rather unusual 
biphasic pattern of melting (Figure 6.20 B). This could be explained by the 
tendency of the protein to melt at either ligand-free temperature or the fully bound 
protein melting temperature. A higher concentration of the ligand would result in 
shifting this biphasic profile to a single peak profile towards the higher melting 
temperature. 
DFS can also be used to get insight into protein/ligand interaction. It will provide 
information on how tightly a ligand is bound to its protein through measuring the 
dissociation constant Kd. An initial screen of the ligand (NAD+) concentration 
suggested that the likely Kd is to be in the range of 93 ± 19 µM (Figure 6.21). 
These observations suggest a high tendency of the ligand to dissociate from its 
protein. In other words, it indicates a lower affinity between TPI-GAPDH and its 
ligand NAD+. This might explain the results presented in the following 
crystallography chapter when solving the structure of the TPI-GAPDH fusion 
protein. It was hard to see the ligand bound to the active site of the fusion protein. 
The lower affinity of the ligand for its protein suggests that the ligand might be 
easily washed off the protein during the various purification and washing steps. 
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Figure 6. 20 Melt curve plot of TPI-GAPDH showing the thermal denaturation profiles of the 
Blastocystis TPI-GAPDH fusion protein purified in different buffering conditions. A: Purification of 
the fusion protein in HEPES. B: Purification of TPI-GAPDH in phosphate buffer with the addition of 
the ligand NAD+ for better stability. It is clear from these data that the different buffer results in 
increased stability of the TPI-GAPDH fusion protein. The second profile shows a progressive 
increase in the fluorescence signal to reach a maximum, followed by a shallow decline. This is 
accompanied by a biphasic melting peaks, indicating a ligand free and ligand bound states of the 
protein in the first derivative of the fluorescence. Observed melting temperature is given on the X-
axis, and the fluorescence signal is given on the Y-axis.   
 
 
A 
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Figure 6. 21 Interaction between Blastocystis TPI-GAPDH and NAD+ using thermal shift assay. Initial 
testing using a wide range of NAD+ concentration (0.01-100 µM), suggesting that the dissociation 
constant Kd is more likely to be in the range of 84-112 µM. Images were prepared using GraphPad. 
The X axis represents the ligand NAD+ concentration. The Y axis is representing the melting 
temperature of the protein in the presence of the ligand. R = 0.9425 (95% confidence intervals) 
6.4.3. Site directed mutagenesis on recombinant fusion Blastocystis TPI-GAPDH 
protein 
In order to study the effect of crucial amino acid residues on protein function, site-
directed mutagenesis was used to produce mutated versions of the Blastocystis 
TPI-GAPDH fusion protein. The QuickChange Lightning Site-Directed 
Mutagenesis Kit (Agilent Technologies) was used to introduce a point mutation in 
the wild type (WT) TPI-GAPDH gene at a single position. This mutation was 
introduced in the TPI part of the gene by mutating a cysteine residue (C 416) into 
an alanine. The whole construct was amplified according to the PCR conditions 
mentioned in Table 2.10 in paragraph 2.2.1.2 in materials and methods using the 
mutation primers mentioned in Table 2.2. The final product of this PCR reaction 
was cloned into pET-14b. This plasmid was transformed into E. coli BL21 cells 
following the detailed method mentioned in 2.2.1.5.2. Putative clones containing 
the mutated version of the gene were sent for sequencing to MWG-Eurofins in 
Germany to confirm the identity of the clones. 
Primers used were FTPGA 1401/ FTPGA901/ RTPGA400/ TPI-GAPDHmut 
check F/ TPI-GAPDHmut check R/ and finally RMM073 and RMM074 for 
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inserting the mutation at position 417 to change Cysteine in the wild type gene 
into alanine. Sequences of these primers can be found in Table 2.2 in materials 
and methods. Figure 6.22 A shows a schematic representation of the sequencing 
procedure to check the mutation was inserted at the right place. A close up of this 
region is presented in Figure 6.22 B.  
This mutated clone was subsequently checked for proper expression levels as 
explained in methods 2.2.3.8. This experiment will help identifying whether there 
is any expression at the colony level and will also give an idea of the variation in 
gene expression between individual colonies. Differences in expression level 
between different colonies grown on the same plate after transforming the mutant 
construct into E. coli BL21 cells can be seen in Figure 6.23. A clear difference 
can be seen between two different plates and also between colonies on the same 
plate in terms of intensity of gene expression. For further experiments, the clone 
showing the higher expression level was isolated. This colony was picked and 
stored in the -80°C freezer after mixing with glycerol to a final percentage of 
 30%. 
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Figure 6. 22 Site-directed mutagenesis of the Blastocystis TPI-GAPDH fusion gene. A(  Schematic 
representation of the sequencing strategy to confirm the entire mutated gene. N and C terminal parts 
were also read from the plasmid to get the double stranded coverage B( Alignment of the mutated 
region. Top row shows the wild type sequence and subsequent rows show individual clones sent 
for sequences. The mutated site is clearly visible C) As in B. but now the amino acid sequence is 
shown where a cysteine is converted to alanine. The point mutation is indicated in red box for both 
the nucleotide and amino acid sequences. The sequence mutated is indicated to by a red box. 
 
A 
B 
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Figure 6. 23 Comparison of Blastocystis TPI-GAPDH gene expression levels. Expression levels were 
compared using anti-his antibody after colony western blotting to identify clones with the highest 
level of expression of the mutated Blastocystis TPI-GAPDH fusion gene. It is clear that differences 
in expression levels exist between clones but also within clones on the same agar plate. 
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6.5. Discussion 
This chapter aimed to characterize the unusual TPI-GAPDH fusion protein found 
in Blastocystis. Because this protein normally exists as two individual proteins in 
other organisms, I aimed to characterise this peculiar fusion protein using a set 
of physical and biochemical approaches, seeking any difference between this 
fusion protein in Blastocystis and other organisms, especially human glycolytic 
enzymes. As no structure has been solved for such a fusion protein, it was crucial 
to identify a protein purification strategy which would result in high yields of clean 
protein folded in its native state.  This would enable, or facilitate, the production 
of good quality crystals that could be used to solve the protein structure. The gene 
encoding the TPI-GAPDH fusion protein was cloned in several cell lines to screen 
for the best expression yield. The best of these were E. coli BL21 cells, which 
gave a very high yield when using the auto-induction technique.  
Purifying the fusion protein was a challenging process because of the protein’s 
tendency to elute in the void volume during gel filtration chromatography. Several 
trials have been performed to modify this elution behaviour. Several 
chromatography approaches were employed, including ion exchange 
chromatography, nickel affinity chromatography and gel filtration 
chromatography. Attempts have been made changing the order of purification 
steps to investigate if that had any role in the final yield. In the end it was decided 
not to include the ion exchange chromatography step as it proved to be 
minimizing the yield of the final protein. 
After overcoming the problems of the low yield, several crystallization screens 
were set up to identify ideal crystallization conditions of the fusion protein. 
Unfortunately, none of these produced any protein crystals which necessitated 
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further investigation using thermal stability assays. Thermal stability assay 
experiments gave an indication that the fusion protein was either present as 
aggregates or in its inactive state.  We hypothesized that it might be possible that 
the fusion protein might be negatively affected by the buffer it was purified in. As 
protein activity assays for TPI and GAPDH are performed in phosphate buffers, 
the purification of this protein was repeated using a phosphate buffer (Bergmeyer 
1965, Ganea and Harding 2000, Evans 2014). 
This phosphate buffer-purified protein was tested for its aggregated status by 
DSF experiments. A huge shift in the DFS signal was observed. This suggests 
that the protein is more stable and possibly in its native form using phosphate 
buffer.  
It is essential to obtain a protein in its native state to be able to solve its structure. 
For this reason several biochemical and biophysical experiments were performed 
on this newly purified fusion protein in addition to the single Blastocystis GAPDH 
protein. Most of performed experiments suggested that the polymeric status of 
the Blastocystis TPI-GAPDH protein is a tetramer. Blastocystis GAPDH seems 
to be following the norm as seen for other GAPDH proteins in archaea, bacteria 
and eukaryotes where it is normally a tetrameric protein, (Moras, Olsen et al. 
1975, Isupov, Fleming et al. 1999, Malay, Bessho et al. 2009, Ayres, Schormann 
et al. 2014). Both results of the fusion TPI-GAPDH and the stand alone GAPDH 
were in agreement with the work of Liaud et al who suggested that the TPI-
GAPDH fusion protein as found in the diatom Phaeodactylum tricornutum, has a 
tetrameric oligomeric status, similarly to its GAPDH (Liaud, Lichtle et al. 2000). 
Their results were based on fast protein liquid chromatography (FPLC) 
experiments using a Superdex 200 (separation range 10-600 kDa) column for 
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calculating the molecular weight of the fusion protein. Evans,  in her recent MSc 
work, had concluded that the fusion protein is dimeric, and not a tetramer protein 
(Evans 2014). She based her results on high performance liquid chromatography 
(HPLC) experiments. Nevertheless, Evans did mention, inter alia, the presence 
of tetrameric TPI-GAPDH, but ignored its significance due to the small 
percentage, and considered it as an aggregation. However, both groups haven’t 
based their results on structure, and were merely depending on approximations 
using chromatography columns. My work clearly shows that the protein can be 
best explained as a tetramer but a more conclusive result will be based on 
structural biology work. This would clearly show what the tertiary structure of this 
unusual fusion protein is. 
The protein obtained in this chapter was used for the crystallography work 
explained in detail in chapter seven.  
More work will need to be performed to fully characterise the individual proteins 
that make up this fusion protein, and also to study the actual enzyme kinetics of 
the fusion protein.  
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Chapter 7. Crystallization and structure determination of the 
fusion recombinant Blastocystis TPI-GAPDH protein 
7.1. Introduction 
7.1.1. Background to protein crystallization  
Protein crystallization was historically used in the laboratories for many years to 
demonstrate the purity of the protein and as a method of its purification.  
Obtaining macromolecular crystal is only achieved when the solution of the 
molecules is in a supersaturated state. Crystallization only occurs when the 
protein concentration is higher than its solubility limits in the solution. This is 
achieved by manipulating the conditions under which the protein-containing drop, 
such as precipitant concentration or pH. While this process is still highly 
experimental and depends mainly on both the patience of the scientist and trials 
and errors; trying different conditions and screens to get a well ordered protein 
crystal and hence obtain a good resolution data. This was especially accurate at 
the start of macromolecular crystallography work, when it was considered as the 
‘art of crystallization’, while scientist efforts to turn this art into science started 15 
years ago, and hence the new terminology of crystallogenesis emerged (Chayen 
2004). 
Crystallization is a process of nucleation followed by crystal growth. For the 
nucleation stage a higher protein concentration is required than for the 
subsequent crystal growth state. The whole crystallization procedure is better 
explained by the phase diagram shown in Figure 7.1. From the diagram it is 
clear that the protein state is described as a function of the variables in the 
crystallization conditions, such as precipitant’s concentration, pH, temperature, 
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additives etc. The conditions of the protein can be classified into under-
saturated and super-saturated phases. The protein in the under-saturated state 
is in its soluble state and will never crystallize in this phase. While the super 
saturated phase can be divided into three zones; the high super saturation 
where the protein will precipitate and will not form crystals; the moderate super 
saturation zone also called the labile zone and the lower super saturation zone. 
In the moderate super saturation phase the protein nucleation will occur. While 
in the lower super saturation zone, protein crystals will grow although nucleation 
is unlikely to happen (Asherie 2004, Chayen 2004). Both protein crystal growth 
and nucleation can occur in the labile zone only, while the high supersaturated 
state can only produce protein precipitants, (Hausmann, Aguilar Netz et al. 
2005). In order to obtain protein crystals we need to get into the lower super 
saturation zone after some nucleation occurs or crystals seeds are added. 
There best crystals can be obtained.  
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Figure 7. 1 Phase diagram representing the phases that a protein goes through until it forms 
a crystal. The lines represent the equilibrium between the solid concentration and the free 
molecule phase. The phases are divided into two major phases of under-saturation and 
super-saturation. The under saturation phase is the one that the protein is at its maximum 
soluble state. The super-saturation phase which itself is divided into two regions; the 
metastable where the crystals start to form; and the labile phase where nucleation takes 
place. The last phase which is a highly super-saturated state which is called the 
precipitation state where the protein precipitates out of the solution. Crystals only grow in 
the first phases of the supersaturated phase. This diagram is taken from Current Opinion 
in Structure Biology (Chayen 2004). 
 
Several factors are tested during the process of producing crystals, in an attempt 
to be able to get the protein to crystallize. These factors include changing the 
protein concentration, precipitants, additives, pH and temperature.  
Naturally, protein crystals grow in a confined environments. As obtaining a crystal 
is such a challenging process, it is generally limited to modifying the conditions in 
order to get the final crystal. The procedure of obtaining crystals can be divided 
into two main steps, the first step is to find the appropriate conditions (physical 
and chemical conditions) at which the crystals are formed. The second step relies 
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basically on varying those conditions by making small alternations to the 
components of the environment in which that initial crystal was formed, this is the 
optimization step. The hardest step is finding the original conditions, which is 
generally rather laborious. It has to be taking into account that some proteins 
simply cannot be crystallized. The optimization step is time consuming as well, 
but often quite important and critical to enhance the quality of the data obtained 
to solve the protein structure. Specially that the quality of the crystal is very 
important when performing the X-ray studies which are aimed at producing best 
possible data for solving the structure afterwards by getting a better diffraction 
pattern.  
The quality of the diffraction pattern and the crystal resolution limit are related to 
the degree of internal order of the protein in the crystal. The higher purity and 
uniformity of the crystal and the more precise its periodic arrangement will result 
in better diffraction to the higher the resolution.  Having a better determination of 
the atomic position is closely related to the quality of the crystal diffraction. The 
higher the crystal order and resulting diffraction resolution, the more accurate the 
final structure would be.  
Knowing that the average protein crystal is composed of 50% of its total volume 
of water and solvent is important; since that those two play an important role in 
the final data quality. Those liquid channels play a double sword role. On one 
hand, the liquid channels and cavities are the cause of poor diffraction pattern. 
This is mainly because the solvent and water make the adjacent molecules far 
away from each other and separated, resulting in a weak lattice forces, and thus 
weakening the forces holding them together. On the other hand those solvents 
help keeping the atoms in their natural environment, which is considered very 
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essential by biochemists. It also worth mentioning that the kinetics of the crystal 
growth is three times slower than the kinetics of growth of the small molecules 
like salt or ion crystals. This is mainly due to the large protein molecule size 
compared to the small molecule. 
Several technical methods are used to obtain crystals; the two main are vapor 
phase diffusion and the batch method. The vapor phase diffusion method is 
based on achieving equilibrium between two reservoirs; one containing the 
precipitating agent and the other reservoir contains the protein droplet mixed with 
small volume of the precipitant either in a sitting or hanging drop. Over time, water 
diffuses from the protein to the precipitant reservoir. This decrease in the droplet 
volume, accompanied by the increase in protein and precipitant concentration, 
brings the protein into the super saturation state, which might start the crystal 
nucleation. Once the crystal starts to form, the protein concentration decreases 
and the solution is brought into metastable growth phase. 
In the batch method, the protein and the precipitants are already mixed in one 
droplet and left undisturbed. Here to obtain a crystal, the protein should already 
be in a high concentration to start nucleation. The droplet should be covered with 
oils such as silicon and paraffin oils, allowing slow evaporation resulting in 
increased concentration of protein and precipitant in the crystal droplet.  
 
7.1.2. X-ray crystallography  
X-rays were first discovered in 1901 by Röntgen, who was the first Nobel Prize 
winner in Physics. Since then X-rays were routinely used for medical work. In 
1912, William Henry Bragg and his son William Lawrence Bragg started a 
different approach for using X-rays; they used diffraction of the X-rays passing 
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through the crystal to determine the structure and arrangement of molecules 
comprising the crystal. Bragg the father had adapted a standard microscope into 
a new one by replacing the normal light source with an X-ray source. After adding 
a focusing tube, the crystal replaced the prism or the optical grating on the 
rotating table, and a rotating ionization chamber for detecting the diffracted X-
rays replaced the optical telescope (Jenkin 2001). While on the other hand, 
William Bragg the son directed his interests into structure solving using his 
father’s- developed microscope, where he thereafter managed to determine the 
structure of sodium chloride crystal using the new technique in 1913.  Nowadays, 
crystallography is used in a wide range of disciplines, such as physics, materials 
science, chemistry and medicine. Now a days, X-ray crystallography is a tool 
used to determine the atomic or molecular structure of the crystal with different 
properties of the X-rays used in each. The X-rays are also used in medicine and 
material science since they are absorbed differently by varying tissues and 
materials, but these has less intensity than used in crystallography. In X-ray 
crystallography, the X-rays are aimed at the crystal, which will in turn be diffracted 
by the crystal depending on its crystal symmetry and the contents of its unit cell. 
The diffraction pattern is registered thereafter and recorded and the images 
obtained are used afterwards to calculate the three dimensional structure of the 
protein. X-ray wavelengths used in solving molecular structure range between 
0.5-1.5Å, the same region where the sizes of the spaces between atoms lies in.   
Protein crystal is composed of regular repetition of unit cells which amplifies the 
diffraction pattern. The unit cell is designated by the three lengths (a, b, and c) 
and the three angles (alpha, beta and gamma). The more unit cells in a single 
crystal the stronger the resulting diffraction pattern. The diffraction occurs on 
parallel planes running through the crystal; those planes have different orientation 
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and spacing between them. The diffraction pattern is made up of a number of 
spots (individual reflections), which correspond to the diffraction from the crystal 
planes. 
 Bragg’s law (Bragg 1913) represents the conditions need to be fulfilled to get a 
diffraction pattern from the crystal, equation 7.1.  
 
n=2dsin 
Equation 7. 1 Bragg’s law, n is an integer,  is the wavelength of the radiation, d is the distance 
between the lattice planes and  is the angle of the incidence of the X-ray beam. 
 
Looking at Bragg’s law, one can see that all the planes running through crystal 
are considered as mirror image as long as the interplanar distance equals an 
integer number of the X-ray wavelength. Each plane gives a reflection spot. The 
X-rays will add up constructively if they start in phase and reach the crystal plane 
in phase, Figure 7.2. 
 
Figure 7. 2 Conditions that satisfy Bragg’s law. Figure adapted from (Asherie 2004). 
 
Bragg’s law shows that the shorter the spacing between the planes, the greater 
the angle of diffraction. Reflections are described by a set of indices called Miller 
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indices (h, k, l), which defines the spacing between the lattice planes of the crystal 
in reciprocal space. Measuring the spacing will allow calculating the dimensions 
of the unit cell.  
During data collection, crystals are rotated until reaching a plane that satisfies 
Bragg’s law, which will produce diffraction thereafter. This rotation allows 
collecting data from planes. This is best explained by what is called Ewald’s 
sphere, which explains Bragg’s law in three dimensions. Ewald’s sphere places 
the crystal at the center, and has a diameter of 1/. Reciprocal lattice points lie 
on Ewald’s sphere and satisfy Bragg’s law and hence producing a diffraction spot, 
Figure 7.3. 
 
 
Figure 7. 3 Ewald’s sphere. A three dimensional illustration of Bragg’s law. Adapted from (Dauter 
1999). 
 
The X-ray diffraction data is used to calculate the electron density throughout the 
unit cell. To calculate the electron density, both the amplitude |Fh| and the phase 
of the diffracted X-rays waves need to be calculated. The amplitude can be 
calculated from the experimental information as it represents the square root of 
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the intensities. The Phase information is lost during data collection and can’t be 
calculated directly using data collected; instead they are calculated using number 
of different methods, which will be described later in this paragraph.  
Once the phase and the amplitude information are calculated for each of the 
Miller indices (h, k, and l), they are all combined to obtain the structure factor (F). 
The total structure factor is a combination of all the atomic structure factors (fj) 
described by the Miller indices, Equation 7.2. Structure factor and electron density 
are related by a Fourier transform. 
 
𝐹ℎ𝑘𝑙 =  │𝐹ℎ│ exp[𝑖𝛼ℎ] =  ∑ 𝑓𝑗
𝑗
𝑒𝑥𝑝2πi(ℎxj + 𝑘yj + 𝑙zj) 
Equation 7. 2 The structure function equation. Fhkl is the structure factor of all Miller indices, fj is 
the atomic structure factor, |Fh| is the amplitude of the reflections, and [iαh] is the phase of the 
reflections. 
 
After calculating the inverse Fourier transform for all Miller indices, we can 
calculate the electron density for all positions in the unit cell, Equation 7.3. 
𝑝(𝑥, 𝑦, 𝑧) =
1
𝑉
∑ Fhkl exp[−2πi (ℎx +  𝑘y +  𝑙z)]
ℎ𝑘𝑙
 
Equation 7. 3 Electron density calculation in a unit cell. P(x,y,z) is the electron density of all 
positions in the unit cell. Fhkl is the structure factor. 
 
The method used in this project to determine the phase problem that was lost 
during data collection is the molecular replacement using a model that has a 
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sequence homology of 25% or more of the unknown structure. To choose a good 
model, one aims at having a model with the lowest r.m.s.d. (indicated by high 
sequence identity), lowest deviation from the target structure and a high 
accuracy, which means that it models a high proportion of the scattering from the 
target structure (Evans and McCoy 2008). The chosen model is used to make an 
estimation of the initial phase. In this method we try all possible orientations and 
positions of the model in the unknown structure and try to find the best match of 
the predicted diffraction with the observed diffraction (Evans and McCoy 2008).  
An electron density map that minimizes the bias of the calculated structure factor 
for the model is being created. This is achieved by subtracting the calculated 
structure factors from a multiple of the observed amplitudes. This map is referred 
to as the 2Fo-FC map, Equation 7.4. where Fo-FC represents the subtraction of the 
calculated structure factor amplitudes from the observed amplitudes, and is used 
to highlight regions where an electron density has been observed in the data 
collected (but has not been observed or computed in the model), and the regions 
where the model has been built but no electron density has been observed. Once 
the electron density map has been calculated, the building of the amino acid chain 
into the map can start using both the calculated and the observed density map.  
 
 
𝑝(𝑥, 𝑦, 𝑧) =
1
𝑉
∑(2 ∣ Fobs ∣ −∣ Fcalc ∣) exp[iαcalc(h)])
ℎ𝑘𝑙
 
Equation 7. 4 The electron density 2Fo-fC map summation. Fobs is the amplitude observed from the 
model. Fcalc is the amplitude calculated from the model. 
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Each protein chain building cycle is always followed by refinement. Each 
refinement should result in improvement in the R factor. Structural refinement 
includes applying geometrical restraints on the bonds lengths, angles, and 
planarity of the bonds. These refinements will be accompanied by alteration in 
the position of atoms, B-factors and occupancy, which will in turn improve the 
phases thereafter. 
The R-factor is the statistical measurement of how well the calculated amplitudes 
to match the observed amplitudes in the diffraction pattern, Equation 7.5.  
The smaller the R-factor value and the closer it is to zero, the better the calculated 
density map. Since R-factor is calculated using structure factors used in both 
structure refinements, is a biased value. Therefore, another statistical R-factor is 
calculated, called the Rfree is calculated to overcome the biased problem of R-
factor. To calculate Rfree, the amplitudes of (2-5%) of the reflection spots are used 
which are not included in the structure refinement process. 
 
𝑅 =
∑ ∣∣ 𝐹𝑜𝑏𝑠 ∣ℎ −∣ 𝐹𝑐𝑎𝑙𝑐 ∣∣
∑ ∣ 𝐹𝑜𝑏𝑠 ∣ℎ
 
Equation 7. 5 The R-factor equation. . Fobsis the amplitude observed from the model. Fcalc is the 
amplitude calculated from the model. 
When no further decrease in the R-factor is observed, the refinement is stopped. 
Thereafter, a validation of the structure is performed using parameters such as 
bond lengths, angles, and stereo-chemical parameters, where the structure is 
thought to be correct when those parameters falls within the calculated 
parameters.  
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The aim of this chapter is describe solution of the structure of the recombinant 
fusion protein Blastocystis triosephospate isomerase/glyceraldehydes-3-
phosphatedehydrogenase (TPI-GAPDH) using X-ray crystallography. 
Blastocystis glyceraldehydes-3-phosphatedehydrogenase (GAPDH) was also 
crystallized separately and X-ray data were collected in a step aimed at solving 
its structure and comparing it to the fusion protein. This is the first work reported 
to solve the structure of the unusual fusion protein Blastocystis TPI-GAPDH. The 
work was performed with the help of Dr Michail Isupov in the Biocatalysis 
department who helped in data collection and data processing and crystal 
structure solution. 
7.2. Materials and methods  
7.2.1. Crystallization 
7.2.1.1. Protein preparation 
The protein obtained from size exclusion chromatography (gel filtration 
chromatography: GF) was pooled and concentrated to 60 mg/ml in the case of 
the Blastocystis TPI-GAPDH and 20 mg/ml for Blastocystis GAPDH. The 
concentrated protein is centrifuged at 15,000 x g at 4°C for 10 min before being 
used in crystallization trials. This centrifugation step is very important as it 
removes any precipitants or aggregates.  
7.2.1.2. Pre – crystallization test: PCT 
A very important factor to be considered when setting crystallization trials is the 
protein concentration. Commercial kits have been developed to test both the 
homogeneity and the suitability of the protein concentration for the crystal trials. 
In this study, a commercial kit called PCT™ (Pre crystallization test) from 
Hampton Research was used. In this experiment, the protein mixed in a certain 
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concentration with equal volumes of the buffers provided. The outcome of this is 
important for identifying the next steps. If the protein concentration is very high, 
an amorphous precipitation will be observed resulting in precipitation and a 
blurred solution in the mixed well. If after adding the protein a very clear solution 
is observed, then the protein is too much diluted or in a very low concentration. 
The optimal case is to have a light precipitation when the protein is mixed with 
the buffer. The various possibilities that might be encountered and which actions 
to take are summarised in Table 7.1.  
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Table 7. 1 Pre-crystallization test (PCT) results and the recommended actions 
(https://hamptonresearch.com/documents/product/hr00559 9_2-140_142_user_guide.pdf)                                                                                                                                                                             
Buffer A1 */ B1*** Buffer A2 **/ B2**** Action taken 
Heavy precipitation Heavy precipitation Dilute the protein  
Heavy precipitation Clear Perform PCT with B1/B2 and check for 
homogeneity  
Heavy precipitation Light granular precipitate  Set the crystal screen 
clear Heavy precipitation Perform PCT with B1/B2 and check for 
homogeneity 
Light granular 
precipitate 
Heavy precipitation Set the crystal screen 
clear Clear Concentrate the protein to half the 
volume 
clear Light granular precipitate Set the crystal screen 
Light granular 
precipitate 
Clear Set the crystal screen 
* A1: 0.1M Tris hydrochloride pH 8.5, 2.0 M ammonium sulphate 
** A2: 0.1M Tris hydrochloride pH 8.5, 0.2 M magnesium chloride hexahydrate, 30% w/v 
Polyethylene glycol 4,000 
*** B1: 0.1M Tris hydrochloride pH 8.5, 1.0 M ammonium sulphate 
**** B2: 0.1M Tris hydrochloride pH 8.5, 0.2 M magnesium chloride hexahydrate, 15% w/v 
Polyethylene glycol 4,000 
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Performing this pre – crystallization test is extremely useful and will save time, 
and most importantly, the precious protein samples as well. In this study the 
fusion protein Blastocystis TPI-GAPDH gave the desired results at 35 mg/ml, 
while Blastocystis GAPDH protein was accepted at around 16 mg/ml.  
In the case a protein always results in a heavy precipitation no matter how diluted 
it is (if it goes beyond 3 mg/ml), then it is advised to check the protein 
homogeneity using methods such as DLS, native gel electrophoresis, etc. 
mentioned in details in the previous chapter. 
7.2.1.3. Initial crystal trials 
Commercial crystal screens were tried for both the Blastocystis fusion protein 
TPI-GAPDH and GAPDH. A list of the screens used is shown in Table 7.2.  
Screens were set at the University of Exeter’s facility using the micro-batch 
method and were prepared using an Oryx 6 crystallization robot (Douglas 
Instruments). The crystal plates which were set using this method were stored at 
4 °C and 18°C. Another set of screens were set up using the vapour diffusion 
method at the Oxford Protein Production Facility (OPPF) at the University of 
Oxford. The OPPF uses a Hydra robot which transfers screen buffers to the 
plates where crystallization screening would take place. It is also used for 
transferring nanoliter amounts of droplets using the dispensing Cartesian 
Microsys instrument. The set crystal plates were stored in a hotel system 
(Formulatrix Storage) supplied with its own imaging system that records the 
growth of the crystals at either 4 or 21°C. These plates were checked afterwards 
using an automated coding system installed at the crystallography unit at the 
OPPF. Protein crystals obtained in this study were the ones stored at 21°C.  
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Table 7. 2 Commercial screens used in this study 
Screen name  (Hampton research) 
JCSG-plus HT-96 
PACT premier 
Morpheus 
Wizard ¾ 
PEG/ion 
Index 
 
7.2.1.4. Optimization of crystallization 
After obtaining crystals that gave a good diffract under x-ray, further trials were 
performed in order to maximize the data obtained and to enhance the quality of 
these data and images collected. The aim of this was to achieve a higher 
resolution of the data obtained. In addition, the original dataset did now allow 
getting data of the holo protein, so additional data acquisition was required. For 
this, Xstep optimization software (Douglas instrument, UK) was used to set new 
conditions for crystallography. This software varies the concentration of the 
protein, precipitant used, buffer strength (pH) and any other additives in the 
primary trial conditions by about ± 30%.  In this work, only the micro-batch method 
was used. The robot used to set the optimization trial plates was the Oryx 6 
crystallization robot (Douglas Instruments, UK). 
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 Each droplet was covered by an oil mixture (Al’s oil) (50: 50 of silicon oil and 
paraffin). The plates were stored at 18°C and checked regularly using a light 
microscope.  
7.2.1.5. Co – Crystallization 
The Blastocystis fusion protein TPI-GAPDH was tried for co-crystallization with 
its cofactor; reduced nicotinamine adenine dinucleotide (NADH+). The cofactor 
was incorporated in two ways; in the first instance the cofactor NADH+ was added 
during the final purification step (gel filtration) but no crystal yield was obtained in 
this instance. The other way of incorporating the cofactor was in the optimization 
step. Here, the cofactor NADH+ was added to the final purified protein, left in 
contact with the gel filtration- purified protein on ice for 2-3 hours. The combined 
mixture was subsequently used for setting new crystallization plates. The cofactor 
was used in concentration of the dissociation factor value 10x Kd) calculated in 
chapter 6, section 6.4.3. To set the crystal plates a final protein concentration of 
35mg/ml was used. The protein-cofactor mixture was centrifuged at 15,000x g 
before setting the crystal plates. 
 
7.2.2.  Preparing crystals for data collection 
7.2.2.1. Cryo-cooling straight from droplet using cryo-protectant 
The crystals obtained in this study were mounted directly from the crystallization 
droplet under the light microscope and placed in the cryo-protectant of choice. 
This cryo-protectant was contained the purification buffer components. The 
crystal was picked up from a cryoprotectant mixture using cryo-loop was then 
plunged into liquid nitrogen to be cryo-cooled and ready for the next step, i.e. 
shooting by x- rays. For a full list of the cryo-protectants used with Blastocystis 
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GAPDH crystals and Blastocystis TPI- GAPDH crystal analyzed in this study see 
Table 7.3 and Table 7.4, respectively. A final cryo-cooler composed of (200mM 
NaCl, 200mM K2HPO4, 16% PEG 3350, 30% PEG 400, pH 8.6) was used for the 
Blastocystis TPI - GAPDH crystal which gave the best X-ray diffraction data.  
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Table 7. 3 Cryo – protectants and conditions used for Blastocystis GAPDH crystals, showing various 
shapes and relative sizes of the crystals. 
 
 
 
 
 
 
 
 
 
Crystal plate conditions Screen name Cryoprotectant used crystal 
0.1 M HEPES 
1.1 M sodium malonate 
0.5% v/v jeffamine ED-2001 
Reagent 
JCSG-plus HT-96 Same as the well conditions, 
exclude jeffamine  
pH 7-8 
 
 
0.1 M TRIS pH=8.50 
0.2 M lithium sulphate 
1.26 M ammonium sulphate 
JCSG-plus HT-96  
 
0.1 M sodium acetate pH 4.60 
2.0 M ammonium sulphate 
JCSG-plus HT-96 1.8 M ammonium sulphate 
30% glycerol 
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Table 7. 4 Cryo – protectants and conditions used for Blastocystis TPI - GAPDH crystals, showing 
various shapes and relative sizes of the crystals. 
 
 
 
Crystal plate conditions  Screen 
name  
Cryoprotectant used  crystal 
0.2 M potassium phosphate 
dibasic 
20% W/V PEG 3350 
pH 9.2 
PEG/ION 
 
200 mM NaCl 
200 mM K2HPO4 
16% PEG 3350 
30% PEG 400 
pH 8.6 
 
20% PEG 3350 
0.2 M ammonium nitrate 
JCSG-plus HT-
96 
Same as the well condition, pH 5.6.  
 
30% v/v jeffamine ED-2001 
Reagent, pH 7.0, 0.1 M HEPES 
pH 7.0 
Index Same as well conditions, delete jeffamine. 
Added 35% PEG44 
 
20% w/v polyethylene Glycol 
monomethyl ether 5000 
0.1 M bis-Tris pH 6.5 
Index 20% PEG 5000 
0.1 M Bis-Tris pH 6.5 
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7.2.3.  X-ray data collection  
7.2.3.1. Synchrotron data collection  
Data were collected on several beam lines for several crystals at the Diamond 
Light Source (Oxford, UK). The data presented in this study for the recombinant 
Blastocystis TPI-GAPDH protein were obtained in beam line I03 at Diamond 
Synchrotron light source using an ADSC Q315 CCD detector. Data were 
collected in cryo-cooled conditions (100 K under a stream of gaseous nitrogen). 
A high resolution dataset was collected at wavelength of 0.976Å at a distance of 
611.9mm. 900 frames were collected at an oscillation of 0.2° for each frame. For 
detailed information about the data collection conditions see Table 7.5. 
Table 7. 5 Cryo-cooling and X-ray data collection conditions for both Blastocystis TPI-GADH and 
Blastocystis GAPDH crystals. 
Crystal  Blastocystis TPI-
GAPDH 
Blastocystis GAPDH 
Cryo-protectant  200 mM NaCl 
200 mM K2HPO4 
16% PEG 3350 
30% PEG 400 
pH 8.6 
1.8 M ammonium sulphate 
30% glycerol 
Cryo-cooling  Straight from drop in addition 
to the purification buffer 
Straight from drop in addition 
to the purification buffer 
Beam Diamond synchrotron I03 Diamond synchrotron I03 
Wavelength (Å) 0.976 (SAD) 0.976(SAD) 
Distance (nm) 611.9  611.9 
No. frames 900 900 
Oscillation (°) 0.2 0.2 
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7.2.4. Structure determination  
7.2.4.1. Data processing  
Data were processed using the XDS (Kabsch 2010, Kabsch 2010), Pointless 
(CCP4), and xia2 (CCP4) programs (Collaborative Computational Project 1994, 
Evans 2006). This part of the work kindly performed by Dr Michail Isupov.  
7.2.4.2. Phase determination  
Phases were determined using molecular replacement using MOLREP program 
(Vagin and Teplyakov 2010), and REFMAC5 (Murshudov, Skubak et al. 2011) 
for refinement cycles after every amino acid building cycle. This procedure is 
discussed in more details later on. Two homologous models were used for this 
tetramer model method. A human placental GAPDH structure (PDB IU8F) as a 
GAPDH tetramer model with 67.5% identity (Jenkins and Tanner 2006) and the 
mealworm (Tenebrio molitor) TPI structure (PDB 2I9E) as a TPI dimer model with 
53.2% identity (Knobeloch, Schmidt et al. 2010). Both were used for molecular 
replacement methods and details can be found in the results of the Blastocystis 
TPI-GAPDH structure solution later in this chapter. This part and all the following 
parts of molecular replacement, model building, refinement and validation were 
performed under the kind help and supervision and guidance of Dr Michail Isupov.  
7.2.4.3. Model building and refinement  
Electron density maps were calculated and the structure was fitted to best fit the 
2F0-Fc and F0-Fc maps. The protein was built using the program COOT (Emsley 
and Cowtan 2004). After each session of model rebuilding performed using 
COOT, a maximum likelihood refinement was performed using REFMAC 5.2 
(Murshudov, Skubak et al. 2011). Phases were improved by four-fold averaging 
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using density modification (DM) (Cowtan 2010). Crystallographic origin ambiguity 
was resolved using Zanuda (Lebedev and Isupov 2014). 
 
7.2.4.4. Structure validation  
The final structure after refinement was checked for quality using the program 
PROCHECK (Laskowski, MacArthur et al. 1993). 
7.3. Results  
The work in this chapter was divided into two parts. The main goal was to solve 
the structure of the unusual Blastocystis TPI-GAPDH fusion protein. The 
recombinant Blastocystis GAPDH was also studied alongside this work to be 
used as a reference as well as for comparing the structure of the fusion protein 
with the structure of the stand-alone GAPDH protein( truncated from the fusion 
protein) of the same organism. Unfortunately, the Blastocystis GAPDH structure 
was not solved due to the poor data quality obtained with a resolution of about 10 
Å, which doesn’t allow for solving the structure. Thereafter, the Blastocystis 
GAPDH structure solution work was ceased at the data collection step. In the 
following sections I will describe the details of work done on both proteins, with 
detailed explanations on only the recombinant Blastocystis TPI-GAPDH fusion 
protein structure solution.  
. 
7.3.1. Crystallization of the Blastocystis TPI-GAPDH fusion protein 
The gel filtration purified recombinant Blastocystis TPI-GAPDH fusion protein 
was concentrated to a final concentration of 35 mg/ml using Amicon Ultra-15 
centrifugal filter units with a cut off 30kDa. This concentration was determined 
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after being tested for optimal concentration to be utilized using the PCT kit as 
mentioned in chapter 7, section 7.2.1.2. Crystallization trials of the protein were 
conducted using the commercial screens mentioned in Table 7.2. The 
screening plates were set by the Hydra instrument under the vapor diffusion 
method. Initial results produced several crystals in different screen buffers, 
yielding varying sizes and shapes. Only one crystal diffracted well at a 
moderate resolution value of 2.6Å in the synchrotron (Figure 7.4), under the 
following conditions: 200 mM sodium chloride (NaCl), 200mM potassium 
phosphate dibasic (K2HPO4), 16% PEG 3350, 30% PEG 400, pH 8.6. 
 
Other crystals have shown some diffraction but not of good quality (i.e. low 
resolution), (see Figure 7.5 A, B, and C). The low resolution value might be 
attributed to either the fact the protein is not ordered enough or might be related 
to the cryoprotectant choice. In the case that the cryoprotectant choice was not 
suitable, ice rings would form. Ice rings in crystals are known for their negative 
effect as they destroy the protein structure, and hence lower the quality of the 
collected data. Based on the initial performed screening, further screening trials 
were performed aiming at optimizing the primary conditions. Optimization 
conditions varied from the initial screen in the percentages of both the buffers and 
the precipitants where a crystal growth was reported. The optimization 
experiments were performed using the micro-batch method, see Appendix 3 for 
optimization conditions. Several types of crystals were obtained, harvested to be 
prepared for analyses at the synchrotron. Unfortunately, none of these crystals 
diffracted indicating that they were not protein crystals.  
From the data collected, no electron density in the active site was obtained, so 
the ligand could not be detected in the final structure. Analyzing the recombinant 
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Blastocystis TPI-GAPDH protein structure using the data obtained from the first 
crystal demonstrated that the crystal is lacking the cofactor in the active site of 
the GAPDH protein. Hence, a new approach was taken in the following 
optimization steps. Optimization was aimed at enhancing the data quality and to 
get data with electron density around the cofactor NADH+. To achieve this, the 
cofactor was added by using one of two approaches. During the final gel filtration 
purification step, where there is a chance that NADH+ has been washed off during 
the consecutive purification steps. So NADH+ was added during the final GF 
purification step. The other approach was to add the NADH+ cofactor after all the 
purification steps were performed. This was performed by a simple incubation 
step by mixing the NADH+ cofactor with the protein on ice in the proportions as 
mentioned in chapter 7, section 7.2.1.5. Both approaches resulted in crystals with 
varied sizes and shapes, but unfortunately, both failed to yield any diffraction.  
 
Figure 7. 4 Crystallization process flow showing the steps to obtain the fusion protein structure from 
setting crystal trials to diffracting the obtained crystal in the synchrotron. 
7.3.2. Crystallization of the Blastocystis GAPDH protein 
Blastocystis GAPDH was expressed, purified and prepared for further 
crystallization work. The protein sample was treated as described in chapter 7, 
section 7.2.1.3. The same set of screening buffers used in the crystallization 
trials of the Blastocystis TPI-GAPDH fusion protein was applied for Blastocystis 
GAPDH as well. Several protein crystals were harvested from this work and 
exposed to X-ray in the synchrotron at Diamond Light Source. Data obtained 
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were all with low resolution and hence no data could be processed for structure 
solution. The low resolution of the data could be enhanced by repeating the 
experiments with choosing better cryo-coolers since most crystals (different 
sizes and varied buffers as presented in Figure 7.5/D, E, F) have shown crystal 
ice rings after being exposed to X-rays. Different approaches might be 
investigated to enhance the quality of data obtained. 
 
Figure 7. 5 Examples of protein crystals obtained in several commercial buffer screens for both 
Blastocystis TPI-GAPDH and Blastocystis GAPDH proteins, with the droplet conditions they grew in.  
1) Blastocystis TPI-GAPDH A: Index (20% w/v Polyethylene Glycol Monomethyl Ether 5000, 0.1 M bis-
Tris, and pH 6.5. B: PACT premier (0.1 M MES, pH 6.0, 20% w/v Polyethylene Glycol 6000, 0.2 M 
Ammonium Chloride), C: Index (30% v/v Jeffamine ED-2001 Reagent pH 7.0, 0.1 M HEPES pH 7.0) . 
2) Blastocystis GAPDH D: Wizard 3/4 (20% (v/v) 1,4‐butanedio, 100mM HEPES/ Sodium hydroxide pH 
7.5, 200 mM Sodium chloride). E: Wizard 3/4 (30% (w/v) PEG 3000, 100 mM Tris base/ Hydrochloric 
acid pH 7.0, 200 mM Sodium chloride). F: PEG / ion (0.2 M Sodium phosphate dibasic dehydrate, 20% 
w/v Polyethylene glycol 3,350, pH 9.1). 
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7.3.3. Structure determination of the fusion protein 
7.3.3.1. X–ray data collection  
Several crystals have been harvested and tested at the synchrotron for 
diffraction. Most of the crystals showed the formation of ice rings which negatively 
affects the diffraction and hence the data quality. Fortunately, one crystal of the 
Blastocystis TPI-GAPDH fusion protein gave a good diffraction results and this 
diffracted to 2.6Å. Data were collected at Diamond Light Source (Oxford, UK) as 
mentioned in methods 7.2.3.1. Indexing and scaling were performed and 
revealed that the crystal belongs to the space group C 1 2 1, with the following 
cell parameters (a = 179.5, b = 77, c = 212.3 Å / α = γ = 90, β = 102.78°). The ice 
ring regions obtained from frozen parts of the crystal were excluded from data 
processing, and to obtain a higher completeness of the data the loop was bent 
360° to minimize the blind region. Data completeness was 99.7%. Table 7.6 
describes the data processing statistics for the Blastocystis TPI-GAPDH fusion 
protein. 
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Table 7. 6 Data processing statistics and solution of the recombinant protein Blastocystis TPI-
GAPDH.  
Crystal Recombinant Blastocystis TPI-GAPDH 
X – ray source I03 
Wavelength (Å) 0.97625 (SAD) 
Resolution range (Å) 2.6 -2.7 (103.52) 
Space group C 1 2 1  
Cell parameter  A= 179.5, b= 76.9, c= 212.3 
α= 90, β= 102.7, γ= 90 
No. parameters in asymmetric unit 1  
No. of measured reflections 279228 
No. unique reflections 83654 
Completeness (%) 99.7 
Multiplicity  3.3 
 70.5  
   Redundancy  0.049 
(1)/σ (I) 12.2 (1.7) 
Rmerge † (%) 0.049 (0.682) 
  
7.3.3.2. Structure solution  
A dimeric coleopteran triosephosphate isomerase (TPI) from Tenebrio molitor 
(yellow mealworm beetle) (PDB 2I9E) and a tetrameric glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) (PDB 1U8F) were used for molecular 
replacement using the program MOLREP (Vagin and Teplyakov 2010).  
The crystal packing suggests four TPI-GAPDH monomers in the asymmetric unit 
of the crystal. The molecular replacement has positioned a single GAPDH 
tetramer and two TPI dimers in the new crystal cell with high contrast. Single 
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monomer of each protein was chosen to carry out the structure building, and then 
extended by non-crystallographic symmetry operators to have a full tetramer.   
The correct rotation function peaks for the tetrameric GAPDH model calculated 
at 3Å resolution were in 27-28σ range. The rotation function peaks for the dimeric 
TPI model were 12.8 and 12.5σ. Translation function was calculated at 4Å 
resolution. The correlation coefficient for the correct position of GAPDH tetramer 
was 47% while the correlation coefficient was 25% for the wrong solution. With 
GAPDH tetramer fixed the correlation was 53% for the first TIM dimer positioned 
and 56% for the second TIM dimer. Each subunit was built separately and the 
model was subjected to rigid – body refinement implemented in MOLREP. The 
final resulting model was refined using REFMAC (Murshudov, Vagin et al. 1997). 
The resulting model did not refine well due to the pseudo-origin problem, since 
native Patterson function contained strong (40% of origin) peaks. The program 
ZANUDA resolved origin ambiguity and further refinement and model rebuilding 
went smoothly. 
 
7.3.3.3. Model building and validation  
7.3.3.3.1. Apoenzyme  
Since the link between the GAPDH and TPI parts is flexible, the tetramer did not 
follow a strict 222 molecular symmetry. The GAPDH component did follow this 
symmetry,  Since rebuilding of four copies of each chain was too time consuming, 
one copy of each chain was originally rebuilt on graphics and then it was 
multiplied four times for each protein chain. The structure solution was manually 
built in COOT (Emsley and Cowtan, 2004) and refined using REFMAC version 
5.6 (Murshudov, Vagin et al. 1997). The R-factor and Rfree were 17.215% and 
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23.72% respectively.  No density was observed in the active site of the GAPDH 
structure.  The final refinement statistics for the native TPI-GAPDH and validation 
results are shown in Table 7.6 and the Ramachandran plot can be accessed in 
Appendix 4. 
Finally the protein was built of four subunits; each subunit consists of 603 amino 
acids forming the monomer unit of TPI-GAPDH.  
The N terminal amino acids (1-18) containing His-tag and part of the signal 
peptide were not visible in the electron density and were not modeled. 135 water 
and several phosphate molecules were modeled. REFMAC gave an estimated 
r.m.s. value of 0.922 in the coordinates based on the Rfree value. The most 
favoured regions of the Ramachanran plots were determined by PROCHECK 
contain (93.04%) the overall G factor.  
The statistics for the final round of refinement of the structure are given in Table 
7.7. The Ramachandran plot is displayed in Appendix 5. 
There are 18044 atoms in the molecule in the final structure analysis. The final 
structure showed four chains: chain A running from amino acid number 18 until 
603, and same for chain C. chains B and D both ran from amino acid 20 till 603. 
Correlation coefficient Fo-FC: 0.965, and correlation coefficient Fo-FC free:   0.928.    
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Table 7. 7 The final X – ray data refinement statistics for Blastocystis TPI – GAPDH structure. 
Crystal  Blastocystis TPI – 
GAPDH 
Refinement   
   Resolution (Å) 2.6 
   R factor/ Rfree (%) 0.17/0.23 
   No. of protein atoms 17772 
   No. of ligand atoms 0 
   No. of water atoms 135 
   R.m.s. deviation from ideality  0.92 
      Bond lengths (Å) 0.012 
      Bond angels (°) 1.675 
   Ramachandran plot (%)  
     Most favored regions  93%  
     Additional allowed regions  5.24%  
     Generously allowed regions  1.89%  
   Average B values (Å2) 74.4 
      Overall   
      Protein atoms  2340  
      Ligand atoms  0 
 
7.4. Discusion 
7.4.1. Secondary structure analysis:  
The PDB file generated for the Blastocystis TPI-GAPDH fusion protein was 
submitted at several structure analysis servers to analyze its secondary structure 
and special features. Submitting the PDB file to PolyView 2D, showed that the 
protein comprises four chains, each chain contains alpha helices and beta 
sheets, Figure 7.6. Looking into this result file of the secondary structure of the 
    
265 
 
protein, one can see a pattern of (βα) 4 in the first 200 amino acids corresponding 
to the TPI sequence. This is in accordance with the universal structure of TIM 
barrel which TPI belongs to, cconfirming the TIM barrel of TPI. And the Rossmann 
fold for GAPDH which is (β-α-β) fold at the nucleotide binding domain (NBD) and 
the α/β fold at the catalytic domain (CAD). The results were confirmed using 
another tool using ESPript3 program, Figure 7.7 which shows that the protein 
consists of four units, each composed of 24 β sheets and either 19 or 20 α helix, 
making a total of 96 β sheets and 78 α helix in the whole protein unit structure.   
     
Figure 7. 6 The secondary structure of the protein Blastocystis TPI-GAPDH fusion protein showing 
that the protein consists of four identical chains. The figure obtained by POLYVIEW-2D program.  
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The green arrow represents beta strands. The red zigzag represents alpha helices. 
 
Figure 7. 7 Flat figure showing the amino acid sequence of the PDB entry file of TPI-GAPDH fusion 
protein adorned with secondary structure elements presented on top (helices with squiggles, β-
strands with arrows and turns with TT letters). This secondary structure only shows two subunits 
since the other two are identical. Solvent accessibility is rendered by a first bar below the sequence 
(blue is accessible, cyan is intermediate, white is buried) and hydropathy scale per residue showed 
by a second bar below (Pink is hydrophobic, white is neutral, and cyan is hydrophilic. The figure is 
produced by ESPript 3 program.  
 
7.4.2. Active sites and signature motifs analysis 
The overall structure of the TPI-GAPDH fusion protein is similar to the typical 
proteins TPI and GAPDH that makes its building body. The TPI sequence 
covered the region between amino acid residues 20-260. GAPDH was divided 
into two main domains, a GAPDH N (nucleotide binding domain) (270-418) and 
a GAPDH C (catalytic domain) (423-580) according to a Pfam sequence search. 
The TPI region showed significant residues playing an important role in substrate 
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binding and active site catalysis; aspargine (N) and lysine (K) at position 26 and 
28 respectively were detected as substrate binding positions. Histidine (H) and 
glutamic acid (E) at position 110 and 179, respectively, were identified as an 
electrophile and a proton acceptor, respectively, with the region 177-187 
(AYEPIWAIGTG) identified as a catalytic site on TPI region as well which covers 
loop 6 region whose position is important in activity and substrate binding.  
In the GAPDH region cysteine was identified as a nucleophilic amino acid in the 
active site region of GAPDH (416-423) (ASCTTNCL).  An important motif was 
also detected in this structure, a consensus N-terminal Glycine-rich phosphate-
binding loop with a consensus sequence GXGXXG which in Blastocystis is 
(GFGRIG) which corresponds to a Rossmann fold motif indicating an NAD 
binding property of the protein. This binding site is located at the N-terminal of 
GAPDH. All the main features of TPI-GAPDH sequence are presented in detail 
in Figure 7.8 in a schematic representation of the fusion protein sequence. 
 
Figure 7. 8 Schematic representation of Blastocystis TPI-GAPDH protein with active sites and main 
domains found in the structure as expected on Prosite.Expasy. Three main domains were detected, 
TIM phosphate binding, GAPDH N, and C super family.  The diamond shape represents active sites 
belonging to the TPI domain. The triangle shape represents active site belonging to the GAPDH 
domain. Red: Amino acid position 26 (N), green: Amino acid position 28 (K), purple: amino acid 
position 110 (H), blue: amino acid position 179 (E), and orange: amino acid position 418 (C).The 
double sided arrow indicates the active site region in: TPI (177-187) (AYEPIWAIGTG), GAPDH (416-
423) (ASCTTNCL). The GAPDH motif (GXGXXG) is also presented on the figure covering (276-282) 
(GFGRIGR). The red loop represents the joint region in the fusion protein covering five amino acids 
in the sequence. 
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7.4.3. Tertiary structure analysis 
The Blastocystis TPI-GAPDH fusion protein structure solved in this project was 
identified to be a tetramer. It consists of two triosephosphate isomerase (TPI) 
dimers and a tetramer of glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH).  
To discuss the three dimensional structure of the fusion protein, I will divide the 
section into two sections, one for TPI and one for GAPDH.  
7.4.3.1. Triosephosphate isomerase (TPI) 
The three dimensional structure of TPI was reported in prokaryotes, unicellular 
eukaryotes, higher eukaryotes and Archaea. It is generally found that catalytically 
active TPI is usually a dimer, but cases of different oligomeric state have been 
described such as a monomer (mutants and not biologically active one), a 
homotetramer in Archaeal hyperthermophiles Thermoproteus tenax and 
Methanocaldococcus jannaschii in addition to a human tetrameric TPI (Walden, 
Taylor et al. 2004, Walden, Taylor et al. 2004, Kinoshita, Maruki et al. 2005, 
Gayathri, Banerjee et al. 2007). The protein belongs to the TIM family and takes 
the (βα)8-barrel assembly. TPI is a highly conserved protein, especially in the 
amino acids that plays a role in the ligand binding, catalysis, subunit interactions 
or stabilizing the protein structure. 
7.4.3.1.1.1. Active site: catalytic residues and catalytic region:  
As triosephosphate isomerase is considered as a highly conserved protein, its 
active site region is one of the main features that need to be inspected closely to 
check for activity of the protein. 
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Eye inspection of the superimposed structure of the studied protein in comparison 
with the model used to build the structure; Coleopteran TPI  (PDB entry 2I9E) 
(Knobeloch, Schmidt et al. 2010) shows the conservation of the main residues in 
the active site of TPI subunits: Asn10, Lys12, His94, and Glu164 in comparison 
to the corresponding residues; Asn26, Lys28, His110, and Glu179 in Blastocystis 
TPI-GAPDH. Loop 6 residues constitutes the amino acids from Pro180- Ala190; 
(PIWAIGTGTKA), which are mostly hydrophobic amino acids. This is in 
agreement with the fact that once the loop closes it needs to be buried inside the 
active site pocket inside the protein core, and hence should be hydrophobic. A 
close up of the conserved catalytic residues in the Blastocystis TPI monomer 
active site domain is shown in Figure 7.9 in a cartoon representation showing the 
main conserved residues of the active site in addition to the 6th lid-loop 
conformation formed.  
 
 
Figure 7. 9 Cartoon representation of the catalytic site residues of the TPI subunit of the fusion 
Blastocystis TPI-GAPDH. The active site residues are displayed as red sticks on the left side figure 
to highlight the location of the active site. Residues representing the active site are: Asn26, Lys28, 
His110, and Glu179 respectively. The right side figure is a close up cartoon presentation of the ten 
residues forming the lid-loop 6 region P-A (covering 180-190).  
To determine the conformation of loop 6 in TPI fraction of Blastocystis fusion 
protein TPI-GAPDH, structural alignment was carried out with other TPI proteins 
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studied so far, particularly the rabbit and the trypanosomal TPI protein as well. 
The rabbit triosephosphate isomerase protein showed unusual conformation of 
loop 6 in closed and open conformation in the same protein crystal (1R2R) (PDB 
entry: 1R2R, 1R2S, 1R2T) (Aparicio, Ferreira et al. 2003). While Trypanosoma 
brucei brucei TPI protein was unique in showing another conformation which was 
an almost closed conformation in one of the subunits in addition to an open 
conformation in the other subunit (PDB entry 5TIM) (Wierenga, Noble et al. 1991), 
see Table 7.8 for a summary of all the models studied and their flexible loop 
conformation. 
Superimposing triosephosphate isomerase from both the Trypanosoma Brucei 
Brucei (PDB entry 5TIM) and the fusion protein TPI-GAPDH of Blastocystis 
shows two possible conformation of the flexible loop (loop 6). According to 
Wierenga study, TPI has shown two conformations; open and an almost closed 
conformation. Aligning with Blastocystis TPI gave also two conformations, which 
means that it is either open or almost closed. To conclude which conformation 
Blastocystis TPI is taken, it was aligned with 1R2T from rabbit, and showed 
different conformation from it. Knowing that 1R2T had shown an open 
conformation only, we can conclude that TPI from Blastocystis TPI-GAPDH is not 
taking the open conformation, as shown in Figure 7.10/A and B (1,2,3). This was 
also confirmed by superimposing with the model protein used to solve the 
structure (2i9e), which also takes only the open conformation, Figure 7.11. Those 
two comparisons lead to the conclusion that TPI from Blastocystis TPI-GAPDH 
is taken an almost closed conformation. Superimposing both; loop 6 in TPI from 
Blastocystis TPI-GAPDH and the TIM structure of the rabbit muscle TPI, shows 
positioning of the lysine residue (K186) in a swung out conformation, Figure 7.12  
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A thorough comparison between several TPI studied proteins and the protein of 
study, confirms that TPI in Blastocystis fusion protein takes the almost closed 
confirmation, when compared to all possible solutions of open/ closed/ almost 
closed loop lids of previously studied proteins, 
This is quite surprising result for two reasons. First, no substrate was added in 
the crystal plate solution or in purification steps. Second, the electron density 
obtained didn’t show any density for a cofactor in the active site. Knowing that 
the open conformation of loop 6 in the active site op triosephosphate isomerase 
is usually found in apo structures, while the close conformation is found in the 
holo structure, where the protein forms complexes with substrate analogous, 
phosphate containing ligands, all add to the uniqueness of this finding. All the 
possible solutions for loop 6 lid conformation were superimposed to TPI unit of 
Blastocystis TPI-GAPDH, and also superimposed between both the rabbit  and 
the trypanosomal TPI having shown special features and differences in their 
subunits (Wierenga, Noble et al. 1991, Aparicio, Ferreira et al. 2003).  
Table 7. 8 Summary of several triosephosphate isomerase flexible loop conformations in several 
organisms. 
Protein name PDB entry Flexible loop conformation 
Coleopteran TPI 2I9E Open 
Rabbit Oryctolagus cuniculus  TPI 1R2R Open and closed 
1R2S Open 
1R2T Open 
Trypanosomal Brucei Brucei TPI 5TIM Open and almost closed 
Blastocystis TPI (study protein) - Almost closed 
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Figure 7. 10 Cartoon representation of lid loop 6 in TPI subunit of several proteins including rabbit TPI 
(PDB entry 5TIM), trypanosomal TPI (PDB entry: 1R2R, 1R2S, 1R2T) and the TPI subunit of the protein 
of study Blastocystis TPI-GAPDH protein. TPI of Blastocystis TPI-GAPDH protein was always 
represented in cyan. A) 1R2T (open) (hot pink) superimposed to TPI of study, showing a closed or 
almost closed conformation of the loop. B) 5TIM (green) superimposed to Blastocystis TPI of study 
(1), showing both open (2) and almost closed (3) conformation of the flexible loop (loop 6).  
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Figure 7. 11 A) Stick representation of the active site residues in a TPI dimer of the Blastocystis TPI-
GAPDH structure, showing the localization of the active site in the interface between the two 
molecules. B) Superimposition of loop 6 in a TPI subunit of Blastocystis TPI-GAPDH with the model 
protein coleopteran TPI (PDB entry 2i9e). The fusion protein is in blue and its loop is green while the 
coleopteran is in yellow and its loop in red. 
 
Figure 7. 12 Superimposition of active site loop 6 in both the studied protein Blastocystis TPI-GAPDH 
and TIM from rabbit muscle. The studied protein is shown in green and the model (PDB entry 5TIM) 
is presented in pink colour, with only lysine residue getting different orientation (swung out 
conformation).  
 
A 
B 
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From what previously discussed, the overall structure of TPI (in Blastocystis TPI-
GAPDH protein), takes almost a similar conformation to other usual TPI 
structures known so far as expected, with one phosphate group found in the 
active site of each unit (shown later in figure 7.15/2). Only one remarkable 
difference was found which is the unusual conformation of the flexible loop 6. 
Several other cases were also reported for a closed conformation of loop 6 in an 
apo enzyme. Those cases of conformational variability were attributed to .an 
inherent flexible nature of the loop, and to changes in the crystallographic 
environment.  
7.4.3.2. Glyeraldehyde 3- phosphate dehydrogenase (GAPDH) 
GAPDH structure was reported in a wide range of the kingdom of life, including 
eukaryotes, bacteria and archaea (Markos, Miretsky et al. 1993, Isupov, Fleming 
et al. 1999, Malay, Bessho et al. 2009, Zhao, Liu et al. 2011). This protein is 
usually reported to be as a tetramer. GAPDH sequence of the Blastocystis TPI-
GAPDH fusion protein is composed of three distinct domains (as analyzed by 
ExPASy- PROSITE); the nucleotide binding domain covering the region 270-418 
(NBD), the catalytic domain (CAD) (423-580) and finally the relatively short 
domain; C-terminal domain (CTD) covering (580-603), consisting of one alpha 
helices only, knowing that this short domain used to be considered as part of the 
NBD. The N-terminal consists of parallel sheets surrounded by helices forming a 
classical Rossmann fold. While the catalytic domain consists of anti-parallel beta 
sheets surrounded by helices. This domain also contains the active site residues 
and the S-loop, Figure 7.13/ A, B, C, shows the total secondary structure of 
GAPDH, the N-terminal and the catalytic domain respectively. 
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Figure 7. 13 Secondary structure of GAPDH in the fusion protein Blastocystis TPI-GAPDH. A) The 
secondary structure of GAPDH in the fusion protein Blastocystis TPI-GAPDH. B) The secondary 
structure of the nucleotide binding domain (NBD) consisting of six parallel β sheets surrounded by 
α helices. The 7th β sheet is anti-parallel. The NBD takes the typical Rossmann fold structure. C) The 
catalytic domain (CAD) consisting of anti-parallel β sheets and α helices. 
GAPDH active site showed the motif signature that is found in Rossmann 
structure proteins; GXGXXG. The sequence of the signature motif in this specific 
project it was GFGRIG covering the amino acid sequences between 276 -281. 
The protein clearly adapts a Rossmann fold motif binding NAD not NADP as the 
signature motif shows (Hanukoglu 2015). The electron density obtained didn’t 
show NAD electron density, but the presence of clear electron density of two 
phosphate groups in the active site of GAPDH might be an indication of the 
possibility of having NAD in this site as a cofactor. The specific details of the 
GAPDH subunit active site are shown in a cartoon representation of GAPDH 
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structure in Figure 7.14. In this figure a clear indication to the active site is 
indicated by the amino acids and the phosphate group.  
The GAPDH obtained in this study was superimposed to another GAPDH whose 
structure was studied in the human placenta with a very high resolution of    1.75Å. 
This human placental GAPDH (PDB entry 1u8f) has shown a clear electron 
density of only three NAD molecules (Jenkins and Tanner 2006). This 
superimposition shows the expected geometric position of the NAD groups in the 
studied structure, which is expected to be washed off from the protein of study 
during the purification steps as indicated earlier in this chapter, Figure 7.15.  
 
 
Figure 7. 14 Cartoon representation of Blastocystis TPI-GAPDH in cyan colour showing four NAD 
binding sites for the four GAPDH subunits in red and magenta. And showing six phosphate 
molecules in orange; one in each subunit and two in the middle pocket of the GAPDH tetramer.  
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Figure 7. 15 Superimposition of the study protein Blastocystis TPI-GAPDH (cyan) with the model used 
for building the structure (human GAPDH, 1u8f) (in lime green). The figure shows the phosphate 
groups that belong to Blastocystis TPI-GAPDH in orange and three NAD molecules belonging to the 
human GAPDH in magenta. 
 
7.4.3.3. TPI-GAPDH quaternary structure 
From all what was previously explained, one can see that the unusual fusion 
protein Blastocystis TPI-GAPDH adapts a tetrameric structure of the protein; 
composed of four subunits of GAPDH and four subunits of TPI. GAPDH localizes 
in the centre of the whole protein molecule, forming a tetramer. TPI is presented 
in this study as a usual dimer, with the fusion protein having two dimmers in its 
total structure separated by a tetrameric GAPDH in the centre.  A different 
presentations of the whole structure of the fusion protein was shown in Figure 
7.16/1, which is a surface representation of the protein superimposed with the 
model proteins used to solve the structure; and also transparent representation 
showing a cartoon fancy helices representation of the TPI and GAPDH inside the 
protein molecule, supplemented with stick presentation of the active sites and the 
phosphate molecules appeared in the electron density data, Figure 7.16/2. The 
fusion protein Blastocystis TPI-GAPDH was also superimposed to both the model 
proteins used to build the structure, (Figure 7.17). When superimposing GAPDH 
to itself, a displacement of TPI dimmers was noticed, indicating a less rigid TPI 
structural organization.  
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Analyzing the secondary structure of the fusion Blastocystis TPI-GAPDH protein 
has shown that the protein structure contains 92 alpha helices (20 in A and C 
and 19 in B and D) and 98 beta sheets (24 in each subunit), Figure 7.6/ 7.7.  
The structure coordinates was also tested using PISA interface on the EMBL-EBI 
server (Krissinel and Henrick 2007). It was found that the final structure contained 
a total of: four monomer chains, each is composed of monomer TPI and monomer 
GAPDH, Figure 7.18, and ten phosphate ligand. For details of the interfacing 
monomers statistics see Table 7.9. 
The interface analysis on PISA showed that the protein has no disulfide or 
covalent bonds. The protein is getting its stability through the presence of 19 salt 
bridges and 45 hydrogen bonds found in (interface, PISA) which are known to 
stabilize the total structure of the protein, especially that no di-sulphide or 
covalent bonds are found in this structure. A total of 4433 atom, 586 residues in 
each chain (contains monomer of TPI and a monomer of GAPDH).  
1 
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Figure 7. 16 1) Cartoon representation of the surface of the fusion protein Blastocystis TPI-GAPDH, 
superimposed with the coleopteran TPI protein (PDB entry 2i9e) with a surface quality of 1 . 2) 
Transparent representation of the fusion protein Blastocystis TPI-GAPDH showing the inside 
structure of the protein in cartoon fancy helices with surface transparency 0.7. TPI active sites 
belonging to the fusion protein structure are presented as sticks and colored red. The NAD 
molecules were colored in green and they belong to the human placental GAPDH protein (PDB entry 
1u8f). Nine phosphate molecules presented in the electron density are colored in dark blue, and 
presented in stick presentation. 
 
1 
2 
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Figure 7. 17 1) Cartoon representation of the recombinant fusion protein Blastocystis TPI-GADH. The 
cartoon illustrates the quaternary structure of the protein represented by a tetrameric GAPDH in the 
core of the protein surrounded by two dimeric TPI proteins flanking the GAPDH subunits. 2) Stereo 
view of superposition of the GAPDH tetramer on itself showing a displacement of TPI dimmers 
indication a less rigid TPI structural organization. The following homologous proteins were used as 
models; a Coleopteran TPI dimer from Tenebrio molitor (yellow mealworm beetle (PDB entry 2i9e) of 
53.2% identity and the human placental GAPDH (PDB entry iu8f) of 67.5% identity. The figures were 
produced using Pymol.  
 
 
 
 
 
1 
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Table 7. 9 interfacing monomers of Blastocystis TPI-GAPDH structure, obtained from PISA service 
at EMBL-EBI 
Range  Class  Structure  Surface  
N. 
atoms 
N. 
residues 
N. 
atoms 
N. 
residues 
Area,Å 
A Protein  4433 586 2402 523 25653.9 
C Protein  4433 586 2404 523 25669.0 
 Average 4433 586 2403 523 25661.5 
B Protein  4422 584 2390 525 25395.2 
D Protein  4422 584 2388 525 25399.9 
 Average 4422 584 2389 525 25397.6 
[PO4]E:1 Ligand 5 1 5 1 189.1 
[PO4]F:1 Ligand 5 1 5 1 188.8 
[PO4]G:1 Ligand 5 1 5 1 187.9 
[PO4]H:1 Ligand 5 1 5 1 188.2 
[PO4]L:1 Ligand 5 1 5 1 188.1 
[PO4]T:1 Ligand 5 1 5 1 187.0 
[PO4]V:1 Ligand 5 1 5 1 188.6 
[PO4]X:1 Ligand 5 1 5 1 187.9 
[PO4]Y:1 Ligand 5 1 5 1 188.5 
[PO4]Z:1 Ligand 5 1 5 1 188.6 
 Average 5 1 5 1 188.3 
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Figure 7. 18 total protein structure as interpreted by PISA, EMBL-EBI. The figure shows the protein as 
four monomers each presented by separate colour. 
7.5. Discussion 
In the aim of solving the structure of the unusual protein Blastocystis TPI-GAPDH, 
each component of this fusion protein was studied separately. For this purpose 
the fusion protein Blastocystis TPI-GAPDH, Blastocystis GAPDH and 
Blastocystis TPI were all expressed and tried for purification and crystallization.  
Expression trials of TPI failed in this attempt and more trials of expression are 
advised to be experimented in the future, which couldn’t be done in this project 
due to the lack of time. Both Blastocystis TPI-GAPDH and Blastocystis GAPDH 
were expressed and purified to a high concentration as previously mentioned.  
Blastocystis GAPDH was sent for data collection but all crystals grown in this 
project gave a very low resolution which prevented further study of its individual 
structure. To enhance the data quality it worth’s considering changing the cryo- 
preservant used, which might enhance the data quality in future work.   
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 The fusion protein Blastocystis TPI-GAPDH has diffracted to a moderately good 
resolution of 2.6Å. The protein structure was solved using the molecular 
replacement method and the protein final structure showed to be a tetrameric 
protein of Blastocystis TPI-GAPDH. The protein subunits were arranged in a way 
that GAPDH occupies the core of the protein and two dimmers of TPI are flanking 
the GAPDH subunits. Searching for interfaces in the data base similar to the 
monomer unit (TPI-GAPDH) came back with negative result, using PISA EMBLE-
EBI server. This shows that there is no protein yet in the data base of similar 
structure to the studied protein (TPI-GAPDH), which makes this the first study to 
solve the structure of the fusion Blastocystis TPI-GAPDH in any organism. 
The final protein structure obtained after refinement and model building was 
lacking the first eighteen amino acids of the electron density of chains A, C, and 
twenty amino acid of chains B and D which represent the N terminal targeting 
signal. 
Electron density was not high enough to show holo protein, and NAD molecules 
didn’t appear in the final solved structure. Indicators of the presence of NAD were 
the presence of phosphate molecules in the center of each TPI subunit and in the 
core of the tetrameric GAPDH. The signature motif of GAPDH indicating to 
Rossmann fold was another marker of having NAD as a cofactor, as previous 
study of Israel Hanukoglu has shown that the sequence motif GXGXXG has 
another version of GXGXXA where the replacement of Glycine residue by Alanine 
changes the enzyme’s cofactor from NAD/FAD to NADP/FADP (Hanukoglu 
2015). 
No significant differences were found in the structure of the protein in either TPI 
or GAPDH subunits, compared to the previously studied structures, in both their 
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catalytic residues and active sites. The only striking difference was the 
conformation taken by the flexible loop (loop 6), which was indicating a structure 
of a holo enzyme. This could either be a positive result and the protein solved in 
this structure is a holo enzyme, confirmed by the phosphate groups found in TPI 
active site and could be from the ligand (2GP). Although this is a week possibility 
specially that no ligand was added in the purification steps, nor in the 
crystallization trials. Another possibility, is that the protein solved is an apo 
enzyme and then conformation of loop 6 in an almost closed position could be 
explained differently. As previous studies showed, closed or almost closed 
conformation of loop 6 in an apo enzyme could be an indicator of heterogeneity 
in the solution and due to an inherent flexibility of loop 6 in TPI structure. Added 
to the remark of unusual DLS results found in chapter 6 of this project, the 
possibility of heterogeneity is the most probable explanation for the flexible loop 
conformation. The conformational heterogeneity of TPI-GAPDH in solution might 
be the origin of the observed almost closed loop in the apo form of the enzyme. 
Same case for GAPDH, no cofactor was in the active site, yet it was indicated to 
by the presence of phosphor group in the electron density. This could be washed 
off during purification steps; especially that DSF experiment in Chapter 5 has 
shown low affinity to the ligand by this enzyme. 
Although no significant differences were found in the structure of the Blastocystis 
TPI-GAPDH fusion protein, yet this work is the first reported to confirm the 
tetrameric structure of the fusion protein that was proposed for the TPI-GAPDH 
fusion protein. The same fusion was found also in diatoms in Liaud et al work 
who suggested a similar structure lay-out of the protein through size exclusion 
chromatography work  (Liaud, Lichtle et al. 2000). As seen in the in silico analysis 
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of the fusion protein Blastocystis TPI-GAPDH, it seems that this protein forms an 
ancestral form or evolutionary indication of its alphaprotobacterial origin, and 
hence it is conserving its structure and function. Yet, it would be interesting to 
investigate if this structure could be a potential drug target as being restricted to  
stramenopiles in a wide spread and few other organisms as indicated in 
Nakayama work (Nakayama, Ishida et al.) and confirmed in the in silico chapter 
of this work. 
Most studies that seek designing species-specific drugs target any structural 
differences in the active site between homologous enzymes which are crucial in 
the organism’s metabolism, for drug development. Since glycolysis is a universal 
pathway, it is quite conserved between species along with the enzymes of this 
pathway. Usually the structure is quite conserved of those proteins between 
species, same for the active site of those enzymes.  Nonetheless, residues might 
vary. To circumvent the problem of conserved catalytic regions, several studies 
had oriented their search towards regions that are not in the active site but close 
to it and still make a difference in enzyme activity and stability. In Trypanosma 
brucei, Giardia and Plasmodia Cys15 or Cys14 are residues that are located in 
the dimer interface close to the active site of TPI. Those residues were always a 
target for drug development, because they are replaced in human TPI by Met 
instead of Cys (Gomez-Puyou, Saavedra-Lira et al. 1995). In Blastocystis this 
residue is Cys 29 found in the interface between the dimmers and forming 
hydrogen bonds, as shown in Table 7.9, so this can be a target as well for 
Blastocystosis remedies. Several studies have made mutations in this specific 
residue and showed a drastic reduction of TPI activity upon this change (Gomez-
Puyou, Saavedra-Lira et al. 1995). Another cysteine residue that was also a 
target in drug delivery is Cys222, which is Cys231 in the protein of this study. 
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Although Cys222 is a non-conserved, non-catalytic residue, studies in Giardia 
lamblia has found that its derivatization with a small non-polar thiomethyl group 
of methylmethane thiosulfonate (MMTS) resulted in the reduction of TPI 
enzymatic activity by half. This loss of activity was restored by replacing MMTS 
by a negatively charged chemical, which suggest that this loss of activity is 
dependent on the physiochemical properties of the derivatizing agent. This might 
be due to the fact that mutating this residue would perturb loop 7 which is 
important as being a region of the enzyme that interacts with the catalytic loop 6 
and hence it is important in ligand binding and enzyme activity (Hernandez-
Alcantara, Torres-Larios et al. 2013). Another study by the same group found that 
this loss of activity is due to the decrease of Giardia TPI affinity to its ligand 2- 
phosphpglycerate (2-PG) Enriquez-Flores, Rodriguez-Romero et al. (2011). All 
those residues are conserved in Blastocystis TPI-GAPDH and can be a very good 
target for further inhibition studies for the sake of drug development against 
Blastocystis. 
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Chapter 8. Conclusion   
Blastocystis and Giardia are the most common protists diagnosed worldwide in 
almost every examined stool sample when investigating the causes of diarrhoea 
and gastrointestinal symptoms. Blastocystis is responsible for up to 60% of the 
cases worldwide. Adding to the challenge in treating Blastocystosis is the fact 
that it could be found both symptomatic and asymptomatic in the detected cases 
which resulted in the current controversy whether Blastocystis actually is a 
pathogenic or non-pathogenic protist. 
The traditional way of treating pathogens, such as targeting DNA, protein, or cell 
wall synthesis might result in unwanted side effects. This is especially the case 
for protists, being eukaryotes themselves, as they might share common features 
with the host, whether this is a human, an animal or a plant. Therefore, targeting 
a specific and unique aspect of the pathogen will be a better approach that will 
minimize any possible side effects. 
From this point it was thought to look at unique features in Blastocystis. Several 
drugs have been approached in this way. 
Blastocystis, is a widespread parasite that is found in the stool of humans, 
animals, birds, etc. This organism belongs to the Stramenopiles and one of its 
unique features is that it is an anaerobic parasite, yet seems to have normal 
mitochondria. This has driven lots of research to be conducted investigating the 
specifications of this organelle. Leading to the discovery that this parasite has an 
unusual fusion protein of two proteins that are an essential part of the glycolysis 
pathway. Being an essential pathway, this unusual fusion protein might be a 
potential drug target. If this unusual fusion protein has indeed specific 
characteristics, or an unusual three-dimensional structure, then disabling this 
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protein might be a good way of depriving this organism from essential glycolytic 
intermediates without affecting the host.  
In Blastocystis, the TPI-GAPDH fusion protein is structured with TPI upstream of 
the GAPDH part. The C-terminus of TPI is attached to the N-terminus of GAPDH. 
Interestingly, it was found that the fusion protein has an N-terminal signal which 
resembles mitochondrial targeting signals. This is quite interesting considering 
the fusion protein consists of glycolytic enzymes. Glycolysis is canonically known 
to be a cytosolic pathway.  
Very few studies have been conducted into such a fusion protein. Liaud et al 
studied the characteristics of a similar fusion protein in the algae Phaeodactylum 
tricornutumand concluded that this protein is a tetramer of GAPDH with two TPI 
dimers on both sides (Liaud, Lichtle et al. 2000). They assumed the protein 
maintained the same function as the glycolytic version of the stand-alone 
proteins. Work by an MSc student in a collaborating laboratory has suggested 
that this protein is forming  a dimer of TPI and a dimer of GAPDH (Evans 2014), 
with the latter being unusual as this would be the first time GAPDH to be reported 
not to be a tetramer.  
Three glycolytic enzymes were studied in this thesis, enolase, triosephosphate 
isomerase and glyceraldehydes-3-phosphate dehydrogenase. The last two were 
in the form of a fusion protein in the studied organism. 
Therefore, I sought in this project to characterize this fusion protein in Blastocystis 
both chemically and physically, seeking any special features that differentiate it 
from its host. The crystallographic structure of the fusion protein have also been 
solved for the first time since the fusion protein TPI-GAPDH was reported. 
Enolase was also studied and characterized both chemically and physically. 
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Enolase, also called phosphopyruvate hydratase, responsible for the ninth 
reaction in glycolysis pathway, which is the conversion of 2-phosphoglycerate (2-
PG) to phosphoenolpyruvate (PEP). In this study, enolase has shown to be a 
highly conserved protein in the organism of this study, Blastocystis, presented by 
its special sequence features that followed the enolase family general 
characteristics. It follows the general characteristic of other enolases, from its 
molecular weight to its general sequence. The Blastocystis enolase has kept the 
essential sequence features for enzyme activity, including residues for substrate 
binding and residues important for protein activity. On the other hand, 
Blastocystis enolase was found not to contain the plasminogen binding site which 
is thought to help in host invasion as found in some other enolases from other 
parasites. In phylogenetic analyses, the Blastocystis enolase had clearly grouped 
within the chromalveolates. Interestingly, the protein has a putative mitochondrial 
targeting signal at its amino-terminus as shown by in silico characterization of the 
protein. Biochemical characterization of Blastocystis enolase showed a similar 
conventional molecular weight comparable to other enolases. This study 
revealed the Blastocystis enolase to be a homo-dimer with a native subunit 
molecular weight of 78 kDa as confirmed by several experiments. However, when 
comparing its enzymatic activity to other studied enolases, it was suggested that 
the Blastocystis enolase has a lower affinity to its substrate, or the data had an 
odd point that might have played a role in the odd results of the protein kinetics. 
In addition to biochemical characterizations, enolase was also looked for from a 
biophysical side by employing biophysical methodologies, and those have shown 
the protein to be an active dimer protein as reported in literature. Blastocystis 
enolase was found to be stable at 66°C and that it performs best in a HEPES-
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Glycine buffer. While its catalytic activity has shown that Blastocystis enolase is 
an active enzyme with a putatively lower affinity to its substrate. 
Triosphosphate isomerase (TPI), catalyses the reversible interconversion of 
dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate. While 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) catalyses the sixth step 
of glycolysis pathway which is the reversible conversion of glyceraldehydes-3- 
phosphate to D-glycerate 1, 3-bisphosphate. Those two proteins were found to 
be fused in Blastocystis and the fusion enzyme was characterized chemically and 
physically. The fusion protein was found to be following the general 
characteristics studied so far for the stand-alone version of the protein. The 
unusual TPI-GAPDH fusion protein has a putative mitochondrial targeting signal 
at its amino terminus as well. Phylogenetic analysis of Blastocystis TPI-GAPDH 
fusion protein indicates that it clusters within the stramenopiles. Conserving all 
features essential for function of TPI and GAPDH and containing all expected 
protein motifs for these enzymes. The structure of the fusion protein was not 
solved or studied before, and this project shows the structure of the solved protein 
for the first time in literature. The fusion protein was found to form a tetrameric 
protein of tetraeric GAPDH flanked with two dimeric TPI. The fusion protein’s 
components were also following the general characteristics of the text book 
enzymes.  
Finally, data obtained in this thesis suggests that at least part of glycolysis in 
Blastocystis takes place in the mitochondrion.  
 
 
    
291 
 
Appendices  
Appendix 1 IMDM formula as described on PAA company. 
Inorganic salts  
mg/m 
Amino acids  
 mg/ml 
 
Vitamins   
mg/ml 
 
Other 
components 
mg/ml 
Calcium Chloride.2 H2O                 
218.97 
L-Alanine                                
25.00 
D-Biotin                                               
0.018 
D-Glucose                                      
4500.00 
Magnesium Sulphate                           
97.67 
L-Arginine. HCl                                
84.00                    
Choline Chloride                                  
4.00 
HEPES                              
5958.00 
Potassium Chloride                        
330.00 
L-Asparagine .  H2O                           
28.40 
Folic Acid                                               
4.00 
Phenol Red.                                        
15.00 
Potassium Nitrate                             
0.067 
L-Aspartic Acid                                   
30.00 
myo-Inositol                                
7.20   
Sodium pyruvate                             
110.00 
Sodium hydrogen carbonate 
(only in liquid solution)                              
3024.00 
L-Cystine                                             
70.00
Niacinamide                                         
4.00   
Sodium Chloride                           
4505.00 
L-Glutamic Acid                                 
75.00 
D-calcium pantothenate 
(Vitamin B5)           
                                                                
4.00                                   
 
Sodium Phosphate 
Monobasic.2H2O   
                                                           
108.68                                       
L-Glutamine                                     
584.00   
Pyridoxal. HCl                                     
4.00  
Sodium Selenite. 5H2O                     
0.017 
Glycine                                                
30.00 
Riboflavin                                              
0.40  
 L-Histidine. HCl.H2O                          
42.00 
Thiamine.  HCl                                     
4.00       
 L-Isoleucine                                      
105.00 
Vitamin B12                                       
0.013  
 L-Leucine                                          
105.00   
 L-Lysine. HCl                                    
146.00   
 L-Methionine                                     
30.00   
 L-Phenylalanine                                 
66.00   
 L-Proline                                             
40.00   
 L-Serine                                               
42.00   
 L-Threonine                                        
95.00   
 L-Tryptophan                                     
16.00   
 L-Tyrosine.  2Na                               
89.47   
 L-Valine                                               
94.00 
  
 
 
 
 
 
 
 
    
292 
 
Appendix 2 Gel filtration standard curve 
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Appendix 3 Crystallization optimization conditions for Blastocystis TPI-GAPDH protein. 
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Appendix 4 Ramachandran plot of the recombinant Blastocystis TPI-GAPDH protein  
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